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This thesis presents a series of clinical research studies focusing on postprandial blood pressure 
(BP), glycaemic and incretin hormone responses in healthy ageing. The studies address the 
underlying pathophysiology, natural history, and approaches to management, of postprandial 
hypotension (PPH), longitudinal changes in and relationship between postprandial plasma 
levels of the incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent 
insulinotropic polypeptide (GIP). 
 
PPH, usually defined as a fall in systolic BP of greater than, or equal to, 20 mmHg within 2 h 
of a meal occurs frequently, particularly in older people and those with type 2 diabetes (T2D). 
PPH increases the incidence of falls, syncope, cerebrovascular disease, angina, and has been 
associated with a higher risk of cardiovascular mortality even when it is asymptomatic. After 
a meal, there is a substantial increase in splanchnic blood flow, leading to a reduction of blood 
volume returning to the heart. PPH occurs when compensatory responses are inadequate to 
maintain BP. Multiple factors are involved in the pathophysiology of PPH, including small 
intestinal nutrient delivery, changes in autonomic function, the release of gastrointestinal 
hormones and changes in splanchnic blood flow. Chapter 1, 2 and 3 are structured as narrative 
reviews which aim to provide a comprehensive background to the studies. Chapter 1 
summarises ‘up-to-date’ knowledge relating to PPH, including the prevalence, clinical 
relevance, pathophysiology and approaches to management. Chapter 2 is a brief review of the 
physiology of gastric emptying, which is pivotal to the pathophysiology of PPH, while 
Chapter 3 focusses on the interrelated relationship between gastric emptying and glycaemia.  
 
In healthy older subjects and patients with T2D, there is a correlation between the magnitude 
of fall in BP induced by glucose with the rate of gastric emptying of glucose, so that relatively 




more rapid gastric emptying is associated with a greater fall in BP. Cross-sectional studies 
indicate that healthy ageing is associated with a modest slowing of gastric emptying, however, 
there is limited information about longitudinal changes in gastric emptying in a healthy, ageing 
population and no studies which have evaluated the natural history of the fall in BP induced by 
glucose with ageing. In the study described in Chapter 4, longitudinal changes in the BP 
response to, and gastric emptying of, glucose were evaluated in 33 healthy older people at an 
initial study and after 5.8 ± 0.1yr. BP, heart rate (HR) and gastric emptying (using a stable 
isotope breath test technique) were assessed concurrently after participants consumed a 300mL 
drink containing 75g glucose and 150mg C13-acetate.  
 
PPH is under-recognised, but common. Following health concerns about excessive 
consumption of sugar, there has been an increasing trend to use low- or non-nutritive 
sweeteners as an alternative. Due to the lack of literature in this area, a systematic review 
described in Chapter 5 was conducted to identify important gaps in information relevant to 
the effects of different types of sweeteners on postprandial BP. 
 
While all macronutrients reduce BP comparably, the hypotensive responses to fat and protein 
occur slightly later than the response to glucose in healthy older people, probably reflecting the 
more prolonged time for digestion. Moreover, xylose, a poorly absorbed pentose sugar, empties 
from the stomach at a comparable rate to glucose, but has no effect on BP in healthy older 
subjects, as is also the case for fructose. The effect of artificial sweeteners, such as sucralose, 
on postprandial BP, was unknown. In the study described in Chapter 6, the effects of 
intraduodenal (ID) infusion of sucralose and glucose versus saline, on BP and HR, superior 
mesenteric artery (SMA) blood flow and blood glucose, were assessed in healthy older 
individuals. 





Current management of PPH is suboptimal. Acarbose is known to attenuate the fall in systolic 
BP induced by oral sucrose in healthy older adults, associated with slowing of gastric emptying 
and enhanced release of GLP-1. Gastric distension with water at a volume as low as 300 mL 
mitigates the fall in BP in response to ID glucose. In the study described in Chapter 7, the 
effects of gastric distension and acarbose, either alone or in combination, on BP, glycaemia 
and SMA flow after oral sucrose were assessed in healthy older people. 
 
A whey protein/guar preload has been shown to reduce postprandial glycaemia in T2D, an 
effect suggested to be mediated by slowing of gastric emptying. However, the latter has only 
been assessed using a stable isotope breath test technique, which cannot discriminate between 
slowing of gastric emptying and a delay in small intestinal absorption. This preload also has 
potential for use in the management of postprandial hypotension. In the study reported in 
Chapter 8, the effects of a guar/whey protein preload on gastric emptying (using scintigraphy), 
glucose absorption, glycaemic/insulinaemic and BP responses to an oral glucose load, were 
evaluated in healthy older people. 
 
The rate of gastric emptying is a major determinant of the glycaemic response to carbohydrate-
containing meals in healthy subjects, as well as individuals with T2D. Gastric emptying also 
influences the release of incretin hormones, GLP-1 and GIP, which impact postprandial 
glycaemic excursions. It is not known whether baseline and/or nutrient-stimulated GLP-1 or 
GIP levels are predictable within an individual or affected by ageing. The study described in 
Chapter 9 re-evaluated a cohort of healthy older subjects after an interval of ~ 5.9 years and 
determined changes in fasting and glucose-stimulated plasma GLP-1 and GIP concentrations 
and their relationships with gastric emptying.  





The incretin hormones, GLP-1 and GIP, are secreted following intestinal macronutrient 
exposure - GIP primarily from the proximal small intestine and GLP-1 from the more distal 
small intestine and colon. Their relative importance to the incretin effect in health has been 
contentious, although recent studies employing a specific GIP antagonist now indicate that GIP 
has the dominant role. It is uncertain whether there is a relationship between GIP and GLP-1 
secretion.  The study described in Chapter 10 evaluates the relationship between GIP and 
GLP-1 responses to a 75g oral glucose load in older individuals with either normal (NGT) or 
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1.1 Introduction  
Postprandial hypotension (PPH) appears to be, an important clinical condition, which is 
certainly under-recognised. PPH may result in an increased incidence of falls, syncope, 
cerebrovascular disease, angina, and is apparently associated with a higher risk of 
cardiovascular mortality [1, 2] even when it is asymptomatic [3]. The clinical significance of 
PPH will, however, remain controversial in the absence of intervention studies demonstrating 
benefit. The latter, by definition, requires an effective and safe intervention which is currently 
lacking. PPH is generally defined as a fall in systolic blood pressure (BP) of greater than or 
equal to 20 mmHg, or a postprandial systolic BP less than or equal to 90 mmHg when the pre-
prandial systolic BP is greater than or equal to 100 mmHg, within 2 h of a meal [1].  
 
PPH is distinct from orthostatic hypotension and prevalence increases with age [4]. PPH occurs 
frequently in healthy older subjects (13-38%) [5] and patients with autonomic dysfunction, 
often secondary to type 2 diabetes (T2D) (∼35%) [1, 5] or Parkinson’s disease (40-100%) [1, 
5]. The ‘early’ dumping syndrome, which is reported in approximately 25–50% of patients 
after gastric surgery including Roux-en-Y gastric bypass for management of obesity, also 
includes PPH [4, 6].  
 
The pathophysiology of PPH is incompletely understood, and a number of factors play a role 
in the fall in BP, including small intestinal nutrient delivery [7, 8], changes in splanchnic blood 
flow [9] and neural and hormonal mechanisms [4], while gastric distension attenuates the fall 
in postprandial BP [10, 11]. After a meal, there is a substantial increase in splanchnic blood 
flow, leading to a reduction of blood volume returning to the heart [1]. In healthy young and 
non-PPH older individuals with intact baroreflex mechanisms, the reduced blood volume in 
the systemic circulation is compensated by concomitant increases in heart rate (HR), stroke 




volume and cardiac output to maintain BP [12]. PPH reflects the inadequacy of these protective 
responses [1]. 
 
Current strategies for the management of PPH include nonpharmacologic and pharmacologic 
approaches. Macronutrient modification [13], consumption of smaller and more frequent meals 
[13], maintenance of adequate fluid intake [1], drinking water before a meal [11, 14, 15], and 
exercise after a meal [16] are non-pharmacological approaches which may attenuate the 
decrease in BP, while caffeine [17], acarbose  [18], and octreotide  [19, 20], variations in the 
timing and doses of antihypertensive drugs [21] are the most common pharmacological 
approaches. While both nonpharmacologic and pharmacologic treatments can have efficacy, 
in general, they appear limited and none is targeted at the underlying pathophysiology. More 
recently, there is evidence that interventions based on slowing gastric emptying [22, 23] and 
small intestinal absorption of nutrients [24], while maximising gastric distension are effective 
in attenuating PPH. Exogenous glucagon-like peptide-1 (GLP-1) and GLP-1 receptor agonists 
have received considerable attention in the last few years as a potential novel therapeutic 
approach to the management of PPH.  
 
This chapter provides current knowledge relating to PPH, with a particular focus on prevalence, 
pathophysiology, and management, including future priorities for research. 
 
1.2 Prevalence of PPH 
The majority of individuals with PPH either are old or have diabetes and/or a neurological 
disorder.  
 




1.2.1 Older people 
PPH was reported to occur in 118 out of 449 (24%) [25] and 41 out of 114 (36%) [26] elderly 
nursing home residents after a standardised carbohydrate meal in two cohort studies. A 
subsequent study demonstrated 57 out of 85 elderly hospitalised patients (67%) had PPH with 
a mean postprandial reduction in systolic BP of ~ 34 mmHg [27], while the prevalence of 
orthostatic hypotension was 52% [27]. Although they are distinct phenomena, there is a strong 
correlation between orthostatic hypotension and PPH, i.e. subjects with orthostatic hypotension 
are much more prone to PPH [28]. A cohort study conducted in 5888 older community-
dwelling individuals found that systolic and diastolic BPs were lower (~ 130.1/66.6 mmHg) 
within the first hour after a non-standardised meal, compared to measurements immediately 
following the meal (~ 133.7/68.8 mmHg) and four hours after the meal (~ 136.5/71.1 mmHg) 
[29]. In 150 long-term care patients receiving a high carbohydrate meal via either oral, 
nasogastric infusion or percutaneous endoscopic gastrostomy feeding (50 in each group), PPH 
was evident in 64 (43%) patients and there was no difference in PPH prevalence among the 
three groups [30]; 9 out of 12 (75%) fed through the gastrostomy tube had PPH [31]. In older 
adults with a history of falls, the prevalence of PPH was 42.1 ± 5.1% after a test meal [32].  
 
The postprandial fall in BP may be exaggerated in the setting of multiple comorbidities [26] 
and multiple-drug therapy [25]. More recently, PPH has been shown to be both prevalent and 
underdiagnosed in older survivors of the Intensive Care Unit (ICU). In a cohort of 35 older 
survivors (>65 years) discharged in the preceding 3 months from ICU, 10 (29%) had PPH [33]. 
Although PPH is widely appreciated as a common condition in healthy older subjects, there 
had been no studies investigating its natural history before the commencement of my PhD. This 
gap in the literature triggered my study which focused on the trajectory of the disorder 
(Chapter 4). 




1.2.2 Diabetes  
T2D and type 1 diabetes (T1D) are both associated with autonomic nerve dysfunction [34], 
which predisposes to PPH [35]. Sasaki et al. reported that among a cohort of 35 patients with 
T2D, PPH was identified in 37% after ad libitum eating and in 20% after the ingestion of a 
glucose load (75g in 300 mL water), and suggested that PPH may be an important 
cardiovascular disorder in T2D [36]. Subsequently, Jones et al. reported in a cohort of 16 T2D 
patients who ingested 75g glucose, the prevalence of PPH was 44% [7]. In these studies only 
a minority of subjects exhibited symptoms of PPH [7, 36], but Sasaki et al. suggested that PPH 
increased the risk of sudden death as well as myocardial and cerebral infarction [36]. More 
recently, Hashizume et al. have demonstrated a postprandial fall in both central and brachial 
systolic BP in patients with T2D – the decrease in BP was more prolonged in those with severe, 
compared with mild, cardiac autonomic dysfunction [35]. Although PPH has also been reported 
to occur in patients with T1D, the prevalence in this group is uncertain [37]. 
 
1.2.3 Neurological diseases 
A recent meta-analysis confirmed that the likelihood of PPH is higher in patients with 
neurological diseases [38]. The mechanisms underlying PPH in neurological diseases have 
generally been attributed to autonomic failure which may be the primary and associated with 
an unknown aetiology (e.g., multiple system atrophy, synonymous with the Shy-Drager 
syndrome and Parkinson’s disease) or secondary as associated with a clearly defined cause 
(e.g., spinal cord lesions, drugs and, as discussed, diabetes) [39]. In patients with autonomic 
failure, a major fall in systolic BP to around 80/50 mmHg, persisting for more than 3 hours in 
the supine position, has been reported [40, 41]. PPH has also been identified in several small 
cohorts of patients with autonomic failure [42-45]. Prevalence of PPH of 42.5 - 82% in patients 




with Parkinson’s disease has been reported [46-51]. In a recent study by Trahair et al. of 21 
patients with mild to moderate Parkinson’s disease (Hoehn and Yahr score 1.4 ± 1), 8 (38%) 
had PPH after a 75g oral glucose load and in a further 8 (38%), the fall in systolic BP was > 10 
mmHg, but < 20 mmHg [52]. Idiaquez et al. [53] found that 70% of patients with severe 
Alzheimer's disease had a fall in BP of ≥ 20 mmHg after a standard meal. PPH also occurs in 
a high percentage (52.9-70%) of patients with multiple system atrophy [38, 54]. 
 
1.2.4 Other illnesses 
Dumping syndrome is a frequent complication of gastric surgery associated with a drainage 
procedure. In the past, such surgery was usually performed for the management of peptic ulcer 
(e.g. Billroth 2 gastrectomy and vagotomy pyloroplasty); an increasingly common reason is 
Roux-en-Y gastric bypass (RYGB) surgery for the management of obesity. Features of 
dumping syndrome have been noted in more than 50% in the early postoperative stage of the 
Billroth  II  gastrojejunostomy [55]. Dumping syndrome can be divided into either ‘early’ or 
‘late’ symptoms. Clinical manifestations of early dumping syndrome include gastrointestinal 
and systemic vasomotor symptoms, such as a postprandial fall in BP, with symptoms occurring 
within 30 min following meal ingestion [55, 56]. Late dumping syndrome occurs occur 1–3 h 
after food ingestion and consists of symptoms associated with hypoglycaemia [55, 56].  
Dumping is associated with a decreased quality of life and increased morbidity [6]. Nguyen et 
al. reported that 2 out of 10 unselected patients after RYGB had the dumping symptoms 
including hypotension and dizziness, following a 50g glucose drink in the sitting position [57]. 
More recently, Takeshita et al. reported a case of severe early dumping syndrome associated 
with markedly increased splanchnic vasodilatation requiring urgent treatment with intravenous 
fluids and vasopressors [58]. 
 




There is a concern that eating during haemodialysis may exacerbate the fall in BP which occurs 
frequently [59-61]. Sherman et al. reported 13 events of symptomatic hypotension in five 
patients who were given a standard meal during dialysis, and two events in one fasting patient 
[62]. Subsequently, the magnitude and frequency of the fall in BP were greater after a standard 
snack (400 kcal) compared with control in 13 patients with chronic renal failure during 
haemodialysis [61]. Borzou et al. reported that food ingestion during haemodialysis induced a 
fall in systolic and diastolic blood pressures, which persisted for one hour (systolic) and one 
and a half-hours (diastolic) following the meal [59]. Given these findings, the prevalence and 
clinical relevance of postprandial hypotension in the dialysis setting need further investigation.  
 
1.3 Significance of PPH 
PPH is a clinically important condition associated with increased morbidity and mortality. It 
has been shown to be associated with an increased risk of falls. For example, Puisieux et al. 
reported a high percentage (23%) of PPH in a cohort of elderly patients hospitalised for either 
syncope or falls [63]. PPH has also been identified as a risk factor for both cerebrovascular 
[64-66] and cardiovascular events [3, 66, 67].  A relationship between evidence of 
asymptomatic cerebrovascular damage on magnetic resonance imaging (MRI) and the 
magnitude of the fall in postprandial BP has been demonstrated, i.e. the prevalence of lacunar 
infarction and advanced leukoaraiosis was greater in individuals with a fall in BP of > 10 
mmHg (83% for both), compared to those in whom the fall in BP was < 10 mmHg (69% and 
50% respectively) and the normal group (44% for both) [64]. A postprandial BP decline is also 
considered important in the aetiology of asymptomatic lacunar infarction in community 
dwellers [2]. A Japanese cross-sectional study was performed from February 2006 to August 
2012 and involving 1308 apparently healthy, middle-aged to elderly, people who underwent 
brain MRI and postprandial BP measurements. Based on the postprandial change in systolic 




BP (ΔSBP), participants were classified into four subgroups: ΔSBP≤ −20 mmHg, −20 < 
ΔSBP≤ −10 mmHg, −10 < ΔSBP ≤ 10 mmHg and ΔSBP > 10 mmHg. There was a significant 
difference in the prevalence of lacunar infarction among the four subgroups (12.7%, 11.4%, 
8.1%, and 7.2% respectively, P = 0.007) [2]. Another study showed that over a 4-year period, 
a breakfast-induced fall in BP was associated with an increased risk of cardiovascular mortality 
in patients with PPH [67]. In a group of 179 elderly low-level-care nursing home residents, 
PPH appears to be an independent predictor of all-cause mortality [68]. Over a period of 4.7 
years, the mortality rate in nursing home patients with PPH was greater than that in patients 
without PPH (145.0 vs. 98.5 per 1,000 person-years) [68]. Moreover, there was a strong 
correlation between the risk of death and the magnitude of the postprandial reduction in BP - 
patients who exhibited a postprandial reduction in BP ≥ 40 mmHg had the highest mortality 
(156.1 per 1000 person-years), followed by those with a postprandial reduction in BP of 20 - 
39, 11–19 and  ≤10 mmHg (144.4, 116.9 and 89.1 per 1000 person-years respectively) [68] 
(Figure 1.1).  
  
1.4 Pathophysiology of PPH 
1.4.1 Gastric emptying  
In both health and diabetes, the rate of gastric emptying has a wide interindividual variation 
from 1 to 4 kcal/min, but minimal intraindividual variation [69, 70]. This range of gastric 
emptying is greater in T2D due to a high prevalence of disordered (slower and more rapid) 
emptying [71]. The rate of gastric emptying is determined primarily by the interaction between 
the motor activity of the fundus, antrum and pylorus, negative feedback arising from the 
interaction of nutrients with the receptors located in the small intestinal, and gastrointestinal 
hormones released in response to food ingestion [69, 72, 73].  





In healthy older subjects [70, 74] and patients with T2D [7] (Figure 1.2), there is a correlation 
between the postprandial fall in BP with the rate of gastric emptying of glucose. The finding is 
supported by the outcomes of several other studies which have used intraduodenal (ID) nutrient 
infusion to ‘bypass’ the potential confounding effects of gastric distension and differences in 
gastric emptying rates between individuals [8, 24, 75, 76]. In healthy older subjects, the rate of 
small intestinal delivery must reach a specific threshold to result in hypotensive effects. 
O'Donovan et al.  reported that 3 kcal/min ID glucose infusion induced a substantial decrease 
in BP and rise in HR in healthy elderly subjects whereas a 1 kcal/min infusion had no effect 
[8]. Similarly, in a more recent study, a 2 kcal/min intraduodenal glucose infusion lead to a 
comparable reduction in BP to a 3 kcal/min infusion, but a 1 kcal/min had no effect [24] (Figure 
1.3). In a recent study involving 9 patients with T2D, the fall in systolic BP was greater when 
ID glucose infusion was increased from 2 kcal/min to 4 kcal/min [76]. Furthermore, dietary 
interventions such as the viscous polysaccharide guar which retards gastric emptying [22, 23] 
and small intestinal absorption of nutrients [24] attenuate the fall in BP effectively. 
 
1.4.2 Autonomic and Neural Mechanisms 
Food ingestion is followed by a redistribution of blood into the splanchnic vessels to optimise 
digestion and absorption of nutrients [77]. In healthy, young subjects, the so-called 
‘‘gastrovascular reflex’’ is associated with postprandial increases in muscle sympathetic nerve 
activity (MSNA), HR, cardiac output and, accordingly BP [1, 63, 78-81]. These responses are 
associated with an elevation of plasma noradrenaline [1]. While similar effects occur in healthy 
older people, albeit to a lesser degree than in young healthy controls [79, 82], the increases in 
the superior mesenteric artery (SMA) flow does not differ between the two groups [83]. 
Accordingly, to stabilise postprandial BP, sympathetic nerve activity must increase to more 




than 200% of basal values in healthy older people [84]. Hypotension reflects an imbalance 
between the increase in splanchnic blood flow and inadequate compensatory responses [84-
87].  
 
A comparable increase in MSNA is also observed in healthy young and older subjects in 
response to ID glucose [88]. That healthy elderly subjects exhibit a fall in BP, is suggestive of 
decreased sympathetic baroreflex sensitivity [88].  
 
Gastric distension increases MSNA [89], but has no effect on plasma noradrenaline in the 
healthy elderly [90]. Vanis et al. [90] reported an increase in plasma norepinephrine 
concentrations following an ID glucose load (3 kcal/min) during intragastric balloon 
distensions of 0, 100, 300, or 500 mL, with no difference in plasma concentrations between 
distensions. In this study, a fall in systolic BP was observed only during the 0 mL intragastric 
distension [90]. Another study reported that MSNA could be increased by progressive gastric 
distension (intragastric bag) in both young and older healthy subjects and that the increases 
were greater in the former group [89].  
 
Nitric oxide, an important neurotransmitter in the gastrointestinal tract, mediates 
vasodilation of blood vessels in both animals [91, 92]and humans [93]. Specific inhibitors of 
its production, such as NG-mono-methyl-L-arginine (L-NMMA) and NG-nitro-L-arginine-
methyl-ester (L-NAME) can be used to address the role of nitric oxide [91, 94] and  Gentilcore 
et al. reported, in healthy older subjects, that acute administration of NG-nitro-L-arginine-
methyl-ester decreased the hypotensive response to oral glucose, but had no effect on gastric 
emptying [95].  
 





1.4.3 Hormonal Mechanisms 
Although there is no conclusive evidence of an important role for hormonal mechanisms in 
PPH, a number of gastrointestinal peptides, including insulin, GLP-1, glucagon-like peptide-2 
(GLP-2), glucose-dependent insulinotropic peptide (GIP), calcitonin-gene-related peptide 
(CGRP), neurotensin, vasoactive intestinal peptide (VIP), bradykinin, and substance P, may be 
involved in postprandial BP regulation [1, 96]. Administration of somatostatin and its 
analogues, which suppress the release of most gastrointestinal hormones, have been shown to 
decrease the postprandial fall in BP [19, 45], although somatostatin may also affect splanchnic 
blood flow directly [97].  
 
1.4.3.1 Insulin 
Several early studies [98-100] supported the role of insulin in modulating PPH through its 
known vasodilatory effects [101], and capacity to modulate sympathetic function [12]. 
However, it is unlikely that insulin plays a primary role in PPH. Intravenous administration of 
glucose [102], which is a substantial stimulus to insulin secretion, has no effect on BP and there 
is a postprandial fall in BP in people who have T1D [37], which is associated with absent 
endogenous insulin secretion. It is also reported that neither fructose nor xylose [103, 104], 
unlike glucose, when administered in an isosmotic solution has an influence on BP.  
 
1.4.3.2 Glucagon-like peptide-1 
GLP-1 is produced in L-cells in the distal small intestine in response to the exposure to nutrients 
and bile acids [105]. As will be discussed in Chapter 3, the main function of GLP-1 is to act 
as an incretin hormone by stimulating insulin secretion and inhibiting glucagon secretion, both 




in a glucose-dependent manner. GLP-1 also modulates gastrointestinal motility and slows 
gastric emptying [106]. Endogenous GLP-1 may play a role to reduce the postprandial fall in 
BP. The effect of acarbose to attenuate the fall in BP induced by oral [18] or intraduodenal 
[107] sucrose in healthy older subjects is associated with the stimulation of GLP-1 [18, 108]. 
In healthy older subjects, the postprandial fall in BP after ID or oral ingestion of glucose is also 
attenuated by intravenous GLP-1 in healthy older subjects [106, 109].  Furthermore, the 
dipeptidyl peptidase 4 (DPP-4) inhibitor, vildagliptin, which stimulates GLP-1 was reported to 
be effective in treating an 85-year-old woman with symptomatic PPH [110]. More recently, 
acute administration of the GLP-1 receptor agonists, lixisenatide, has been shown to prevent 
the fall in BP induced by glucose in healthy older subjects and T2D patients [111]. This study 
is described in more detail in the “management” section.  
 
1.4.3.3 Glucagon-like peptide-2 
GLP-2, which is co-secreted with GLP-1 from L-cells with the ratio 1:1 [112], increases 
mesenteric blood flow [113-115] and may contribute to the pathogenesis of PPH [96]. There 
is, however, little information relating to the relevance of GLP-2 to PPH. Fukushima et al. [96] 
reported no difference in postprandial plasma GLP-2 concentrations in multiple system atrophy 
patients with and without PPH. In animal models, GLP-2 reduces antral contractility and fundic 
tone [112] but does not appear to affect gastric emptying in humans [112].  
 
1.4.3.4 Glucose-dependent insulinotropic peptide 
GIP is secreted from K-cells, which are located primarily in the proximal small intestine [116]. 
As will be discussed in Chapter 3, GIP stimulates the release of insulin and glucagon from β 
and α cells in a glucose-dependent fashion [117]. Unlike GLP-1, GIP has little or no effect on 




gastric emptying [118]. Several animal studies have demonstrated that after food intake, GIP 
secretion potentiates the release of GLP-1 [119] but this is not the case in humans [119] - a 
direct role for GIP in postprandial BP regulation has hitherto not been evaluated due to the 
absence of a GIP antagonist.  
 
1.4.3.5 Vasoactive intestinal polypeptide, substance P, calcitonin gene-related peptide 
VIP is both a neuromodulator and neurotransmitter [120, 121]. Its primary functions are to 
regulate smooth muscle activity, epithelial cell secretion, and blood flow in the gastrointestinal 
tract. Because of its vasodilatory properties, it might be relevant to the pathogenesis of PPH, 
although there is no difference between pre- and postprandial plasma levels of VIP in patients 
with autonomic neuropathy or in older subjects [12]. Furthermore, plasma concentrations of 
VIP are not affected by the administration of octreotide, which markedly attenuates the 
postprandial fall in BP [20]. 
 
Substance P, like VIP, probably functions more as a neurotransmitter than as a circulating 
vasoactive hormone [122] and does not appear to have a role in PPH [102]. Ingestion of glucose 
or a meal has no effect on plasma substance P concentrations in either patients with autonomic 
failure or healthy older subjects [20, 101, 123]. 
 
CGRP is a neuropeptide with vasodilatory effects. Edwards et al. have reported a significant 
relationship (R = -0.37, P = < 0.05) between the increase in CGRP and the change in BP after 
a 75 g glucose load in healthy older subjects [124] and in the group of subjects who exhibited 
a fall in BP > 15 mmHg, the increase in  CGRP was greater in older subjects than in young and 
middle-aged subjects [124]. Further studies are warranted to define the role of CGRP in the 
hypotensive response to meals. 






Neurotensin, a potent vasodilatory peptide may increase intestinal blood flow after a meal [125, 
126]. There is an increase in SMA blood flow after intravenous administration of neurotensin 
[102]. Observations relating to the impact of neurotensin on postprandial BP are, however, 
inconsistent [102]. In comparison with healthy individuals, plasma neurotensin levels increase 
more markedly after oral glucose in patients with autonomic neuropathy and PPH [127]. In 
contrast, Hoeldtke et al. found no change in plasma neurotensin after breakfast in patients with 
PPH [20], while Fukushima et al. reported that the plasma neurotensin levels increased 
comparably in patients with multiple system atrophy with or without PPH after a meal [96]. 
 
1.4.4 Meal Composition 
Of the macronutrients, carbohydrate appears to have the greatest and most rapid suppressive 
effect on BP in healthy people and those with PPH [12, 40, 128]. Observations relating to the 
effects of fat and protein on postprandial BP have been inconsistent. While some studies have 
found that fat [128, 129] and protein [130] result in comparable postprandial falls in BP to 
glucose, other studies have reported that there is no change in BP after fat [12, 130, 131] and 
protein [12, 131] meals. Gentilcore et al. reported that glucose, fat, and protein evoke 
comparable falls in systolic BP after being infused intraduodenally, but the onset of the effect 
of glucose is earlier [9]. This may be because the effects of fat and protein on BP are dependent 
on their digestions to amino acids and free fatty acids [9].  
 
A simple carbohydrate meal may induce a greater hypotensive effect than an isocaloric 
complex carbohydrate meal in healthy older people, probably reflecting the different 




absorption rates in small intestine [132]. While both glucose and sucrose trigger comparable 
postprandial falls in BP in healthy older subjects, albeit with a delayed effect for sucrose [133], 
it is clear that fructose [133, 134] has no effect on BP and xylose [40, 103] only causes a modest 
fall in BP. These outcomes suggest that the hypotensive effect of carbohydrates is probably 
dependent on digestion to monosaccharides and their affinity for glucose transporters  
[133, 134]. Accordingly, sucrose, a disaccharide, must be converted to glucose and fructose for 
its hypotensive effect [133].  
 
1.4.5 Superior Mesenteric Artery blood flow 
After a meal, there is an approximately twofold increase in SMA blood flow, associated with 
decreases in systemic vascular resistance and skeletal muscle blood flow [1, 135, 136]. Sidery 
et al suggested that the increase in splanchnic flow is likely to be implicated in the fall in BP 
in healthy older subjects [129]. In favour of this argument, octreotide, which is known to 
suppress the release of gut hormones, markedly decreases the postprandial increase in SMA 
blood flow, and attenuates the postprandial fall in BP in autonomic failure patients [137]. 
However, the increase in mesenteric flow after a high carbohydrate meal in healthy young and 
older subjects is comparable [129], suggesting that PPH reflects, in the broadest sense, 
inadequate cardiovascular compensation for the increase in SMA blood [129, 135]. 
 
Many studies indicate that factors such as the size and composition of the meal, and the rate of 
small intestinal nutrient delivery affect the magnitude of the postprandial increase in mesenteric 
blood flow. A large meal might induce a greater postprandial hormonal response, leading to 
increased mesenteric vasodilatation [13]. The latter has been shown to be dependent on the 
macronutrient content [138] so that the increase in mesenteric blood flow is highest after 
glucose ingestion, followed by, in the absence of bile salts, fat and then protein. In contrast, 




when bile salts are present, several long-chain fatty acids appear to have more potent 
hyperaemic effects than glucose [138]. In healthy older subjects, ID infusion of glucose has a 
greater, and earlier, effect on the increase in SMA blood flow, compared with fat or protein, 
and protein induces a lesser SMA blood flow than fat [9] (Figure 1.4). The rate of small 
intestinal nutrient delivery also influences SMA flow [24]. For example, 3 kcal/min ID glucose 
infusion triggers a greater increase in SMA blood flow, compared to 1 kcal/min and 2 kcal/min 
infusions [24].  
 
1.4.6 Gastric distension 
Gastric distension attenuates the postprandial fall in BP probably by triggering the 
‘gastrovascular reflex’ [89]. ID glucose infusion (75g glucose/300 mL) induces a greater fall 
in BP in comparison to an equivalent oral glucose load [139] (Figure 1.5).  
 
There is little information regarding the role of specific regions of the stomach in postprandial 
BP, however, there is some evidence that the proximal stomach may be more important [10, 
89, 140]. Proximal gastric distension created with a so-called ‘barostat’ triggers ‘gastrovascular 
reflex’ leading to increases in BP, HR and MSNA in healthy young and older subjects [10, 89]. 
However, the gastrovascular reflex is attenuated in the latter group [89]. Jones et al. have 
reported relationships between increases in systolic BP with the volumes of the whole or 
proximal, but not the distal, stomach [140] and the magnitude of the ‘gastrovascular reflex’ is 
proportional to the gastric distension volume [140]. In the same way, drinking water has been 
shown to attenuate the postprandial fall in BP in healthy older subjects [141, 142], as well as 
patients with multiple system atrophy and pure autonomic failure [141-143]. Gentilcore et al. 
also reported that even a low volume of water (300 mL) infused intragastrically diminishes the 
fall in BP induced by ID glucose in the healthy elderly [15].  Interestingly, patients with 




autonomic failure appear to have a greater pressor response to drinking water, compared to 
control subjects [142]. In a recent study by Trahair et al., the acute pressor response to water 
was preserved and, possibly exaggerated in patients with PPH [144].  
 
1.5 Management  
A standardised approach to the management of PPH remains to be established. Current 
strategies are both non-pharmacologic and pharmacologic - none is particularly effective. The 
majority of studies relating to the management of PPH have focussed on patients with 
autonomic failure without PPH, and asymptomatic healthy older people [145]. There is a major 
need for a safe, and clinically effective, targeted therapeutic strategy. 
 
1.5.1 Non-pharmacologic  
1.5.1.1 Dietary modifications 
Meal frequency 
It has been suggested that eating small meals frequently and reducing the carbohydrate portion 
of meals may attenuate postprandial falls in BP [13, 146]. A larger meal was shown to induce 
a greater increase in cardiac output, and greater decreases in peripheral vascular resistance and 
mean arterial pressure (MAP) in four healthy younger individuals, when compared to a smaller 
meal [146]. Consistent with this, Puvi-Rajasingham et al. reported that postprandial BP was 
lower in all positions (standing, sitting and lying) after consuming three large meals compared 
with six smaller meals with identical caloric intake in seven subjects with primary autonomic 
failure (Figure 1.6) [13]. Increasing the carbohydrate load was reported to induce greater 
postprandial falls in systolic and diastolic BP and exacerbate symptoms in elderly patients with 




PPH [147]. Avoiding simple carbohydrate and consuming small-volume meals is also advised 
in patients with dumping syndrome [57, 148]. 
 
Glucose substitutes 
As discussed, glucose is the most potent of the monosaccharides and more potent than fat and 
protein in inducing a fall in BP. The replacement of glucose with low nutritive sweeteners as 
well as non-nutritive sweeteners might represent a simple, and effective, way in preventing 
PPH. This issue represents the focus of the study reported in Chapter 6 and the systematic 
review reported in Chapter 5.  
 
Protein intake 
Watson et al. have shown that short-term consumption (12 weeks) of a small amount of protein 
before meals twice daily in patients with well-controlled T2D reduces postprandial blood 
glucose by slowing gastric emptying [149], a strategy which may be applicable to the 
management of PPH. In a pilot study, high protein meals had no effects on symptoms of 
hypotension in patients undergoing haemodialysis [150]. The study reported in Chapter 8 
evaluates the effect of a protein ‘preload’ on postprandial BP in healthy older subjects.  
 
1.5.1.2 Fluid intake 
Intuitively, maintenance of intravascular volume in subjects predisposed to a postprandial fall 
in BP is important [1]. Ensuring adequate fluid and salt intake may facilitate the maintenance 
of intravascular volume and, therefore, minimise postprandial hypotension and its symptoms 
[151]. Similarly, it may be appropriate to withdraw or reduce diuretic therapy [152, 153]. 
Frusemide has been shown to increase the risk of PPH and is best-avoided [154]. 
 




1.5.1.3 Slowing of gastric emptying and small intestinal nutrient exposure 
Guar gum, a gel-forming, unpalatable, and unabsorbable carbohydrate, derived primarily from 
the ground endosperm of guar beans and used as a bulking agent, has been shown to attenuate 
the postprandial fall in BP in healthy older subjects [22] and patients with T2D [155] when 
administered with a 50g glucose drink. The effects of guar on BP may be attributable to a 
number of mechanisms, including slowing of gastric emptying by increasing the viscosity of 
the intragastric content, and delaying small intestinal nutrient absorption by acting as a physical 
barrier between glucose and the small intestinal mucosal cells [22, 155]. Jang et al. have 
reported that postprandial systolic BP is greater, and the prevalence of PPH is less, after 
ingestion of a semi-fluid (rice (210g), soup (100g) and side dishes (70g)) with 9g guar, 
compared with control [156]. Consistent with these observations, an ID infusion of glucose (3 
kcal/min) and guar (4g) was associated with a lesser fall in BP in comparison to a glucose 
infusion alone in healthy older subjects [23]. The potential use of guar in the management of 
PPH, unfortunately, is compromised markedly by its poor palatability and frequent 
gastrointestinal adverse effects including diarrhoea and flatulence.  
 
As discussed, gastric distension has the potential to represent a simple and effective treatment 
for PPH [11, 140, 142, 157]. In patients with autonomic failure and in elderly people, drinking 
water prior to a meal attenuates the postprandial decrease in BP [11, 140-142]. Shannon et al. 
demonstrated that drinking water even in volume as low as 120 mL induced a substantial 
pressor effect in patients with primary autonomic failure [11]. Furthermore, in this study, 
systolic BP was substantially higher when the volume of water was increased to 480 mL [11]. 
Consistent with this, Jones et al. demonstrated that the fall in systolic and diastolic BP is greater 
during the first 60 min when glucose is given in a smaller volume (200 mL vs 600 mL) in 
healthy older subjects [140]. (Figure 1.7), while Gentilcore et al. reported that gastric distension 




by intragastric infusion of water (300 mL) substantially inhibits the hypotensive response to 
the con-current ID glucose infusion in healthy elderly [15]. The effects of gastric distension 
are addressed further in Chapter 7.  
 
1.5.1.4 Exercise 
The effect of postprandial exercise on PPH appears limited. Oberman et al. found that a 20-
minute walk after a meal had a pressor effect in frail older people [16]. However, this effect 
was transient and existent during the exercise [16]. More recently, 2 other studies have reported 
that intermittent walking attenuates the hypotensive response to a 50g glucose load in patients 
with PPH [158, 159]. Further studies are indicated.  
 
1.5.2 Pharmacological  
1.5.2.1 Caffeine 
Caffeine suppresses adenosine-mediated splanchnic vasodilatation, and has accordingly, been 
suggested as a treatment for symptomatic patients [160, 161]. While there is evidence that 
caffeine may attenuate the postprandial fall in BP in healthy older subjects and patients with 
autonomic neuropathy when it is given immediately before or after a meal [160, 161], these 
studies were conducted in small cohorts (n ⩽ 6).  In contrast, Lipsitz et al found that ingesting 
250 mg caffeine during a meal failed to decrease the fall in systolic BP in autonomic failure 









1.5.2.2 α-glucosidase inhibitors 
α-glucosidase inhibitors such as acarbose, voglibose and miglitol are often used in the treatment 
of T2D to lower blood glucose. Their suppressive effect on postprandial hyperglycaemia 
without the risk of hypoglycaemia has been attributed to slowing gastric emptying [18, 162, 
163] and small intestinal absorption of carbohydrate [164, 165]. More recently, these drugs 
have been found to attenuate the fall in postprandial BP in healthy older people, patients with 
T2D and in those with neurologic disorders [18, 126, 166, 167], possibly in part, by inhibiting 
the release of  vasodilatory peptides [126, 166] and stimulating the release of GLP-1 [18, 162, 
163, 168-170]. A patient with T1D and severe PPH symptoms was reportedly treated 
successfully with acarbose [37]. Interestingly, Gentilcore et al. reported that when the 
protective factor of gastric distension is ‘bypassed’ by infusing sucrose directly into the 
duodenum, acarbose still attenuates the rise in splanchnic blood flow and the postprandial fall 
in BP [107]. α-glucosidase inhibitors are associated with a high prevalence of gastrointestinal 
adverse effects which may compromise their use [107, 167], however, they appear promising 
in pharmacologic management for PPH. Moreover, acarbose has the potential to have additive 
or synergistic effects to those of gastric distension. This use is addressed in the study reported 
in Chapter 7.   
 
1.5.2.3 Somatostatin analogues 
Octreotide, a somatostatin analogue, attenuates the postprandial fall in BP in healthy older 
people, patients with autonomic failure and hypertension [19, 45, 171, 172]. Its anti-
hypotensive effect probably reflects suppression of the secretion of vasoactive gastrointestinal 
hormones and/or insulin and increasing splanchnic and peripheral vascular resistance [19, 171]. 
In a seminal study, Jansen et al. showed that a single dose of subcutaneous octreotide (50 




micrograms) completely abolished the postprandial decrease in systolic BP in healthy older 
people and hypertensive patients following an oral glucose load [19]. In another study 
involving 18 patients with primary autonomic failure, both systolic and diastolic BPs were 
greater after octreotide compared with control [172]. Octreotide has also been shown to delay 
gastric emptying in healthy subjects [173-175]. Although octreotide has been proven promising 
in PPH treatment, its use is compromised by its expense, the inconvenience of daily injections 
and a high prevalence of adverse effects [20, 45]. Lanreotide, a long-acting somatostatin 
analogue, reportedly reduces the meal-induced splanchnic hyperaemia in healthy subjects 
[176], and has the potential to improve both compliance and patient quality of life [177]. 
However, there have been no studies focusing on its effect on postprandial BP.  
 
1.5.2.4 GLP-1 receptor agonists  
GLP-1 receptor agonists (GLP-1RAs) are now widely used in the management of T2D. ‘Short-
acting’ GLP-1RAs (exenatide BID and lixisenatide) reduce postprandial glycaemic excursions 
markedly, primarily as a result of slowing gastric emptying [178].  
 
In a recent study by our group [111], both healthy (n = 15) and T2D (n = 15) participants were 
given an acute subcutaneous administration of either 10mcg lixisenatide or matching placebo 
30 min before a 75g glucose drink. This study was stimulated by the positive effects of 
intravenous GLP-1 to reduce the hypotensive response to oral [109] and ID [106] glucose. 
Lixisenatide markedly slowed gastric emptying of the glucose drink [111, 179] (Figure 1.8), 
but also attenuated the increase in SMA flow and prevented glucose-induced fall in BP. In 
T2D, intravenous exenatide has been reported to attenuate the fall in BP during an ID glucose 
infusion, presumably via slowing of small intestinal absorption and transit [180]. These studies 
have established ‘proof-of-principle’ for the use of ‘short-acting’ GLP-1 RAs in the 




management of PPH. These drugs are relatively expensive, but in general, well-tolerated: 
further studies are required.   
 
1.5.2.5 Metformin 
Metformin, the oldest and most widely used glucose-lowering drug, is the ‘first-line’ 
medication for the treatment of T2D [181]. Metformin may have a preventive effect on 
cardiovascular disease [182]. A meta-analysis reported that in patients without diabetes, 
metformin is able to decrease systolic, but not diastolic, BP [183]. The effect of metformin on 
BP in T2D patients is inconsistent. Some early studies, in T2D patients with hypertension, 
reported a slight decrease in systolic BP after metformin [184, 185], however, this was not the 
case in all studies [186, 187]. In contrast, Borg et al. recently reported that compared with saline 
control, an acute dose of metformin (1g) administered intravenously 60 minutes before a 50g 
glucose in subjects with well-controlled T2D prevented any fall in SBP, slowed gastric 
emptying and increased plasma GLP-1 concentrations [188]. The number of participants in this 
study was small (n = 10) and more evidence is required about the potential applicability of 
metformin in the management of PPH in patients with and without diabetes. 
 
1.5.2.6 Other medications 
Levodopa, combined with a peripheral decarboxylase inhibitor (PDI) such as carbidopa, is the 
most effective and most frequently used medication in the treatment of elderly patients with 
Parkinson’s disease [189, 190]. Levodopa therapy has also been shown to slow gastric 
emptying, supporting the concept that dopaminergic therapy induces clinically important 
delays in gastric emptying [191, 192]. However, surprisingly, there have been no studies 
investigating the effect of an acute levodopa intake on gastric emptying in Parkinson’s disease. 




If levodopa is found to delay gastric emptying, this may represent a new therapeutic approach 
to the management of PPH, particularly in Parkinson’s patients who are not on dopaminergic 
medication.  
 
Numerous other pharmacologic agents have been explored in the treatment of PPH, but none 
of them has consistently shown benefit. These include midodrine (an α-1 agonist) [193, 194], 
dihydoergotamine mesylate [193, 194], denopamine (beta-1 agonist) [194], nitrendipine [12], 
hydrochlorothiazide [195], indomethacine, cimetidine, diphenhydramine [196], 5-
hydroxytryptamine [197] and vasopressin [85].  
 
1.6 Conclusions  
This chapter represents a summary of current knowledge in relation to PPH, with a particular 
emphasis on the prevalence, clinical relevance, pathophysiology and management strategies. 
In this thesis, studies were performed to evaluate the following:  
 
1. Longitudinal changes in the BP responses to, and gastric emptying of, an oral glucose 
load in healthy older subjects (Chapter 4).  
2. Systematic review: Acute effects of nutritive and non-nutritive sweeteners on 
postprandial BP (Chapter 5).  
3. Effects of ID administration of the artificial sweetener, sucralose, on BP and SMA 
blood flow in healthy older subjects (Chapter 6).  
4. Acute effects of acarbose and gastric distension, alone and combined, on postprandial 
blood pressure in healthy older adults (Chapter 7). 
 




5. Effects of guar and whey containing preload (Omniblend) on gastric emptying, 
glycaemia, small intestinal absorption and BP responses to oral glucose in healthy older 























Figure 1.1. Kaplan-Meier survival analysis by degree of postprandial fall in systolic blood 
pressure. Log‐rank test P = 0.009 [68]. 
  





Figure 1.2. a) Change in mean arterial pressure (MAP) from baseline after a 75g glucose load 
in patients with T2D, as well as healthy young and older subjects and b) relationship between 
the area under the curve for the change in MAP between 0 – 15 min and the 50% emptying 
time of glucose in patients with T2D (n = 16). Data are mean values ± SE [7]. 
  





Figure 1.3. Effects of ID glucose at loads of 1 kcal/min (G1), 2 kcal/min (G2) 3 kcal/min (G3), 
or saline (S) on change in systolic BP in healthy older subjects (n = 12). Data are mean values 
± SE [24]. 
  






Figure 1.4. Effects of ID infusion of glucose, fat, protein and saline on SMA flow in healthy 
older subjects (n = 8) : *P < 0.01 for glucose compared with saline; †P = 0.04 for glucose 
compared with fat; ‡P < 0.05 for glucose compared with protein; P < 0.01 for fat compared 
with saline; #P < 0.05 for protein compared with saline; P < 0.01 for fat compared with protein. 
Data are mean values ± SE [9]. 
  





Figure 1.5. Changes (Δ) in systolic BP in 8 healthy older subjects after 75g glucose oral (○) 
and ID (•) glucose. Data are mean values ± SE [139]. 
  





Figure 1.6. The effect of meal size on postprandial systolic (SBP) and diastolic (DBP) BP in 
patients with autonomic failure (n = 7).  Data are mean values ± SE [13]. 
  






Figure 1.7. Effects of drink volume on systolic (A) and diastolic (B) BP after ingestion of 12% 
glucose drinks (25 g/200 mL vs. 75 g/600 mL) in healthy older subjects (n = 10). Data are mean 
values ± SE [140]. 
  







Figure 1.8. Effects of lixisenatide on (A, B) systolic blood pressure (BP), (C, D) diastolic BP 
and (E, F) heart rate (HR) responses to a 75g glucose drink in healthy participants (n = 15) and 
participants with T2D (n = 15). Data are mean values ± SE [111].  
 
 






Physiology of gastric emptying 
  




2.1 Introduction  
The primary functions of the stomach are to accommodate, mix and grind ingested food, and 
deliver nutrients into the small intestine at a regulated rate for their optimal digestion and 
absorption. This chapter reviews recent insights into gastric motor function, with a focus on 
the physiological role of the proximal and distal stomach, particularly in relation to gastric 
emptying. 
 
2.2 Physiology of gastric emptying  
Historically, substantial technical challenges compromised the extent of experimental 
investigation and, accordingly, the capacity to understand the physiology and pathophysiology 
of gastric emptying in humans [69, 198]. However, during the past 4 decades the development 
and application of sophisticated techniques, particularly, the ‘gold standard’ measurement of 
gastric emptying, scintigraphy, have provided fundamental information about normal and 
disordered gastric physiology [199]. Recently, several studies have provided novel insights into 
factors of importance to the physiology of gastric emptying, including neural loops, 
gastrointestinal hormones, smooth muscle and the interstitial cells of  Cajal [200].  
 
2.2.1 Role of the stomach  
During the ‘active’ state when food is ingested into the stomach, gastric emptying can be 
divided into three separate, but inter-related, phases [69, 198, 200]:  
(i) initial ‘storage’ of ingested food with increases in gastric compliance and fundic volume to 
accommodate food,  
(ii) ‘mixing’ ingested food with gastric acid and pepsin and ‘grinding’ of solids to particles 1 - 
2mm in size within the gastric antrum,  




(iii) controlled ‘delivery’ of chyme into the small intestine, via coordinated antral and pyloric 
contractions regulated by inhibitory feedback arising from the small intestine.  
 
The stomach can be divided into the proximal and distal segments by a mid-gastric transverse 
band, which may be functionally important in the intragastric redistribution of ingested solids 
[201]. In contrast to liquids which propagate quickly throughout the stomach, solids initially 
remain in the fundus, then are dispersed slowly towards the antrum by fundal rhythmic 
contractions [202, 203]. The integration of motor activity in the proximal stomach, antrum, 
pylorus and proximal small intestine [69, 204] generates bidirectional flow (antegrade and 
retrograde), which is variable between individuals [205] (Figure 2.1). This process is 
characterised by predominantly pulsatile, rather than continuous, movement of liquefied food 
(chyme) from the stomach into the duodenum [69, 203, 204]. Smooth muscles in different 
regions of the stomach vary in their contraction phenotype [200]. For example, while smooth 
muscles in the proximal stomach primarily exhibit tonic contractions, contractions are 
characteristically periodic in the distal stomach, and both tonic and periodic phenotypes are 
evident at the pylorus [200].  
 
2.2.2 Proximal stomach  
Food delivered from the oesophagus is initially retained in the fundus and upper part of the 
corpus of the stomach. During ingestion, vagally mediated transient ‘receptive’ relaxation is 
followed by the activation of the proximal stomach to accommodate ingested food. Therefore, 
an increasing volume of ingested food only causes minor elevations in intragastric pressure 
[202, 206, 207].  
 




2.2.3 Distal stomach  
In the fasted state, the antrum exhibits three patterns of motor activity with a duration of ~ 100 
minutes: (i) quiescence (phase 1 with a duration of ~ 40 minutes), (ii) irregular contractions 
(phase 2, with a duration of ~ 50 minutes), and (iii) regular contractions at a frequency of ~ 
3/min for 5-10 minutes, the so-called ‘migrating motor complex’ (MMC) [208] (Figure 2.2). 
Larger nondigestible solids > 2 mm in size are emptied during phase 3 of the MMC.  
 
After solids have moved into the distal stomach, they are mixed and broken down into 1-2 mm 
particles by peristaltic contractions and gastric digestive fluids, before passing through the 
pylorus - so-called ‘trituration’ [208]. This process is modulated by a ‘pacemaker’ located high 
on the greater curvature at the boundary between the fundus and antrum, which discharges 
electrical signals at a rate of about three per minute [202, 203]. The ‘pacemaker’ represents a 
network of the interstitial cells of Cajal, found in the circular and longitudinal muscle layers 
within the gastric wall. Although the precise roles of the cells of Cajal are incompletely defined 
[209], these cells are likely to modulate gastric motility in a number of ways, including 
initiating and pacing slow waves [210], driving electrical signals into smooth muscle cells 
which induce slow waves [211] and serving as mechanosensors [212]. Distal stomach 
contractile activity is always associated with gastric slow waves [208], however, the slow-wave 
persists even in the absence of gastric contractile activity [208, 213]. Contractile activity is 
only initiated when excitatory neurotransmitters are released. In humans, the velocity of slow 
waves increases from proximal to the distal stomach - the velocity at the mid-corpus 








2.2.4 Pylorus and proximal duodenum  
The pylorus serves as a brake to prevent particles larger than 2 mm from entering the duodenum 
[215] by exerting both tonic and phasic contractile activity over a narrow zone of 
approximately 2mm. Moreover, the pyloric sphincter and the proximal duodenum interact 
closely to stimulate or inhibit emptying during the digestive state [200, 216] - so-called 
“antroduodenal coordination” [200]. The pyloric sphincter closes to prevent further gastric 
emptying when the proximal duodenum contracts to pump the chyme aborally into the second 
segment of the duodenum. In contrast, the duodenum ‘relaxes’ to facilitate gastric emptying 
during antral contractions [200].  
 
2.2.5 Patterns of gastric emptying 
Normally, it takes approximately 2-3 hours for the stomach to empty the majority of both 
liquids and digestible solids during the digestive state. The small percentage of remaining 
unground food empties into the duodenum during the inter-digestive state [217]. The patterns 
of gastric emptying are strongly determined by the physical and chemical composition of 
ingested food and there is a striking difference between the emptying of liquids and solids from 
the stomach [69, 202].  
 
2.2.5.1 Solids  
Following a meal, solids are confined within the proximal stomach which functions as ‘the 
housekeeper’ of the stomach. Solids are then emptied from the stomach through a biphasic 
pattern including the lag phase and the linear emptying phase. The lag phase lasts ~ 20 - 40 
minutes during which solids are distributed from the proximal to the distal stomach and 
triturated into smaller particles (1–2 mm). The following phase occurs over 3–4 hours, almost 




in a linear pattern, with digestible solids passing through the pylorus (Figure 2.3) [73, 202, 
218]. The interaction between nutrients and duodenal receptors induces negative feedback in 
order to maintain a constant outflow from the stomach [202].  
 
2.2.5.2 Liquids  
Liquids are rapidly distributed within the stomach and their emptying commences essentially 
immediately following ingestion, with a minor, if any, lag phase. Emptying of non-nutrient 
liquids normally follows a mono-exponential pattern (Figure 2.3) reflecting the effects of 
intragastric volume and gravity [218]. In contrast, emptying of densely nutrient liquids follows 
a linear pattern similar to that of solids, but without a lag phase. The stomach is able to process 
gastric emptying of solids and liquids separately [219]. Liquids empty preferably so that ~ 80% 
empties before solid emptying commences so that emptying of solids is delayed by liquids.  
 
2.3 Regulation of gastric emptying  
The regulation of gastric emptying is complex and a number of interactive mechanisms 
generate inhibitory small intestinal feedback. As a result of this, nutrients are normally 
delivered into the duodenum at a rate between 1– 4 kcal/min [220, 221].  
 
2.3.1 Neural regulation 
Although the stomach possesses its own intrinsic neural plexuses that allow it to operate 
autonomically to a certain degree via the MMC, extrinsic neural signals arising from the central 
nervous system through parasympathetic and sympathetic pathways are also important [222]. 
While the sympathetic nervous system is primarily responsible for inhibiting intraluminal 
muscle activity and mucosal secretion and modulating blood flow, the parasympathetic nervous 




system exerts both inhibitory and excitatory effects to regulate gastric emptying (ie. tone, 
contractility) through the inhibitory and excitatory vagal loops [200, 222, 223].  The inhibitory 
vagal motor loop is fundamental to the regulation of gastric motility, while the excitatory loop 
contributes to the release of gastric acid and hormones [222]. Inhibition of the MMC in the 
stomach by food induces vagal stimulation [200, 222, 224].  
 
2.3.2 Nutrient composition 
The rate of gastric emptying when expressed as kcal emptied per min, in a given individual, is 
relatively predictable irrespective of the volume and caloric content of a meal - but the 
interindividual variation is much larger. The exposure of nutrients to luminal receptors 
distributed throughout the small intestine creates neurohormonal feedback. Various nutrients 
(i.e. glucose, fatty acids, and amino acids) and their characteristics (i.e. acidity, osmolarity) are 
sensed by specific small intestinal receptors with differences in regional distribution, number 
and type [208, 225]. Using magnetic resonance imaging to quantify gastric emptying of three 
macronutrients, Goetze et al. reported that while glucose and protein were emptied comparably, 
the gastric emptying rate of fat was significantly slower [226]. This probably reflects the 
physical characteristics of fat which, as an ‘oil’ phase, has the capability to ‘layer’ on top of 
more dense meal components as determined by posture/gravity [227]. Intraduodenal infusion 
of triglyceride, protein or fat, induces a substantial slowing in the rate of gastric emptying by 
suppressing antroduodenal pressure waves, triggering local pyloric tonic and phasic 
contractions and attenuating the tone of the proximal stomach [228]. The magnitude of small 
intestinal feedback is determined by the length and region of small intestine exposed to 
nutrients [221]. Repeated nutrient exposure may also impact gastric emptying function through 
adaptive mechanisms [229]. For example, previous exposure to a high-fat diet is associated 




with a faster gastric emptying rate of fat at subsequent meals [229]. This is also the case when 
the gastric emptying of glucose accelerates after short-term consumption of glucose [230, 231]. 
 
2.3.3 Hormonal regulation 
The ingestion of macronutrients induces the release of several hormones from the 
gastrointestinal tract and other tissues [232-234]. These hormones can be divided into two 
groups according to their effect on the rate of gastric emptying: inhibitory hormones include 
cholecystokinin (CCK), glucagon-like peptide-1 (GLP-1) and leptin, while ghrelin and motilin 
have stimulatory properties [200]. CCK release from the intestinal I cells largely results from 
digestion of dietary lipid into long-chain fatty acids [235], and inhibits the secretion of both 
gastrin and gastric acid while also decreasing gastrointestinal motility by activating vagal 
afferent fibres [235, 236]. GLP-1 is released from L cells in the small intestine and colon; and 
as discussed in Chapter 3, stimulates insulin secretion while inhibiting glucagon secretion in 
a glucose-dependent fashion [119]. GLP-1 has been shown to increase fasting and postprandial 
gastric volumes while slowing gastric emptying [237], possibly reflecting stimulatory effects 
on vagal nitrergic pathways [237, 238] and vagal afferents originating from the gastrointestinal 
tract [238, 239]. Leptin is secreted from gastric chief (parietal) cells in the gastric mucosa [240] 
and has complex effects [241], interacting with the vagus nerve and CCK to delay gastric 
emptying in response to protein meals [241]. Leptin insufficiency is associated with an 
increased rate of gastric emptying [242]. Interestingly, the secretion of stimulatory hormones 
is temporarily inhibited during the inter-digestive state [200]; ghrelin and motilin are only 
secreted when there are no nutrients remaining in the stomach or duodenum to expedite gastric 
emptying [200, 243]. Ghrelin, released from G cells of the stomach, stimulates gastric emptying 
of liquids and solids through effects on autonomic functions [243]. Agonists of ghrelin have 
been developed and may be of therapeutic benefit for the management of gastroparesis [243, 




244]. Motilin is secreted from M cells of the stomach and accelerates gastric emptying through 
its interaction with gastric enteric neurons [243]. Agonists of motilin - the first characterised 
was the antibiotic, erythromycin [245] are in use, and development for the management of 
gastroparesis [246, 247].   
 
2.3.4 Ageing and gastric emptying 
Ageing is associated with a modest slowing of gastric emptying, however the rate still generally 
varies within the physiological range from 1-4 kcal/min [248-250]. Normal ageing is associated 
with impaired regulation of gastric emptying [249] - although the frequency of antegrade flow 
pulses decreases with age [251], the overall gastric contractile activity is well-preserved [250, 
252]. Notably, there is a significant reduction in sensory response to mechanical distention, 
particularly at proximal stomach [250], due to age-related loss in enteric neurons and interstitial 
cells of Cajal [249, 250]. This neuron cell loss also results in decreased acid secretion (~30%) 
[253], and increased pre and postprandial CCK and GLP-1 levels [254, 255] which may be 
related to delayed gastric emptying, decreased ghrelin [256, 257] and increased leptin levels 
[249, 258].  
 
2.4 Measurement of gastric emptying 
There are several available techniques to quantify gastric emptying which can be divided into 
imaging and non-imaging groups. This section describes the most widely used techniques with 
a focus on the two techniques used in my research studies described in Chapter 4, 8 and 9: 
scintigraphy and the stable isotope breath test. 
 
 





Scintigraphy, regarded as the ‘gold standard’ technique for the assessment of gastric emptying 
[259] and intragastric meal distribution [260]. The rate of gastric emptying can be determined 
by imaging radiolabelled meal components with a gamma camera. The duration of the study 
can range from as short as 60 minutes up to 4 hours, depending on the composition of the meal, 
to improve the diagnosis of disordered emptying [259]. Radioisotopic images are acquired 
anteriorly or posteriorly with a single-headed camera or simultaneous anterior and posterior 
images with dual-headed camera in the standing, sitting or lying position in either dynamic 
mode ie 30-60 sec frames for the first 30-60 min (to capture the so-called lag phase – the time 
immediately preceding that in which food empties into the small intestine), followed by 2-3 
min frames for the remainder of the study following ingestion of a radiolabelled test meal [259]. 
Data are then corrected for subject movement, gamma-ray attenuation and radionuclide decay, 
depending on the radiopharmaceutical employed, and in the case of a dual-isotope study in 
which two different meal components eg solids and liquids, can be measured simultaneously 
using two different radioisotopes, data can be corrected for downscatter from one energy 
window into another. Regions of interest are drawn around the stomach manually or using an 
automated program and the percentage retention of the meal can be plotted to generate a gastric 
emptying curve where time zero is 100%. Despite its long-term and common use in clinical 
and experimental settings, the technique is associated with some limitations i.e. variations in 
test meal, duration of image acquisition and patient positioning, lack of availability in a rural 









2.4.2 Stable isotope breath test 
The stable isotope breath test is a non-invasive, non-imaging method, representing an 
alternative to scintigraphy to measure gastric emptying [260]. This method utilises stable 
isotopes eg 13C-octanoic acid, 13C-spirulina platensis or 13C-acetate to label solid or liquid 
meals. The method is indirect i.e. it relies on gastric emptying and subsequent absorption from 
the small intestine [260]. 13C is subsequently oxidised in liver and expelled through lungs as 
CO2 [262]. Exhaled end-tidal breath samples are collected into sealed bags right prior to the 
ingestion of test meal and every 5 min for the first hour, and then every 15 min for up to the 
subsequent 3 hours. The time points and duration of breath sample collection can be adapted 
to different study protocols. Concentrations of 13CO2 are measured using computer isotope 
ratio mass spectrometry [263]. A 50% emptying time (T50) can be calculated using the formula 
described by Ghoos et al. [264]. Compared to scintigraphy, the stable isotope breath has some 
advantages. It can be performed at the bedside or in a doctors office and there are no risks 
induced by radiation exposure, hence it can be used safely in pregnant and breastfeeding 
females and children. The test is much more economical and may be repeated several times 
with reasonable reproducibility [265].  However, some factors should be taken into account 
during the result interpretation. Given that it is an indirect technique, dependent on the 
involvement of multiple organs including the small intestine (absorption), liver (oxidation), 
and lungs (emission) [263]. While this technique has been shown to correlate with scintigraphy, 
it produces a longer gastric emptying time [266].  The accuracy of the test may also be 
compromised by conditions that alter the normal absorption rate of the small intestine [260, 
263]. Therefore, the results of stable isotope breath tests should be considered notional rather 
than accurate [7]. 
 
 





2.4.3 Wireless motility capsule 
The wireless motility capsule (WMC) is a non-digestible capsule orally ingested to monitor 
chronologically the change in pH, pressure and temperature of the gastrointestinal tract [263]. 
Gastric emptying is calculated indirectly based on the recorded increase in intragastric acidity 
[263]. Despite the advantage of a non-radiation method, this technique only demonstrates a 
modest agreement with data measured by scintigraphy [267, 268]. Furthermore, WMC data 
only reflects the phase III contraction of migrating motor complex (MMC), which is altered by 
hyperglycaemia and proven weaker in T2D, rather than gastric emptying because the device 
empties from the stomach with indigestible solids during the inter-digestive period [262]. 
Accordingly, further evaluation is warranted before the conclusion that it may be used 
alternatively in the assessment of gastric emptying can be drawn [268]. 
 
2.4.4 Ultrasound  
Ultrasound providing real-time measurements of gastric distension and gastric emptying at 
fixed time intervals after a standardised solid/liquid meal has been used widely in research and 
clinical settings [269]. It has also been used to evaluate non-lumen occlusive antral 
contractility, and transpyloric flow [267].  2D ultrasound involves measuring changes in the 
antral area to calculate gastric emptying, whereas 3D ultrasound can be used to assess changes 
in the volume of the entire stomach. The latter provides more accurate information on gastric 
emptying but requires an expensive 3D transducer and processing software [261]. Advantages 
of ultrasound include the absence of radiation exposure, lower running costs and quantitative 
information on intragastric distribution and volume [260, 261]. Ultrasound has been shown to 
be well correlated with scintigraphy in measuring the gastric emptying of liquids [270]. 




However, the use of this modality requires an experienced operator and can be associated with 
some technical difficulties e.g. the presence of bowel gas or when scanning obese subjects 
[261]. 
 
2.4.5 Magnetic resonance imaging  
Magnetic resonance imaging (MRI) has the potential to become an imaging modality of choice 
in the assessment of both gastric emptying and gastric motility at the same time [271]. 
Compared to scintigraphy, it is not associated with a radiation burden and has a shorter 
acquisition time [271]. A previous study demonstrated a good correlation between MRI and 
scintigraphy in quantifying gastric emptying on lung transplant patients [271]. However, this 
technique remains primarily used in the research setting and further studies are required before 
it can be used widely for clinical purposes [261]. 
 
2.4.6 Acetaminophen absorption technique 
Acetaminophen absorption, a non-imaging old-fashioned technique to measure gastric 
emptying, is based on the principles that no or very little, if any, acetaminophen is absorbed 
from the stomach and that there is a linear correlation between the acetaminophen absorption 
rate into the bloodstream and gastric emptying [272]. This technique does not require any 
special equipment. However, the test result primarily presents the gastric emptying rate of 
liquids [261] and a portion of paracetamol is emptied from the stomach much quicker than the 
meal [273]. Furthermore, this technique is affected by variations in several extragastric factors 
such as first-pass hepatic metabolism, volume of distribution, and elimination of 
acetaminophen [261]. Accordingly, it should not be considered an accurate method. 
 




2.5 Conclusions  
This chapter outlines the current understanding of normal gastric motor function and gastric 
emptying. The major roles of the stomach are to initially store and then convert ingested food 
into chyme, as well as regulate gastric emptying to deliver nutrients into the duodenum. Gastric 
emptying is a rhythmically pulsatile process and regulated tightly and primarily by small 
intestinal feedback. Gastric emptying is now considered a major determinant of the 
postprandial fall in blood pressure as discussed in Chapter 1, and postprandial glycaemia as 
discussed in Chapter 3, while the effects of ageing on gastric emptying in relation to 
postprandial hypotension (PPH) and incretin hormones are explored in Chapter 4 and Chapter 
9 respectively.  







Figure 2.1. Motor events during normal gastric emptying. The fundus relaxes to accommodate 
the meal, while the antrum grinds and sieves solids, pumping the resultant chyme into the 
duodenum against resistance generated by phasic and tonic pyloric contractions. The presence 
of nutrients in the small intestine generates neurohumoral feedback on gastric motor function, 
enhancing fundic relaxation and pyloric contraction, while suppressing antral motility, with the 
net effect that further emptying is closely regulated [198]. 
  








Figure 2.2. Schema of migrating motor complex (MMC) which occurs periodically (1–2 hour 
cycle) during the digestive state and is characterised by three phases usually arising in the 
antrum: contractile activity is absent during phase I, irregular activity occurs during phase II, 














Figure 2.3. Gastric emptying curves for a solid (▲) and liquid (●) meal in a healthy volunteer. 
Liquid emptying begins immediately and follows an exponential fashion, while the solid 
emptying is linear after an initial lag phase  [275]. 
 
 







Gastric emptying and glycaemia 
  





3.1 Introduction  
Type 2 diabetes (T2D) is characterised by dysfunctional nutrient metabolism that leads to an 
abnormally increased glucose concentration. While the pancreatic hormones, insulin and 
glucagon, play major roles in regulating both fasting and postprandial glycaemia, it is now 
appreciated that the regulation of blood glucose homeostasis is complex, involving 
multifactorial interactions between the brain-gut axis, liver, kidney, gastrointestinal tract, and 
muscle. This chapter focuses on the interdependent relationship of gastric emptying with 
glycaemia in healthy and diabetes that are relevant to the studies pursued by the PhD candidate 
and reported in Chapter 9.  
 
The gastrointestinal tract is recognised as crucial to the regulation of plasma glucose 
concentrations, which are tightly controlled in health even though there is a substantial 
difference in glucose concentrations between the inter-digestive (fasting) and intra-digestive 
(fed) states. In the inter-digestive state, the plasma glucose concentration represents the balance 
between the release of endogenous glucose and glucose uptake by body organs as determined 
by insulin and glucagon secretion [276] and accounts for ~50% of the variance in blood glucose 
concentrations [276]. Food intake drives more complex glucose-regulatory processes given 
that absorbed nutrients represent an exogenous glucose source [277]. Insulin secretion from 
pancreatic beta cells increases sharply to transport glucose into peripheral tissues and 
suppresses glucose generation by the liver. In addition, glucagon released from pancreatic α 
cells is suppressed to also limit the magnitude of the postprandial rise in blood glucose [277], 
which is determined by the surplus of glucose production and glucose disposal.  In healthy 
subjects, blood glucose concentrations rise approximately 10 minutes after ingestion of a 
carbohydrate-containing meal to usually achieve a maximal value within the first hour [278]. 
If the maximal rise in blood glucose occurs after 2 h, it is suggestive of disordered glucose 





disposal into peripheral issues [278]. The gastrointestinal tract accounts for two pivotal 
contributions to postprandial glucose regulation - the ‘incretin effect’ and the rate of gastric 
emptying (Figure 3.1).  
 
3.2 The incretin effect - GLP-1 and GIP 
The ‘incretin effect’ refers to the phenomenon by which oral, or enteral, administration of 
glucose results in a substantially greater insulin secretory response when compared to an 
intravenous infusion resulting in the same glucose concentrations [279], accounting for 50 – 
70% of total insulin secretion following oral glucose in healthy subjects [119] (Figure 3.2). The 
interaction between nutrients and the small intestine signals enteroendocrine cells to release 
the two known incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent 
insulinotropic peptide (GIP). K cells, located predominantly in the proximal small intestine, 
secrete GIP primarily in response to glucose or fat ingestion [119]; while L cells, located 
predominantly in the distal ileum and colon, secrete GLP-1 in response to fat, carbohydrate, 
protein and bile acids [280, 281].  
 
The insulinotropic effects of both hormones are glucose-dependent, requiring a ‘threshold’ 
blood glucose > 8 mmol/L [119]. In addition, GLP-1 suppresses, while GIP may stimulate, 
glucagon secretion. While GIP has little or no effect on gastric emptying [282], GLP-1 delays 
gastric emptying [282] and enhances satiety to reduce food intake [119]. The circulating half-
lives of GLP-1 and GIP are very short (2 min and 5-7 min respectively) and both are degraded 
quickly by the ubiquitous enzyme, dipeptidyl peptidase-4 (DPP-4) [119]. In healthy subjects 
and patients with T2D [283-285], exogenous GLP-1 slows gastric emptying of liquids and 
solids in a dose-dependent fashion, by suppressing antro-duodenal contractility, enhancing the 
pyloric tone and relaxing the proximal stomach [286]. Accordingly, GLP-1 reduces, rather than 





increases, postprandial insulin concentrations [285]. The magnitude of the slowing of gastric 
emptying by exogenous administration of GLP-1 diminishes with sustained administration for 
〜 24 h, i.e. there is tachyphylaxis, but the magnitude of the slowing is still substantial at this 
time [287].  
 
In T2D the insulinotropic action of exogenous GLP-1 is relatively maintained [288]. In 
contrast, the insulinotropic effect of GIP, which may be the dominant incretin in health, is 
markedly attenuated [119, 289, 290]. This has stimulated the development of GLP-1 based 
medications for the management of T2D.  Currently, two GLP-1 therapies are in use [291]: 
oral DPP-4 inhibitors (e.g. sitagliptin, vildagliptin and alogliptin) [292], which enhance the 
effects of endogenous GLP-1 by inhibiting its breakdown, and subcutaneous GLP-1 receptor 
agonists (e.g. exenatide, liraglutide and lixisenatide) [293], which mimic the effects of 
endogenous GLP-1 by binding to GLP-1 receptors but are resistant to DPP-4 induced 
biodegradation [291]. Based on their half-lives, GLP-1 receptor agonists can be categorised as 
‘short-acting’ (e.g. exenatide twice daily and lixisenatide) and ‘long-acting’ (e.g. exenatide 
once weekly and liraglutide) [291, 294]. ‘Short-acting’ GLP-1 receptor agonists have a 
dominant effect to reduce postprandial glycaemia, while with ‘long-acting’ agonists effects on 
preprandial glucose predominate [295]. With GLP-1 agonists, the risk of hypoglycaemia is low 
because of the glucose-dependency of insulinotropic and glucagonostatic effects [296]. DPP-4 
inhibitors have broader effects than GLP-1 receptor agonists because of influences on other 
gastrointestinal hormones including glucose-dependent insulinotropic peptide (GIP), 
glucagon-like peptide-2 (GLP-2) and peptide YY (PYY).  
 





3.3 Impact of gastric emptying on glycaemia and incretin hormones 
Small intestinal nutrient delivery, which in health is tightly regulated at a rate of approximately 
1-4 kcal per minute [297], is an important determinant of the early (~15 – 60 min) and overall 
glycaemic responses to a meal so that gastric emptying accounts for up to ~35% of the 
fluctuation in the glycaemic response to oral glucose in health [298, 299], type 1 diabetes (T1D) 
and T2D [300, 301]. In T1D and T2D, gastric emptying is more variable - abnormally delayed 
gastric emptying occurs frequently in longstanding, poorly-controlled diabetes [302, 303], 
whereas, as a group well-controlled T2D is associated with relatively more rapid emptying 
[304] (Figure 3.3). The relationship between late (~120 – 180 min after a glucose load) 
glycaemia with gastric emptying is dependent on the timing of insulin secretion triggered by 
the early increase in blood glucose, e.g. in healthy subjects the relationship between the 120 
min glucose and gastric emptying after a 75g glucose load is inverse, rather than direct [299, 
301].  
 
Several studies employing intraduodenal administration of glucose at rates within a 
physiological range of 1–4 kcal/min have established that the correlation between glycaemia 
with small intestinal delivery is non-linear in healthy subjects [305, 306] and patients with diet-
controlled T2D [307]. The increase in blood glucose is moderate after an intraduodenal 
infusion of glucose at 1 kcal/min. In contrast, 2 kcal/min, 3 kcal/min, and 4 kcal/min infusions 
induce much more prominent glycaemic responses with relatively little difference between 
them (Figure 3.4). These findings can be attributed to a substantially greater insulin response 
to the higher glucose infusions (i.e. ≥ 2 kcal/min) which reflects the secretion of GLP-1 and 
GIP [308] - GLP-1 secretion is only substantial at intraduodenal glucose loads > 2 kcal/min 
[306] whereas that of GIP is linear. Accordingly, it is likely that when gastric emptying is ≤ 2 
kcal/min, GIP accounts for a greater contribution to the incretin effect, which is outweighed by 





GLP-1 at higher rates of gastric emptying ≥ 3 kcal/min [306], Consistent with this, Marathe et 
al. demonstrated that the magnitude in the incretin effect is dependent on the intraduodenal 
glucose load in healthy subjects, as well as patients with T2D [308]. However, with the same 
overall intraduodenal load, the stimulation of the incretin effect and insulin secretion by a 
greater early small intestinal glucose delivery only induces a greater insulin concentration at 
the early stage compared to a constant infusion, but does not affect the total glycaemic response 
[309].   
 
Gastric emptying has been modulated by dietary and pharmacological means to improve 
glycaemic control in T2D - these strategies including nutrient ‘preloads’, ‘short-acting’ GLP-
1 receptor agonists and the amylin analogue, pramlintide, which all slow gastric emptying [149, 
310-312]. This approach has been stimulated by the recognition that the major determinant of 
glycated haemoglobin, a marker of the risk of microvascular complications of diabetes in 
patients with ‘reasonable’ glycaemic control (i.e. 7 < HbA1c ≤ 8%), is postprandial glycaemic 
excursions and that the latter need to be normalised to achieve good control.  
 
3.4 Effects of glycaemia on gastric emptying  
The relationship between gastric emptying and glycaemic response is bidirectional, i.e. 
postprandial glucose concentrations also impact on gastric emptying [297, 313]. Acute 
hyperglycaemia - even variations in glucose within the normal postprandial range [314] - slows 
gastric emptying, while acute insulin-induced hypoglycaemia accelerates it substantially [315] 
(Figure 3.5). The blood glucose concentration should, accordingly, be quantified during clinical 
measurements of gastric emptying in people who have diabetes [261] and it is recognised that 
hyperglycaemia may attenuate the response to drugs which accelerate gastric emptying [316] 
and potentiate the response to drugs, including GLP-1, which may slow it [317]. High plasma 





glucose concentrations are known to be associated with the presence of gastric electrical 
dysrhythmias [318] and inhibition of both pre and postprandial antral motor activity [318-320] 
although the underlying mechanisms remain uncertain [321]. The acceleration of gastric 
emptying by hyperglycaemia is likely to represent an important counter-regulatory response 
by increasing the rate of carbohydrate [315, 322].  
 
3.5 Measurement of blood glucose concentrations 
Venous blood sampling is the easiest and most frequently used method to quantify blood 
glucose concentrations [323]. In the fasting state, glucose concentrations measured from 
arterial, capillary and venous blood are highly comparable, whereas the difference between 
arterial and venous blood concentration is up to 20% in postprandial state [324]. This 
arteriovenous discrepancy has been shown to be higher in healthy people compared to diabetic 
patients. Capillary blood glucose concentrations have been shown to correlate well with arterial 
blood glucose ones [325]. However, the use of capillary blood is hindered by a requirement of 
multiple finger pricks for multiple consecutive measurements. The arterialised-venous 
technique, achieved by warming the arm used for venous blood sampling, is applied to utilise 
the convenience of venous sampling method as well as to obtain more comparable readings 
with capillary blood [323]. 
 
3.6 Conclusion  
The relationship of gastric emptying with postprandial glycaemia is important and interrelated, 
and modulated by several factors, particularly the incretin hormones. Gastric emptying is a 
major determinant of postprandial glycaemic excursions which represent the dominant 
contribution to overall glycaemic control (i.e. HbA1c < 8.0%) in diabetes which has stimulated 





the development and widespread application of strategies to improve glycaemic control in T2D 
by slowing gastric emptying. 
 







Figure 3.1. Summary of the interdependent relationships of gastric emptying, incretin 
hormones, and postprandial glycaemia [326].  
  






Figure 3.2. The incretin effect. There is a much greater release of insulin in response to oral 
glucose administration as compared with administration of an isoglycaemic intravenous (IV) 
glucose infusion [327].  
  







Figure 3.3. (A–C) Relationship between the blood glucose increment (at t = 30 and 60 min 
after the meal and the iAUC for blood glucose during 0 to 120 min) and the rate of gastric 
emptying in all patients with T2D. (D–F) Relationship between the blood glucose increment 
(at t = 30 and 60 min after the meal and the iAUC for blood glucose during 0 to 120 min) and 
gastric emptying in the patients with T2D taking metformin. (G–I) Relationship between the 
blood glucose increment (at t = 30 and 60 min after the meal and the iAUC for blood glucose 
for 0 to 120 min) and gastric emptying in the patients with T2D without metformin [304]. 






Figure 3.4. Blood glucose (A) and plasma insulin (B), glucagon-like peptide-1 (GLP-1; C), 
glucose-dependent insulinotropic polypeptide (GIP; D), and cholecystokinin (CCK; E) 
concentrations in response to 120-min intraduodenal glucose (25%, 1,390 mosmol/l) infusions 
at 1 (“G1”), 2 (“G2”), or 4 (“G4”) kcal/min or saline (4.2%, 1,390 mosmol/l) control (“C”) in 
10 healthy males. Data are means ± SE. A: *P < 0.05 vs. control. #P < 0.05 vs. G1. §P < 0.05 
vs. G2. B: *P < 0.05 vs. control. #P < 0.05 vs. G1. §P < 0.05 vs. G2. C: *P < 0.05 vs. control. 
#P < 0.05 vs. G1. §P < 0.05 vs. G2. D: *P < 0.01 vs. control. #P < 0.05 vs. G1. E: *P < 0.05 
vs. control. #P < 0.01 vs. G1. §P < 0.01 vs. G2 [305].  
 
 






Figure 3.5. Gastric emptying and intragastric distribution of the solid (left) and liquid (right) 
components of the meal (100 g lean minced beef labelled with 20 MBq 99mTc-sulfur colloid 
chicken liver and 150 mL water labelled with 7 MBq 67Ga-EDTA) during hypoglycaemia 
(black circles) and euglycaemia (white circles) in patients with T1D. Data are mean ± SEM. *, 
P < 0.05; #, P < 0.01 compared with euglycaemia (ANOVA) [315].
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4.1 Introduction  
Postprandial hypotension (PPH), diagnosed by measurement of the blood pressure (BP) 
response to oral glucose or a meal [1], is now recognised as an important clinical problem, 
particularly in healthy people (prevalence 13-38%) [5, 74] and patients with autonomic 
dysfunction, often secondary to type 2 diabetes (T2D) (∼35%) [1, 5] or Parkinson’s disease 
(40-100%) [1, 5]. PPH is associated with a number of adverse sequelae, including syncope and 
falls [1, 4] and is an independent risk factor for death [68]. 
 
While the pathophysiology of PPH is complex and incompletely understood, it is clear that the 
interaction between autonomic mechanisms, the release of gastrointestinal hormones, gastric 
distension, and small intestinal nutrient delivery are all important in the regulation of 
postprandial BP. After a meal, there is an approximate doubling of superior mesenteric artery 
(SMA) blood flow [1], which, in health, is accompanied by concomitant increases in heart rate 
(HR), peripheral vascular resistance, stroke volume and cardiac output [5]. In patients with 
PPH, these compensatory responses are inadequate to maintain BP [1]. The rate of gastric 
emptying, which exhibits a substantial inter-individual variation [220], is a major determinant 
of the hypotensive response to a meal [7, 8, 24]. We have shown that in T2D patients [7] and 
healthy older people [74], the postprandial fall in BP is greater when gastric emptying is more 
rapid. Although cross-sectional studies suggest that healthy ageing is associated with a modest 
slowing of gastric emptying [328], longitudinal studies have hitherto not been reported. While 
ageing is known to be associated with an increase in BP in older people [329, 330], there is no 
information about the hypotensive response to oral nutrients, or the natural history of PPH.  A 
cohort of healthy older participants was re-evaluated after an interval of ~ 5.8 years to 
determine changes in the BP response to, and gastric emptying of, oral glucose, as well as the 
relationships between the hypotensive response to glucose with gastric emptying. 




4.2 Materials and methods 
4.2.1 Participants 
Eighty-six older individuals who took part in an initial study (July 2010 - July 2012) evaluating 
BP, glycaemia and gastric emptying of a 75g oral glucose load [74] were invited by mail to 
participate in this follow-up study. Of the original cohort, 33 participated; 8 had medical 
conditions that precluded their involvement, 10 were taking antihypertensive drugs which 
represented an exclusion, 13 refused to participate, 21 did not respond to the letter of invitation 
and in 1 case, the invitation letter was returned and the individual considered to be lost to 
follow-up. Of the 33 individuals (17 female; 16 male) who agreed to return, the mean age at 
the initial study was 71.0 ± 0.7 years and body mass index (BMI) 25.6 ± 0.5kg/m 2. At ‘follow-
up’ (mean interval 5.8 ± 0.1 years) age was 77.0 ± 0.7 years and BMI 26.2 ± 0.5kg/m2. 
 
The study was conducted in accordance with the Declaration of Helsinki, and approved by the 
Human Research Ethics Committee of the Royal Adelaide Hospital.  
 
4.2.2 Protocol 
The protocol was identical to that undertaken at the initial study [74]. Individuals presented at 
∼08.30h after an overnight fast (14h for solids; 12h for liquids) [74]. They were seated in an 
armchair, an intravenous cannula was inserted into an antecubital vein for blood sampling and 
an automated BP cuff placed around the opposite arm. After a ‘rest period’ of 15-30 min, 
individuals consumed a drink containing 75g glucose and 150mg 13C-acetate (Cambridge 
Isotope laboratories, Tewksbury, MA, USA), made up to 300mL with water. Time zero (t = 0) 
was defined as the time of completion of the drink. Measurements of gastric emptying, BP and 




HR were performed at regular intervals until t = 120 min [1]. At the end of the study, 
participants were offered a light lunch. 
 
4.2.3 Measurements 
4.2.3.1 Blood pressure and heart rate 
Systolic BP (SBP), diastolic BP (DBP) and HR were measured with an automated oscillometric 
BP monitor (DINAMAP ProCare 100, GE Medical Systems, Milwaukee, WI, USA) every 
3 minutes during the ‘rest period’, and every 5 minutes until t = 120min. Baseline (fasting) BP 
was calculated as an average of the measurements obtained at t = -9, t = -6, and t = -3min. PPH 
was defined as a fall in SBP≥20 mmHg that was sustained for ≥30 min [7]. 
 
4.2.3.2 Gastric emptying  
Exhaled breath samples were collected before ingestion of the drink (t = -3min), every 
5 minutes for the first hour (commencing at t = 5 min) and then every 15 minutes for the 
subsequent 3 hours, for assessment of gastric emptying. The 13CO2 concentration in the breath 
samples was measured by an isotope ratio mass spectrometer (ABCA 20/20; Europa Scientific, 
Crewe, UK), and the gastric 50% emptying time (T50) calculated [264]. 
 
4.2.4 Statistical Analysis 
BP, HR and gastric emptying were analysed and presented as absolute values. The maximum 
falls in SBP and DBP, and rise in HR was defined as the greatest change from baseline between 
0-120min and 60-120min. One-way ANOVA was used to analyse the effects of time on the 
change from baseline values for BP and HR. Areas under the curve AUCs) were calculated 
using the trapezoidal rule and differences between the initial study and follow-up were assessed 




using Student's paired t-test. Pearson's correlation was used to evaluate relationships between 
variables. All analyses were performed using SPSS version 24 (SPSS, Chicago, IL, USA). A P-
value < 0.05 was considered significant in all analyses. Data are presented as mean 
values ± SEM. 
 
4.3 Results  
The studies were well tolerated and there were no adverse events. In 7 subjects, a nonlinear 
regression model fit to the measured 13CO2 concentrations was not feasible. Accordingly, 
paired BP and HR data were available in 33 participants, while gastric emptying data were 
available in 26 participants. 
 
4.3.1 Blood pressure and heart rate  
Three subjects (9.1%) at the initial study and six subjects (18.2%) at follow-up had PPH. Two 
subjects had PPH on both studies. The third subject with PPH at the initial study exhibited a 
maximum fall in SBP of more than 20mmHg at the follow-up, but this was not sustained for 
30 min. There was an increase in baseline SBP from the initial study to follow-up (120 ± 2.5 
vs 128 ± 2.2mmHg, P = 0.001), with no change in baseline DBP (68 ± 1.4 vs 69 ± 1.0mmHg, 
P = 0.58) or HR (64 ± 1.3 vs 63 ± 1.4bpm, P = 0.65). 
 
4.3.1.1 Systolic blood pressure   
Following the drink, there was a modest rise, followed by a fall (P < 0.001 for both) in SBP on 
both study days (Figure 4.1A). Between t = 0-120min, there was a difference (P = 0.001) in the 
AUC of SBP, such that SBP was greater at follow-up compared with the initial study. There 
was no significant difference in the maximum fall in postprandial SBP between the initial and 




follow-up studies over the 2-hour follow-up (-13.6 ± 1.6 vs -15.8 ± 1.6mmHg, P = 0.18), 
however, the maximum fall in postprandial SBP between t = 60-120min was significantly 
greater at follow-up (-11.7 ± 1.4 vs -15.2 ± 1.6 mmHg, P = 0.04) (Figure 4.1A). 
 
4.3.1.2 Diastolic blood pressure  
Following the drink, there was a transient, modest rise, followed by a fall (P < 0.001 for both) 
in DBP on both study days (Figure 4.1B). There was no difference (P = 0.53) in the AUC of 
DBP between the initial study and follow-up, nor was there any difference in the maximum fall 
in postprandial DBP over the 2-hours (-11.8 ± 0.8 vs -11.8 ± 0.6mmHg, P = 0.99) nor the 
maximum fall in postprandial DBP between t = 60-120min (-10.8 ± 0.8 vs -10.9 ± 0.7 mmHg, 
P = 0.84) (Figure 4.1B). 
 
4.3.1.3 Heart rate  
Following the drink, there was no change in HR at the initial study (P = 0.53) or at follow-up 
(P = 0.45) (Figure 4.1C). There was no difference (P = 0.72) in the AUC of HR between the 
initial study and follow-up, nor was there any difference in the maximum rise in HR (8.1 ± 1.0 
vs 8.8 ± 0.9bpm, P = 0.57) nor the maximum rise in postprandial HR between t = 60-120min 
5.4 ± 1.0 vs 7.5 ± 1.0 bpm, P = 0.09) (Figure 4.1C). 
 
4.3.2 Gastric emptying  
Gastric emptying (T50) was slower at the follow-up study than at the initial study (137.9 ± 5.4 
vs 153.8 ± 8.6min, P = 0.04) (Figure 4.2). 
 
 




4.3.3 Relationships among blood pressure and gastric emptying  
There were correlations between the AUCs of SBP (R = 0.64, P < 0.001) and between the 
maximum falls in SBP (R = 0.48, P = 0.004) (Figure 4.3A) between the two studies. At both 
the initial study and at follow-up, there was an inverse relationship between the maximum fall 
in SBP and baseline SBP, i.e. when baseline SBP was greater, the maximum fall was also 
greater (R = −0.68, P < 0.001 vs R = −0.50, P = 0.003). Moreover, the change in the magnitude 
of the maximum fall in SBP from the initial study to follow-up was related directly to the 
increase in baseline SBP between the two study days (R = -0.63, P < 0.001) (Figure 4.3B).  
 
There was a relationship between gastric emptying at the initial study and at follow-up (R = 
0.53, P = 0.005). There were also relationships between the AUC of SBP and gastric emptying 
at the initial study (R = 0.54, P = 0.005; Figure 4.3C) and at follow-up (R = 0.41, P = 0.04; 


















Figure 4.1. SBP (A), DBP (B) and HR (C) in older subjects following a drink containing 75g 
glucose at the initial study and follow-up (after ~5.8 years). Data are presented as mean change 
from baseline (fasting) values ± SEM (n = 33).  





Figure 4.2. 50% gastric emptying time (T50) after 75g glucose at the initial study and follow-
up (n = 26). 
 
 
Figure 4.3. Relationship between (A) the maximum falls in SBP after a drink containing 75g 
glucose at the initial study and follow-up (n = 33), (B) the change in the magnitude of the 
maximum fall in SBP and the increase in baseline SBP from the initial study to follow-up (n = 
33), (C) the AUC0-120min of SBP and the gastric emptying (T50) at the initial study and (D) the 
AUC0-120min of SBP and the gastric emptying (T50) at follow-up (B) (n = 26).




4.4 Discussion  
This study represents the first longitudinal evaluation of the BP responses to, and gastric 
emptying of, an oral glucose load in healthy older people. Over a mean period of ~5.8 years, 
there was a modest increase in SBP and, consistent with the initial cross-sectional study, a 
significant relationship between the magnitude of the drink-induced fall in SBP with the rate 
of gastric emptying. Important novel observations are that the hypotensive effect of glucose 
was greater, and gastric emptying slower, with increased age. Moreover, the hypotensive 
response was greater when baseline (fasting) SBP was relatively higher. The prevalence of 
PPH also increased. 
 
Many studies have reported that resting SBP rises with age, probably primarily reflecting a 
reduction in the wall elasticity of large arteries after age ~60 years. In contrast, DBP may 
decrease [329, 330]. Accordingly, the observed significant increase in baseline SBP at follow-
up was predictable, although we failed to observe any change in DBP. As observed in our initial 
study, there was a sustained fall in SBP following the glucose drink and the magnitude of the 
fall in BP was greater when baseline SBP was greater [63, 331]. This is not surprising given 
that the frequency of PPH is known to be greater in hypertensive older people [1]. In a study 
in Europe including 530 older patients with isolated systolic hypertension, up to 70% exhibited 
a substantial fall in postprandial BP [332]. It is also not surprising that the magnitude of the 
hypotensive response in elderly people was greater after 5.8 years. Approximately twice as 
many subjects had PPH when compared to the initial study. Normal ageing is associated with 
a reduction in the sensitivity of the arterial baroreceptor reflex, which may account for the 
greater hypotensive response by leading to a reduction in cardiac output [333].  
 




Hitherto, there has been little information about the natural history or intra-individual 
reproducibility of PPH. Puisieux et al. (2002) reported that 15 (30%) of 50 geriatric patients 
had PPH on two consecutive morning tests when PPH was defined as a SBP decline ≥20mmHg 
within 2h of a meal [334]. In our follow-up study, the intra-individual reproducibility of PPH 
over ~5.8 years was 66.7%, which was higher than the previous study [334] even though we 
used more stringent criteria to diagnose PPH which also considered the sustainability of the 
fall in SBP [7]. Jansen et al [335] reported a high level of reproducibility in measurements of 
the maximum falls in SBP in consecutive measurements within 2 weeks (0.88 (95% confidence 
intervals (CI) 0.85-0.97)), but this study was performed in nursing home residents, where the 
prevalence of PPH is known to be much higher than in community-dwelling healthy older 
adults. 
 
Previous cross-sectional studies suggest that healthy ageing is associated with a modest 
slowing of gastric emptying [328], consistent with the findings in our longitudinal follow-up 
study. The mechanisms underlying the modest slowing are uncertain [328]. Similarly, the 
clinical relevance of this slowing, if any, remains to be determined. Gastric emptying is known 
to modulate the pharmacokinetics of many orally administered medications [336], as well as 
postprandial glycaemia [326] and appetite [328]. In relation to the latter, it is now recognised 
that healthy ageing is associated with physiological anorexia, which is likely to predispose to 
pathological weight loss [328]. This follow-up study confirms that although gastric emptying 
was slightly slower, the magnitude of the fall in SBP is related to the rate of gastric emptying. 
In other words, the faster gastric emptying, within the normal range, the greater the postprandial 
fall and the higher the risk of PPH. Hence, although our study establishes that changes in gastric 
emptying are not responsible for the increased prevalence of PPH with age, this has clear 




implications for management providing a rationale for the use of dietary and/or pharmacologic 
strategies to slow gastric emptying [22-24]. 
 
While this study represents the first longitudinal evaluation of the BP response to, and gastric 
emptying of, oral glucose in healthy older people, the limitations should be appreciated. The 
size of the cohort was relatively small, baseline BP was normal in most cases and only 38.4% 
of those studied initially either agreed to participate or were excluded due to antihypertensive 
medication, introducing the potential for selection bias. Specifically, it would not be surprising 
if the participants who returned for follow-up represented a “super-healthy” cohort and, if so, 
the prevalence of PPH over a ~5.8-year period may be greater than estimated. Because the 
prevalence of PPH was only 18.2% the relationship of the hypotensive response to glucose 
with gastric emptying was evaluated in the group as a whole. Gastric emptying was measured 
by the indirect breath test technique where measurements should be regarded as notional, rather 
than precise (e.g. the observed gastric emptying T50 was longer than would be anticipated with 
scintigraphy [7]), but this has been shown to correlate closely to scintigraphy, the ‘gold 
standard’ technique [337, 338]. Gastric emptying of solids was not evaluated, but measurement 
of gastric emptying of solids and high-nutrient liquids appears to have comparable sensitivity. 
We did not assess patterns of nutrient intake, but there was no change in body weight.  
 
This study establishes that in healthy older people the prevalence of PPH increases within ~5.8 
years and that the rate of gastric emptying, which was slower, is a determinant of the 
hypotensive response. 
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5.1 Introduction  
The consumption of nutritive sweeteners has dramatically increased worldwide due to 
increasing urbanisation and beverage promotion [339]. Nutritive sweeteners commonly found 
in foods and beverages include glucose, fructose and sucrose [340, 341]. More recently, some 
other sweeteners like D-xylose, xylitol, erythritol, maltose, maltodextrin, stevia and tagatose 
with lower energy have been used [340, 341]. There has been a long history of debate as to the 
detrimental health effects of sucrose, glucose, and more recently, fructose, particularly when 
consumed in excess. The effects of both nutritive and non-nutritive sweeteners on 
cardiovascular risk factors, including blood pressure (BP), have been extensively investigated, 
however, less is known about their specific effects in the postprandial state. Postprandial 
hypotension (PPH), a fall in systolic BP (SBP) ≥ 20 mmHg after a meal, is now recognised as 
a frequent and important clinical problem, with a reported prevalence of 24-48% in the healthy 
elderly [5]. PPH is particularly common in conditions associated with autonomic dysfunction 
e.g. in type 2 diabetes mellitus (T2D) (~40%) [1, 5] and Parkinson’s disease (PD) (40-100%) 
[1, 5]. Patients with PPH are at increased risk of syncope and falls [63], and importantly the 
presence of PPH has been established as an independent predictor of increased mortality [68]. 
In a cohort study of 401 elderly ambulatory hypertensive subjects, 292 (72.8%) were found to 
have PPH, and over a 4 year period, 34 died from cardiovascular disease; the post-breakfast 
BP fall was the strongest predictor of mortality in this cohort [67]. In a 29-month prospective 
study of 499 nursing home residents, the maximum fall in postprandial BP was shown to be an 
independent predictor of subsequent falls, syncope, new cardiovascular events (myocardial 
infarction and stroke) and total mortality [3]. 
 
The pathophysiology of PPH is multifactorial and incompletely understood, however, involves 
the interplay between autonomic and neural mechanisms, including the release of gut 




hormones, which are influenced by meal composition, gastric distension, and small intestinal 
nutrient delivery [5]. After a meal, there is a doubling of the superior mesenteric artery (SMA) 
blood flow [1] and in healthy young individuals with intact baroreflex function, the increase in 
splanchnic blood flow is accompanied by concomitant increases in heart rate (HR), peripheral 
vascular resistance, stroke volume and cardiac output [12]. In patients with PPH, these 
compensatory responses are inadequate [1]. The postprandial fall in BP is greater when gastric 
emptying is more rapid [7, 70, 155], whereas gastric distension attenuates the fall in BP in both 
healthy young and older participants [7, 70, 155]. The macronutrient composition of the meal 
is also an important determinant of postprandial BP, with carbohydrate inducing an earlier fall 
in BP compared with protein and fat [9] (Figure 5.1). The interaction between nutrients and the 
small intestine stimulates the secretion of the incretin hormones, glucagon-like peptide-1 
(GLP-1) from L-cells and glucose-dependent insulinotropic polypeptide (GIP) from K-cells 
[342]. GLP-1 stimulates insulin secretion, inhibits glucagon secretion and slows gastric 
emptying [109, 283]. Acute infusion of GLP-1 has been shown to attenuate the fall in BP and 
increases SMA blood flow following oral [109] or intraduodenal (ID) glucose [106, 109]. In 
contrast, exogenous GIP has been shown to increase the rate of gastric emptying [282], 
although results have been conflicting [343] and there have been no studies directly 
investigating the effect of GIP on postprandial BP. A reduction in BP is not observed following 
intravenous administration of glucose [102], which is a substantial stimulus to insulin secretion, 
suggesting that insulin by itself if not an important mediator of PPH. Furthermore, PPH is seen 
in the absence of insulin secretion i.e. in those with type 1 diabetes (T1D) [37]. 
 
In recent years, due to several negative health effects from the excessive consumption of added 
sugar, a variety of non-nutritive sweeteners have increasingly been used in the food industry 
as an alternative to sugar among people of all ages, particularly directed to the obese and those 




with diabetes, with the aim of reducing energy intake and minimising the risk of obesity, 
diabetes and cardiovascular disease [341, 344]. Beverages account for the highest percentage 
of non-nutritive sweetener utilisation in the world [345, 346]. In the United States, non-
nutritive sweeteners were used in up to 32% and 19% of beverages consumed by adults and 
children respectively from 2007 to 2010 [347]. In 2018, the American Heart Association 
suggested that short-term use of ‘non-nutritive’ sweeteners instead of ‘nutritive sweeteners’ 
can reduce caloric intake in the management of overweight and obesity [348]. 
 
There are some differences between regulatory bodies regarding approval of nutritive and non-
nutritive sweeteners. The six non-nutritive sweeteners approved by Food and Drug 
Administration (FDA) as food additives in the United States include sucralose, Acesulfame-K, 
aspartame, saccharin, neotame and advantame [340, 349, 350]. Stevia [350, 351] has not 
received official FDA approval but has been rated as generally recognised as safe (GRAS) and 
is being increasingly used as a non-nutritive sweetener [352]. Maltitol similarly has not 
received official FDA approval, but may be used in food manufacture [352]. The nutritive 
sweeteners currently approved by the FDA include mannitol, xylitol, sorbitol and erythritol 
[353]. The European Food Safety Authority (EFSA) has approved the non-nutritive sweeteners 
Acesulfame-K, aspartame, cyclamate, neohesperidin dihydrochalcone, saccharin, sucralose, 
neotame, thaumatin and stevioside, while approved nutritive sweeteners include erythritol, 
isomalt, lactitol, maltitol, mannitol, sorbitol and xylitol [352]. 
 
There have been a number of short-term studies evaluating the physiological responses to 
nutritive and non-nutritive sweeteners that have included assessment of BP. With the 
increasingly widespread use of non-nutritive sweeteners and the documented severe clinical 
sequelae of PPH, it is clearly important to ascertain the extent to which these agents decrease 




postprandial BP. To date, a published systematic summary of the impact of nutritive and non-
nutritive sweeteners on postprandial BP has not been performed. For this systematic review, 
the aim was to establish current scientific evidence of the effects of some of the most commonly 
used FDA-regulated nutritive and non-nutritive sweeteners on postprandial BP, as well as their 
potential applications in the management of PPH. 
 
5.2. Approach 
Based on the pathophysiology of PPH, a systematic review of the PubMed database was 
conducted up to March 2019 to identify articles related to the effects of different types of 
sweeteners on postprandial BP. The following keywords were used: “sweeteners” or “nutritive 
sweeteners” or “caloric sweeteners” or “sucrose” or “fructose” or “glucose” or “xylose” or 
“xylitol” or “erythritol” or "maltose" or "maltodextrin" or "tagatose" or “non-nutritive 
sweeteners” or “non-caloric sweeteners” or “sucralose” or “Acesulfame-K” or “aspartame” or 
“saccharin” or “stevia” or "steviol glycoside" or "neotame" or "advantame") and (“postprandial 
blood pressure” or “postprandial hypotension” or “hypotensive response”).  
 
Screening of studies was performed initially by assessment of the relevance of the abstract by 
2 independent reviewers. The reference lists of relevant articles were also reviewed. Study 
inclusion was based on the guidelines for preferred reporting items for systematic reviews and 
meta-analyses (PRISMA) [354]. 
 
5.3 Results  
A total of 150 papers were identified from the database search. There were no duplicate papers. 
Of the 150 papers, papers without full text (n = 2), irrelevant papers (n = 55), animal studies (n 




= 12), reviews (n = 9), papers that were unavailable in the English language (n = 7), letters to 
the editor or comments (n = 1), and case reports (n = 2) were removed, leaving a total of 62 
papers which were reviewed. Figure 5.2 summarises the selection process. 
 
5.4 Nutritive sweeteners 
5.4.1. Glucose  
Glucose is the most abundant monosaccharide and is synthesised from water and carbon 
dioxide through photosynthesis and concentrated to create starch [355]. Foods containing 
relatively higher proportions of naturally occurring glucose include some fruits, such as grapes 
and bananas (~6-8%), while the glucose content of honey may approach ~38% [356, 357]. It 
is an essential energy source for the red blood cells and brain, although the latter can also utilise 
ketone bodies [340, 358]. Ingested complex carbohydrates are hydrolysed to monosaccharides 
before being absorbed [358]. The majority of studies investigating PPH have utilised an oral 
[7, 19, 22, 33, 36, 40, 42-45, 50-52, 54, 70, 74, 79, 104, 109, 111, 124, 126, 128, 133, 134, 139, 
140, 144, 155, 158, 159, 161, 188, 359-365], and/or ID glucose [8, 9, 15, 23, 24, 75, 76, 83, 
88, 90, 106, 180, 197, 366-369] load that induces a substantial fall in BP. There have been a 
total of 58 studies related to effects of glucose on postprandial BP in a range of cohorts 
including health [7-9, 15, 19, 22-24, 36, 40, 44, 45, 50, 54, 70, 74, 75, 83, 88, 90, 104, 106, 
109, 111, 124, 126, 133, 134, 139, 140, 144, 158, 161, 197, 359-361, 364-368, 370], PPH [88, 
144], diabetes [7, 36, 43, 76, 109, 111, 155, 158, 159, 180, 188, 369], autonomic failure [40, 
42-45], PD [43, 50-52], hypertension [19, 79, 362-365], multiple system atrophy (MSA) [43-
45, 54] and other conditions [33, 42, 79, 126, 134, 367] (Table 5.1). Intensive care unit (ICU) 
survivors are more predisposed to PPH; a marked and prolonged decrease in SBP and diastolic 
BP (DBP) was observed in 35 older patients discharged from the ICU [33], 10 of whom 




experienced PPH [33]. In healthy older participants [7, 70, 74] and patients with T2D [7, 111], 
the fall in BP following glucose ingestion has been shown to be related to the rate of gastric 
emptying of glucose, i.e. faster gastric emptying is associated with a greater fall in BP. In 
contrast, in healthy young participants, there is little fall, and in some cases an increase, in SBP 
following oral glucose [79, 370]. The fall in postprandial BP appears to be on a continuum so 
that with increasing age the fall in BP is greater. In a study by our group, following a 75g 
glucose drink in 300 mL water, there was a fall in SBP and a rise in HR in both healthy older 
participants and people with PPH compared with iso-volaemic water [144], however, the 
maximum postprandial fall in SBP was greater in the participants with PPH [144]. 
 
5.4.1.1 Intraduodenal glucose infusion 
When the protective mechanism of gastric distension [90, 368] is bypassed by infusing glucose 
directly into the duodenum, the fall in BP is greater compared to oral glucose in healthy older 
participants [139]. Vanis et al. showed that gastric distension, by as little as 100 mL water, 
could mitigate the fall in BP induced by ID glucose in healthy older participants, supporting 
the potential use of non-nutritive gastric distension in the management of PPH [90]. ID glucose-
induced reductions in BP are observed in both older people [15, 88, 139] and patients with T2D 
[76, 180, 369]. The hypotensive response to ID glucose depends primarily on the small 
intestinal glucose load, but solution concentration does not appear to be important [75]. Within 
the normal physiological range of gastric emptying (1-4 kcal/min) [220], the rate of small 
intestinal delivery correlates with the magnitude of the fall in BP [8, 76, 83]. Trahair et al. 
reported that SBP decreased significantly during 2 kcal/min and 3 kcal/min glucose infusions, 
but not during 1 kcal/min glucose infusion; indicating that a threshold for the fall occurs 
between 1-2 kcal/min [306]. On the contrary, young healthy participants with sufficient 




cardiovascular responses remain normotensive [83] or become only slightly hypotensive [88] 
after ID glucose infusion. There is no difference in postprandial BP following ID glucose 
infusion between young healthy and obese groups [367].  
 
5.4.1.2 Management of PPH 
Due to its ability to induce a prominent hypotensive response, several studies investigating 
non-pharmacological [22, 23, 90, 158, 159, 368] and pharmacological [19, 43, 45, 106, 111, 
126, 161, 180, 197, 362, 363, 369] approaches to the management of PPH have used glucose 
as test meals. Interventions based on slowing gastric emptying [22, 23] and small intestinal 
absorption of nutrients [24] attenuate the postprandial fall in BP. Guar gum, a vegetable-based, 
gel-forming non-absorbable carbohydrate, commonly used as a bulking agent, delays gastric 
emptying, slows the intestinal absorption of glucose and, accordingly, attenuates the magnitude 
of the fall in BP after oral and ID glucose [22, 23, 155]. Intermittent walking may also be 
effective in preventing PPH induced by glucose ingestion [158, 159]. In terms of the 
pharmacologic management of PPH, numerous medications have been tested. One study has 
shown that maximal postprandial fall in sitting SBP after a standardised 400 kcal glucose drink 
is attenuated by caffeine [161], although the benefits of caffeine as a treatment for PPH are 
inconsistent and largely empirical. The effects of the somatostatin analogue, octreotide, in 
attenuating the fall in BP after oral glucose has been demonstrated in 3 studies [19, 45, 363]. 
These effects are not mediated via the inhibition of insulin secretion [363]. Voglibose, an α-
glucosidase inhibitor, is effective in attenuating PPH in neurologic patients [126]. More 
recently, GLP-1 based therapy has drawn more attention. In a placebo-controlled study, 
intravenous GLP-1 infusion (0.9 pmol kg−1.min−1) in 14 healthy older individuals and 10 
patients with T2D, resulted in the slowing of gastric emptying and attenuation in the fall in BP 
following ingestion of a radiolabelled 75g glucose drink [109]. GLP-1 also reduces the 




maximum fall in SBP in response to ID glucose [106]. Both short-acting GLP-1 receptor 
agonists, exenatide [180] and lixisenatide [111], known to slow gastric emptying, markedly 
attenuate the decrease in BP compared to placebo. In contrast, the dipeptidyl peptidase-4 (DPP-
4) inhibitor, vildagliptin, known to block the degradation of the incretin hormones GLP-1 and 
GIP, did not attenuate the fall in SBP and DBP during ID glucose administration compared 
with placebo in T2D [369]. Recent evidence suggests that GIP may have detrimental effects to 
lower postprandial BP and it is possible that the beneficial effects of GLP-1 by DPP-4 
inhibition, were nullified by GIP. The effect of the anti-diabetic medication, metformin, has 
also been evaluated in two studies [188, 369], but the outcomes are inconsistent and more 
studies are warranted. Other investigators have reported that the antihypertensive, nitrendipine 
[362], or a combination of selective α1 and β1-adrenergic agonists [43], might attenuate the 
postprandial fall in BP after glucose ingestion, while the antiemetic drug, granisetron, a 5-HT3 
antagonist, [197] has no benefit in the management of PPH. 
 
5.4.2 Fructose 
Fructose, a monosaccharide found in fruit, honey, and some vegetables [340], may be preferred 
over glucose by consumers and cooks due to its intrinsically greater sweetness and ability to 
improve the appearance and texture of baked goods [371]. Fructose has been used increasingly 
as an alternative to glucose or sucrose [372-374] in several processed foods and beverages, 
especially in diets targeting patients with T2D, as it provides fewer calories for the same level 
of sweetness as glucose [375, 376]. In contrast to glucose, the metabolism of fructose primarily 
occurs in the liver, entering cells in an insulin-independent fashion [377]. Fructose is not an 
insulin secretagogue [377], inducing a substantially lower glycaemic response compared with 
glucose [374]. However, although there is no clear consensus in the literature, the potential for 




increased de novo lipogenesis from excessive fructose intake, particularly in those with insulin 
resistance, has raised the concern regarding the widespread use of this monosaccharide [378]. 
Compared with glucose, fructose is absorbed more slowly from the intestine [379, 380]. There 
has been a total of 5 studies relating to the effects of oral fructose on postprandial BP in a range 
of cohorts including in healthy participants [133, 134, 359, 360, 370] and hypertensive patients 
[134] (Table 5.2). 
 
Some studies have demonstrated no change in BP in healthy young [134] and older participants 
[133] as well as those with hypertension [134] following ingestion of fructose. In healthy older 
people, SBP decreased significantly from baseline following glucose: -3.961.38mmHg but 
not after the fructose drink: 2.591.62 mmHg [134] (Figure 5.3). Two other studies reported 
an increase in BP in healthy young participants following ingestion of fructose [359, 360]. This 
may be due to the slower intestinal absorption rate of fructose and lower glycaemic response 
compared with glucose [381, 382], which may also result in a limited increase in SMA blood 
flow. However, there have been no studies comparing the difference in postprandial intestinal 
vascular perfusion following oral glucose and fructose. In addition, due to the lower 
insulinotropic effects of fructose compared with glucose and sucrose [383], effects on total 
vascular peripheral resistance may be mitigated [359, 370]. 
 
5.4.3 Sucrose  
Sucrose is a common table sugar produced naturally in fruit and vegetables and often added to 
many processed foods [384]. Sucrose tastes sweeter than glucose, but not as sweet as fructose. 
The digestion of sucrose is initiated in the mouth and stomach, but the majority of this 
disaccharide is hydrolysed and digested in the small intestine by the α-glucosidase sucrase to 
release an equimolar mixture of glucose and fructose [385]. There have been 5 studies relating 




to effects of sucrose on postprandial BP in healthy participants [18, 107, 133, 360, 386] (Table 
5.2): 4 used an oral load [18, 133, 360, 386] while one study used an ID infusion [107]. 
 
The cardiovascular effects of sucrose are more similar to those observed following glucose 
than fructose, despite its equimolar constitution [387]. Visvanathan et al. reported that ingestion 
of 50g sucrose or 50g glucose-induced a comparable fall in SBP in healthy elderly individuals, 
but the decrease in SBP occurred earlier after glucose, than sucrose, ingestion [133] (Figure 
5.3). This may be due to the fact that sucrose is a disaccharide, requiring hydrolysis prior to 
mediating cardiovascular effects [133]. In comparison, a 60g sucrose drink had no substantial 
impact on BP in healthy young participants [360], which may be due to the more effective 
postprandial haemodynamic responses compared with an older population. The α-glucosidase 
inhibitor, acarbose, is approved for the treatment of T2D and is known to reduce postprandial 
glycaemia [164] through stimulation of GLP-1 [168], and slowing of gastric emptying [18, 
162]. In healthy older participants, acarbose substantially decreases falls in SBP and DBP 
induced by not both oral [18], and ID [107] sucrose, loads.  
 
5.4.4 D-Xylose and Xylitol  
Xylose, a monosaccharide of the aldopentose type consists of five carbon atoms and is derived 
from wood. The free aldehyde group reduces its sweetness and makes it a widely used 
alternative for glucose in the diabetic diet. Xylose is primarily absorbed by passive penetration 
through the wall of human duodenum and jejunum [388], with the remainder delivered to the 
ileum and the colon. Xylose is emptied from the stomach at a similar rate to glucose [104]. 
There have been 3 studies related to effects of oral xylose on postprandial BP in healthy older 
participants [40, 42, 104], orthostatic hypotension (OH) [42] and autonomic failure [40, 42] 
patients (Table 5.2). While Mathias et al. [40] reported xylose induced a milder and more 




transient fall in postprandial BP compared with glucose in those with chronic autonomic 
failure, Robinson et al. reported that glucose and xylose ingestion induced a comparable fall in 
SBP at 60-90 min in supine patients diagnosed with OH and autonomic failure [42]. In a 
previous study by our group, designed to compare effects of glucose and xylose on BP, gastric 
emptying and incretin hormones, xylose emptied from the stomach at a comparable rate to 
glucose, with a greater and more prolonged effect on GLP-1 secretion in healthy older 
participants [104]. However, there was no change in postprandial BP observed, potentially due 
to the effects of GLP-1 in delaying the nutrient absorption in the distal small intestine. These 
findings support the replacement of glucose by xylose as a simple management to decrease the 
postprandial fall in BP [104]. 
 
Reduction of xylose by catalytic hydrogenation produces xylitol [389]. Xylitol has a 
comparable sweetness to sucrose and contains less than one-third of calories in conventional 
sugars. As xylitol is metabolised in an insulin-independent manner, its use has been widely 
advocated in the prevention and control of hyperglycaemia, obesity, and related metabolic 
disorders [390, 391]. However, xylitol is often associated with diarrhoea due to its stimulatory 
effect on the intestinal transit and the release of plasma motilin [392]. Salminen et al. [392] 
reported that 30g xylitol solution was emptied from the stomach at a significantly slower rate 
than a 30g of glucose, suggesting that xylitol might protect against PPH, although further 
studies are required. 
 
5.4.5 Erythritol 
Erythritol, a four-carbon pentose, is made through food fermentation but may occur naturally 
in a wide variety of fruits and mushrooms. Erythritol has a sweetness of ~70% compared with 
sucrose and has minimal insulinotropic effects [393, 394]. Nevertheless, the effect erythritol 




on BP has not been studied. In patients with T2D, acute consumption of erythritol has 
vasoprotective effects by decreasing oxidative stress and endothelial dysfunction [395]. 
 
5.4.6 Maltose and maltodextrin  
Maltose, or malt sugar, a disaccharide composed of two glucose units, is an intermediate in the 
intestinal breakdown of glycogen and starch and is found in germinating grains [396]. 
Maltodextrin is a nutritive saccharide polymer consisting of D-glucose units with low 
sweetness (dextrose equivalency of less than 20). It is often used in the production of soft 
drinks, candy, and processed food [397]. Both maltose [398] and maltodextrin [399] are 
emptied more slowly from the stomach compared with sucrose, although there is no significant 
difference in gastric emptying between maltodextrin and glucose [399]. To our knowledge, 
there have been no studies investigating the effects of maltose on postprandial BP. There has 
been only one study related to effects of oral maltodextrin on postprandial BP in healthy older 
participants [386] (Table 5.2) in which postprandial MAP and DBP were shown to be greater 
after sucrose compared to after maltodextrin [386]. The underlying mechanisms remain unclear 
[386].  
 
5.4.7 Tagatose  
Tagatose has a very similar structure to sucrose, is commonly found in dairy products [400] 
and is low calorie; only 20 to 25% of ingested D-tagatose is absorbed through the small 
intestine to provide 1.5kcal/g [401]. The remaining ingested tagatose is fermented into short-
chain fatty acids by colonic bacteria [340, 402]. Tagatose has a substantial hypoglycaemic 
effect without major adverse effects, contributing to its potential therapeutic benefits in obese 
people and patients with T2D [403-406]. While tagatose has been shown to slow gastric 




emptying [407, 408], to our knowledge there is no information regarding the effect of tagatose 
on BP. 
 
5.5 Non-nutritive sweeteners 
5.5.1 Sucralose 
Sucralose, a noncaloric artificial sweetener with a sweetness approximately 600 times higher 
than that of sucrose [409], is increasingly being used as a sugar substitute to reduce calorie 
intake, especially in obese people and those with diabetes [341]. It is almost unabsorbed in the 
small intestine and excreted in the faeces in both animal [410, 411] and human [412] 
experiments. In healthy participants, sucralose empties at a similar rate to saline [413]. 
 
There have been 2 studies investigating effects of sucralose on postprandial BP [366, 414] 
(Table 5.3). Kazmi et al. reported that there was no change in BP following oral sucralose in 
200 young healthy participants compared to saline. In a recent study by our group, while ID 
infusion of glucose at a rate of 3 kcal/min induced a substantial fall in postprandial BP and 
increase in SMA blood flow in 12 healthy older participants, there were no significant effects 
on BP or splanchnic blood flow following an ID infusion of sucralose [366] (Figure 5.4). 
Studies by others have shown that sucralose has no effect on insulin, GLP-1 or GIP secretion 
or SMA blood flow [413, 415], supporting a therapeutic role for sucralose in the dietary 
management of PPH.   
 
5.5.2 Acesulfame-K 
Acesulfame-K, a non-nutritive sweetener, was invented in 1967 by the pharmaceutical 
company, Hoechst AG. It is estimated to be 200 times sweeter than sucrose and is often mixed 




with sucralose or aspartame in foods and beverages [349]. In 2009, Brown et al. reported that 
the GLP-1 release increased by more than 30% after drinking “diet soda”, comprising 
sucralose, aspartame and Acesulfame-K compared to carbonated water [416]. However, this 
finding was not replicated in subsequent studies [415, 417]. Acesulfame-K alone or combined 
has no effect on GLP-1 secretion, insulin, or blood glucose. There has been only one study 
investigating the effect of Acesulfame-K on BP [414] (Table 5.3). Kazmi et al. reported that 
SBP was lower at 60 min following the ingestion of 3.24gm (45 mg/kg) of Acesulfame-K in 
50 healthy young participants compared to controls. The design of that study was, however, 
suboptimal, as SBP and DBP were only measured at 30, 60, 90 and 120 min and the baseline 
measurement was not taken into account. 
 
5.5.3 Aspartame  
Aspartame, a methyl ester of aspartic acid and phenylalanine dipeptide, was approved as a non-
nutritive sweetener in 1996 by the FDA. It is 160 to 220 times sweeter than sucrose and the 
only non-nutritive sweetener providing energy (4 kcal/g). However, due to the intense 
sweetness, only a tiny quantity is used in foods and soft drinks and the number of calories is 
negligible, hence, it is considered ‘non-nutritive’ [340, 341]. Little et al. [418] demonstrated 
that the gastric emptying of aspartame does not differ from that of water. There has been only 
one study investigating the effect of aspartame on BP [414] (Table 5.3). In this study, young 
healthy participants experienced falls in SBP at 60, 90 and 120 min following the ingestion of 
10.8 g (150mg/kg) aspartame compared to 10 g of cellulose (control) (109.82 ± 11.39 vs. 
116.92 ± 8.98,  112.54 ± 11.18 vs. 117.84 ± 10.2 and 112.02 ± 10.54 vs. 117.16 ± 8.62 
respectively) [414]. Again, the design of that study was, suboptimal, as SBP and DBP were 
only measured at 30, 60, 90 and 120 min and the baseline measurement was not taken into 
account. 






Saccharin is the oldest non-nutritive sweetener that is currently approved, is not metabolised 
in humans and is considered non-carcinogenic [340, 341]. To date, there are no studies 
investigating the acute effects of saccharin on BP.  
 
5.5.5 Steviol glycoside 
Steviol glycoside sweeteners are extracted and purified from the leaves of the Stevia rebaudiana 
Bertoni plant, which is native to South America. Its sweet potency is reported to be 200 to 400 
times sweeter than table sugar [419, 420]. Steviol glycoside has been categorised as a non-
caloric sweetener and widely used in the food and soft drinks by millions of people and is well 
tolerated [400]. In one study, postprandial blood glucose and insulin levels were significantly 
lower when healthy lean and obese participants consumed a steviol glycoside preload before 
meals compared with an isocaloric sucrose preload [421]. Another study in participants with 
T2D reported that steviol glycoside reduced postprandial blood glucose without a significant 
change in insulin levels [422]. Furthermore, steviol glycoside was also shown to significantly 
reduce food intake [421]. Peirera et al [423] did not demonstrate any effect of steviol glycoside 
on gastric emptying of a liquid test meal in 10 male healthy volunteers. Most of the studies in 
the literature have evaluated the effect of long-term steviol glycoside intake on BP and 
demonstrated that it may be effective in decreasing SBP and DBP compared with placebo in 
hypertensive [424, 425], but not in normotensive or hypotensive, participants [426, 427]. 
However, there have been no publications evaluating the acute effect of this sweetener on 
postprandial BP.  
 




5.5.6 Neotame and advantame 
Neotame is closely related to aspartame in terms of the chemical constitution. It is 7000–13,000 
times sweeter than sucrose [428]. Advantame is considered the most potent non-caloric 
sweetener with sweetness approximately 20,000 times greater than sucrose [428]. Advantame 
is derived from isovanillin and aspartame [429]. To our knowledge, there have been no studies 
evaluating the effects of these sweeteners on BP. 
 
5.6. Conclusions  
PPH is associated with an increased incidence of falls, syncope, angina and transient ischaemic 
attacks, particularly in older people and patients with autonomic failure that is frequently 
secondary to diabetes mellitus and PD. For nutritive sweeteners, glucose induces the greatest 
fall in postprandial BP and should be limited in people with PPH. Most of the currently 
available literature indicates that non-nutritive sweeteners have little effect on BP. While 
pharmacological and dietary approaches are being explored, current management of PPH 
remains suboptimal. This literature review supports the view that low nutritive (D-xylose, 
xylitol, erythritol, maltose, maltodextrin, and tagatose) and non-nutritive sweeteners could be 
used to replace high nutritive sweeteners (glucose, fructose, and sucrose) in the dietary 













Figure 5.1. Changes from baseline in (A) Systolic blood pressure (BP) and (B) Heart rate 
in 8 healthy older participants in response to intraduodenal (ID) infusion of glucose, fat, 
protein, and saline. Data are mean values ± SEM.  *P < 0.05 for glucose compared with 
saline; †P < 0.05 for glucose compared with fat; ‡P < 0.0001 for glucose compared with 
protein; ̂ P < 0.05 for fat compared with saline; #P < 0.05 for protein compared with saline; 
+P < 0.05 for fat compared with protein [9]. 
  





Figure 5.2. Flow diagram for the selection of studies for review based on the preferred 
reporting items for systematic reviews and meta-analyses (PRISMA) 2009 statement. 
  





Figure 5.3. Change from baseline in (A) Systolic blood pressure (BP) and (B) Heart rate 
in 10 healthy older people following ingestion of four different study drinks (○, glucose; 
■, sucrose; ∆, fructose; ●, water). Data are mean values ± SEM [133]. 
 
Figure 5.4. (A) Mean arterial pressure (MAP) and (B) Heart Rate in 12 healthy older 
subjects after intraduodenal (ID) infusion of glucose (▲), sucralose (), and saline (). 
Data are mean values ± SEM. MAP: P < 0.05 for glucose compared with sucralose or 
saline, and P = 1.0 for sucralose compared with saline. Heart rate: P < 0.05 for glucose 
compared with sucralose, P = 0.07 for glucose compared with saline, and P = 1.0 for 
sucralose compared with saline [366]. 




Table 5.1. Studies relating to the effects of glucose on blood pressure 
 Study Year Participant characteristics Study Design Test meal Effects on blood pressure 
Borg et al. 
[188] 
2019 10 diet controlled T2D patients, 




ID metformin (1g) or saline (control) 
60 minutes before ingesting a 50g 
glucose drink labelled with 150 mg 
13C‐acetate. 
SBP and DBP decreased following oral 
glucose on both days. The fall in SBP was less 
after metformin than control.  
Brown et al. 
[359] 
2008 15 healthy normal-weight 




500 mL of either water, 60g glucose, 
or 60g fructose. 
Oral fructose, but not glucose, significantly 
increased SBP and DBP. The maximum rise in 
SBP after fructose was 6.2 ± 0.8 mmHg. 
Charriere et al. 
[370] 





500 mL of water containing 60g of 
either glucose, fructose or galactose. 
The increase in SBP after fructose (7–8 
mmHg) was greater than after glucose (4–5 
mmHg) or galactose (2–3 mmHg). DBP 
increased to a greater extent with fructose (~5 
mmHg), compared to non-significant increases 
of only 2–3 mmHg after glucose or galactose. 
Edwards et al 
[124] 
1996 10 young (20-40 years), 9 middle-
aged (41-50 years), and 10 old (61-83 




75g glucose in 300 mL water SBP decrease was significant in both the older 
groups. A fall in SBP >15mmHg observed in 5 
individuals; 4 aged > 60 years and 1 middle-
aged. 
Fagius et al. 
[361] 
1994 39 participants in 5 groups: glucose (n 
= 8, 4M:4F, mean age 25.8 years), fat 
(n = 8, 5M:3F, mean age 25.5 years), 
protein (n = 8, 5M:3F, mean age 25.6 
years), mixed meal (n = 8, 6M:2F, 
mean age 26.2 years) or water (n = 7, 
4M:3F, mean age 24.9 years). 
Parallel study 100g glucose in 300 mL of water (n = 
8), 50g fat in 250 mL of water (n = 8), 
100g lean meat (40g protein) with 250 
mL water (n = 8), 300 mL water alone 
(n = 7) or a mixed meal (n = 8). 
Small and sometimes significant increases in 
BP occurred during the sessions.  
Fagius et al. 
[79] 
1996 3 groups - A: 9 young healthy, 5M:4F, 
aged 26.2 ± 2.8 years; B: 9 older 
healthy, all M, aged 73.0 ± 0.7 years; 
C: 9M with insulin resistance aged 




100g D-glucose in 300 mL Significant fall in BP observed in groups B and 
C but not in group A, who demonstrated an 
increase in SBP. 
Gentilcore et al. 
[75] 
2006 8 healthy older participants, 3M;5F, 




50g glucose in either 300 mL 
(16.7%), 600 mL (8.3%), or 1200 mL 
(4.1%) or saline (0.9%) at a similar 
rate of 3 kcal/min 
SBP and DBP decreased, and HR increased, on 
all days following the glucose infusions with 
no difference between them. 




Gentilcore et al. 
[197] 
2007 10 healthy older participants, 5M:5F, 




Granisetron (10mcg/kg) or control 
(saline) at t = -25min; ID glucose 
infusion (3 kcal/min) for 60min, 
followed by ID saline for a further 
60min. 
There were falls in SBP and DBP and a rise in 
HR during ID glucose; granisetron had no 
effect on these responses. 
Gentilcore et al. 
[9] 
2008 8 healthy older participants, 4M:4F, 




ID glucose (64g), fat (10% oil 
emulsion), protein (72g whey), or 
saline (0.9%) infusion at a rate of 2.7 
mL/min for 90min, followed by ID 
saline for 30min 
The maximum falls in SBP during the glucose 
(11.7 ± 2.8 mmHg), fat (11.7 ± 4.8 mmHg), 
and protein (11.0 ± 1.5 mmHg) infusion did not 
differ significantly. The fall occurred 
significantly earlier during the glucose (18 ± 3 
min) than during the fat (46 ± 11 min) and 
protein (33 ± 7 min) infusion. 
Gentilcore et al. 
[15] 
2008 8 healthy older participants, 5M:3F, 




(1) ID glucose (50g) or (2) ID glucose 
(50g) with intragastric infusion of 500 
mL water or (3) ID saline (0.9%) with 
intragastric infusion of 500 mL water. 
The fall in SBP and DBP greater during (1) and 
(2) when compared with (3) and (1) compared 
with (2). Gastric distension attenuated the fall 
in BP. 
Gentilcore et al. 
[139] 





Day 1: ingestion of 75g glucose in 
300 mL. Gastric emptying rate 
(kcal/min) quantified by 3D 
ultrasound between t = 0-120 min. 
Day 2, ID glucose infused at the same 
rate as day 1. 
SBP was greater less after oral, compared with 
ID glucose. 
Grasser et al. 
[360] 
2014 12 healthy young adults, 7M:5F, aged 




500 mL drink of either 60g sucrose, 
60g glucose, 60g fructose or 30g 
fructose. 
Ingestion of fructose (60 or 30 g) elevated SBP, 
DBP and mean arterial pressure (MAP). 
Ingestion of glucose elevated SBP. Ingestion 
of sucrose showed no BP changes. The 
increases in DBP and MAP were significantly 
higher for fructose (60 or 30 g) than for either 
glucose or sucrose. The increase in SBP was 
significantly higher for fructose than for 
sucrose. 
Heseltine et al. 
[161] 





400kcal glucose drink with either 
caffeinated coffee or decaffeinated 
coffee 
Maximal postprandial fall in sitting SBP was 
attenuated by caffeine. Four participants 
developed symptomatic PPH after placebo 
which was prevented by caffeine. 
Hirayama et al. 
[44] 
1993 10 patients with MSA, 9M:1F, aged 
57 ± 7 years, 3 patients with peripheral 




75g glucose in 225 mL water In MSA, ingestion of glucose resulted in a 
rapid and significant fall of SBP and DBP. In 
peripheral autonomic neuropathy, BP 




35-57 years and 16 controls, 14M:2F, 
aged 38 ± 11 years. 
decreased within 15 min of oral glucose 
ingestion, but soon recovered. BP in the 
controls remained unchanged. 
Hirayama et al. 
[43]  
1993 5 patients with MSA, 3M:2F, aged 50-
71 years, 2 patients with pure 
autonomic failure, 2M: 54-78 years 
and 1 71-year-old F patient with 
autonomic failure and Parkinson's 
disease. All with PPH and OH 
Crossover 
study 
Denopamine and midodrine 
administered 30 min before 75g 
glucose drink on one day versus no 
drug a few days prior. 
PPH was prevented by denopamine and 
midodrine. 
Hoeldtke et al. 
[45] 
1989 6 MSA patients, 4M:2F, aged 53-73 
years, 5 progressive autonomic failure 
patients, 3M:2F, aged 41-84 years) 




SMS-201-995 (0.8mcg/kg) or 
placebo injection sc before 
consuming a 50g glucose drink. 
In patients with progressive autonomic failure 
and MSA, glucose ingestion caused a decrease 
in BP which was attenuated by SMS-201-995. 
Jansen et al. 
[134] 
1987 10 young normotensive people, aged 
28 ± 1 years (YN), 10 young 
hypertensive patients, aged 44 ± 2 
years (YH), 10 elderly normotensive 
people aged 75 ± 2 years (EN), 10 
elderly hypertensive patients aged 75 




300 mL drink of either 75g glucose or 
75g fructose.  
Glucose decreased MAP significantly in the 
EH, EN and YH group. After fructose, BP 
remained unchanged in 4 groups. 
Jansen et al. 
[362] 
1988 Hypertensive patients: randomised to 
nitrendipine: 4M:5F, aged 70-78 years 
– or hydrochlorothiazide: 3M:10F, 
aged 70-84 years 
Randomised 
parallel study 
75g glucose drink before and after 
treatment with 20mg nitrendipine 
once daily or 50mg 
hydrochlorothiazide once daily for 12 
weeks. 
After 12 weeks of treatment, nitrendipine 
reduced the fall in MAP after oral glucose (6%, 
P< 0.01) but this was not significant for 
hydrochlorothiazide (4%, NS). 
Jansen et al. 
[19] 
1989 10 hypertensive participants, 3M:7F, 
aged 74 ± 4 years; and 10 
normotensive participants, 4M:6F, 




Octreotide (50mcg sc) or placebo 
(154mmol/l NaCl) before oral 75g 
glucose in 300 mL water 
Octreotide attenuated the fall in MAP (15 ± 1 
mmHg in the 10 hypertensive participants and 
7 ± 2 mmHg in the 10 normotensive 
participants) induced by oral glucose. 
Jansen et al. 
[363] 
1989 10 hypertensive participants, 7M:3F, 




Octreotide (50mcg sc) at t = −30 min 
followed by placebo or insulin 
(0.3U/kg) sc at t = −10 min and oral 
glucose (75g in 300 mL water) at t = 
0 minutes 
The fall in MAP after oral glucose was 
attenuated by octreotide with no difference 
between the insulin and placebo study days. 
Jansen et al. 
[364] 
1989 15 older hypertensives (EH), 7M:8F, 
age 73 ± 3 years, 15 older 




75g glucose in 300 mL water In both elderly groups MAP decreased 
significantly after the glucose load, whereas no 




4 years and 10 young normotensives 
(YN), 5M:5F, age 26 ± 4 years. 
change was observed in the YN. Glucose load 
did not influence baroreflex sensitivity. 
Jones et al. [7] 1998 16 T2D patients, 11M:5F, aged 39–79 
years; 10 young healthy participants, 
9M:9F, aged 19–26 years; 9 older 
healthy participants, 6M:3F, aged 40–




75g glucose in 350 mL water The fall in MAP was significantly greater in 
the T2D than in older healthy participants with 
no change in young healthy participants. The 
magnitude of the fall in BP was related to the 
rate of gastric emptying. 
Jones et al. 
[140] 
2005 10 healthy participants, 6M:6F, aged 




25g glucose in 200 mL (12.5%), 75g 
glucose in 200 mL (37.5%), 25g 
glucose in 600 mL (4%), and 75g 
glucose in 600 mL (12.5%) 
Increased drink volume attenuates the fall in 
BP with no effect of glucose concentration. 
Jones et al. [22] 2001 10 healthy participants, 5M:5F, aged 




300 mL water containing 50g glucose 
with 30 mL lemon juice made up to 
300 mL with or without 9g guar gum 
SBP, DBP and MAP fell on both days. The 
magnitude of the falls in SBP, DBP, and MAP 
were less, after guar. 
Jones et al. 
[111] 
2019 15 healthy participants, 9M:6F, aged 
67.2 ± 2.3 years and 15 T2D patients, 




Lixisenatide (10 mcg) or placebo sc 
30 min before 75g glucose drink on 
two separate days. 
Lixisenatide attenuated the decrease in SBP 
and DBP compared to placebo in healthy 
participants and those with T2D 
Marathe et al. 
[76] 





ID glucose (25g/100 mL) infused at 2 
kcal/min or 4 kcal/min 
SBP and DBP fell at 30min with 4 kcal/min, 
but not 2kcal/min infusions. The fall in SBP 
was greater after the 4kcal/min infusion. 
Maruta et al. 
[76] 
2006 28 neurologic patients (11 with PD, 
4M:7F, aged 61-86 years; 6 with 
MSA, 4M:2F, aged 53-76 years; 11 
with T2D, 8M:3F, aged 62-85 years) 
and 20 healthy controls (13 older 
participants, 5M:8F, aged 62-80 years; 




75g glucose with or without 200 mcg 
voglibose. All participants were 
studied on the day without voglibose. 
11 of them (4 with PD, 5 with MSA, 
1 with T2D, 1 older control), who had 
PPH, were studied on the day with 
voglibose. 
The fall in BP was less (without voglibose: 
41.5 ± 13.2 mmHg, with voglibose: 21.0 ± 13.0 
mmHg) and the duration of PPH was shorter 
(without voglibose: 52.3 ± 28.0 minutes, with 
voglibose: 17.3 ± 22.5 minutes) after 
voglibose. 
Masuo et al. 
[365] 
1996 12 young normotensive (NT) 
participants, aged 47.8 ± 2.6 years; 21 
elderly NT, aged 77.9 ± 1.5 years; 17 
young hypertensive (EH) patients, 
aged 49.0 ± 1.9 years and 32 elderly 




75g glucose in 225 mL water Postprandial BP reduction, defined as 10% or 
more decline in MAP was recognised in 3/12 
(25%) young NT, 9/21 (43%) elderly NT, 5/17 
(29%) young EH, and 20/32 (63%) elderly EH. 
The frequency of postprandial BP reduction 
was significantly greater in elderly 
hypertensives compared to elderly 
normotensives and was greater in young 
hypertensives compared to young 
normotensives. 




Mathias et al. 
[40] 
1989 6 patients with chronic autonomic 
failure (CAF), 4M:2F, aged 42-68 
years, 6 age-matched participants 
without CAF, aged 45-70 years; and 8 




An iso-osmotic solution of glucose 
(1g/kg body weight) or xylose 
(0.83g/kg body weight) in 250 mL 
water. 6 patients with CAF attended 2 
on both glucose and xylose days. 6 
age-matched participants and 8 male 
normal participants attended only on 
the glucose day.   
Xylose caused a lower and more transient fall 
in BP than glucose in patients with CAF (15 ± 
6% vs. 34 ± 7%). After glucose, there was a 
substantial fall in 6 age-matched participants 
but a minimal change in 8 male normal 
participants.  
Nair et al. [159] 2015 13 participants with PPH, 4M:9F, 




Ingestion of 50g glucose in 200 mL 
on both days. On one day, participants 
walked at their usual pace for 30 m 
every 30 minutes for 120 minutes. 
On the control day, there were significant falls 
in SBP and DBP. On the intervention day, 
there was no significant fall in SBP, however, 
DBP still fell significantly. 
Nair et al. [158] 2016 29 older participants,18F aged 77.1 ± 





3 treatments: glucose (50g in 200 mL) 
(G) or water (200 mL) and 
intermittent walking (WW) or 
glucose and walking (GW) 
16 participants had PPH. In PPH, there was a 
significant fall in SBP (26.69 ± 8.43 mmHg) 
on the “G” day and no change on “GW” or 
“WW” days. In those without PPH, there were 
no changes in SBP on the “G” or “GW” days, 
with an increase in SBP on the “WW” day. 
Nguyen et al. 
[33] 
2018 35 older participants, 28M:7F, aged 
73 ± 5 years, discharged at least 




300 mL drink containing 75g glucose There were significant reductions in both SBP 
and DBP. Ten participants (29%) had 
postprandial hypotension. The maximal fall in 
SBP and DBP were −29 ± 14 mmHg and −18 
± 7 mmHg. The maximal fall in SBP was 
greater in patients with PPH than in those 




2002 8 healthy elderly participants, 4M:4F, 




25% glucose solution was infused 
intraduodenally at a rate of either 1 or 
3 kcal/min for 60min followed by 0.9 
% saline for a further 60min 
Between t = 0-60min, there was a fall in SBP, 
DBP and MAP during the 3 kcal/min glucose 
infusion, but not during the 1 kcal/min 
infusion.   
O'Donovan et 
al. [23] 
2005 8 healthy older participants, 4M:4F, 




ID glucose infusion (3 kcal/min) with 
or without guar gum (4g) for 60min, 
followed by 0.9% saline 
intraduodenally for a further 60min. 
Between t = 0-60min, SBP was lower during 
the glucose-only infusion than during the 
glucose and guar infusion. The maximum fall 
in SBP on the glucose-only study was 10 ± 4 
mmHg. Between t = 0-30min, DBP fell during 
the glucose-only infusion, but did not change 
with the glucose and guar infusion. 




Pham et al. 
[366] 
2018 12 healthy participants, 6M:6F, aged 




ID infusion of either glucose (25%, 
∼1400 mOsmol/L), sucralose (4 
mmol/L, ∼300 mOsmol/L) or saline 
(0.9%, ∼300 mOsmol/L) at a rate of 3 
mL/min for 60min followed by ID 
saline for a further 60min.  
MAP decreased during glucose but not during 
sucralose or saline. By t = 60 min, MAP was 
lower after glucose (85.9 ± 2.8 mmHg) than 
after sucralose (93.1 ± 2.2 mmHg) infusions 
without significant difference between 
sucralose and saline infusions. 
Pham et al. [70] 2019 33 healthy older participants, 






75g glucose in 300 mL water The prevalence of PPH doubled from 9.1% to 
18.2%. 
There was a fall in SBP and DBP on both study 
days. The AUC of SBP was greater at follow-
up. The maximum fall in postprandial SBP 
between t = 60–120 min was significantly 
greater at follow-up (−11.7 ± 1.4 vs −15.2 ± 1.6 
mmHg). 
Robinson et al. 
[42] 
1992 5 participants with age-related OH, 
2M:3F, aged 73-88 years), 3 
participants with autonomic failure, 
1M:2F, aged 72-79 years and 5 




50g glucose or 42g xylose in 100 mL 
water 
In OH and autonomic failure groups, the SBP 
decreased comparably following glucose and 
xylose, DBP was lowered 60-90 min after 
glucose. No significant BP changes in the 
control group.  
Russo et al. 
[155] 
2003 11 patients with T2D managed by diet 




50g glucose and 30 mL lemon juice, 
with or without 9g guar gum in 300 
mL. 
There was significant fall in SBP between 
baseline and 30min on the control day (143.9 ± 
4.7 mmHg vs 139.0 ± 4.2 mmHg; P < 0.01), 
but not after guar (145.1 ± 4.8 mmHg vs 142.6 
± 4.5 mmHg, P = 0.6). There were significant 
falls in DBP and MAP between baseline and 
30min on both study days. 
Sasaki et al. 
[36] 
1992 15 normal participants, aged 25-63 
years and 35 outpatients with T2D, 




Daily meals and 75g glucose in 300 
mL water 
No significant change in BP in the normal 
participants. 
The incidence of PPH in diabetics was 37% 
after daily meals and 20% after 75g glucose.  
Takamori et al. 
[54] 
2007 17 MSA patients, 9M:8F, aged 59.8 ± 
7.9 years and 8 healthy controls, 




75g of glucose in 225 mL of water Of 17 MSA patients, 9 had PPH. 8 controls 
were PPH negative. The falls in SBP and DBP 
in MSA with PPH were significantly greater 
than in MSA without PPH or in controls. 
Thazhath et al. 
[180] 
2017 9 patients with T2D, managed by diet 




Intravenous exenatide (7.5mcg) or 
volume-matched saline control from 
−30 to 120min + ID glucose 
(3 kcal /min) from 0–60min. 
During the ID glucose infusion, SBP, DBP and 
MAP increased with exenatide, but fell with 
saline control. The AUC for DBP and MAP, 




but not SBP, was higher with exenatide than 
control. 
Trahair et al. 
[109] 
2015 14 older healthy participants, 6M:8F, 
aged 72.1 ± 1.1 years and 10 patients 





Between t = −30-120min: intravenous 
infusion of GLP-1 (0.9pmol/kg/min) 
or saline (154 mmol/LNaCl).  
At t = 0min: 75g glucose drink in 300 
mL water 
After the glucose drink, there were falls in SBP 
and DBP in both groups.  
The fall in DBP in older individuals; and the 
fall in SBP and DBP in patients with T2D were 
less after GLP-1 infusion compared to control. 
Trahair et al. 
[83] 
2012 12 healthy young participants, 6M;6F, 
aged 22.2 ± 2.3 years and 12 healthy 
older participants, 6M; 6F, aged 68.7 




ID infusion of glucose at either 1, 2 or 
3 kcal/min or 0.9% normal saline for 
60min followed by ID saline for a 
further 60min. 
In young participants, there were no changes in 
SBP and DBP during the four infusions. In 
older participants, there were falls in SBP and 
DBP during 2 kcal/min and 3 kcal/min 
infusions, but not during 1 kcal/min infusion. 
Trahair et al. 
[106] 
2014 10 healthy older participants, 9M: 1F, 




Between t = -30-60min, intravenous 
infusion of GLP-1 (0.9pmol/kg/min), 
or saline for 90. Between t = 0-60min, 
ID glucose was infused at 3 kcal/min. 
During ID glucose infusion, there were falls in 
SBP and DBP with both GLP-1 and control. 
The maximum fall in SBP was greater with 
control than GLP-1 (−13.6 ± 3.1 mmHg vs 
−8.7 ± 2.3 mmHg). 
Trahair et al. 
[74] 
2015 88 healthy older participants, 




75g glucose in 300 mL water SBP and DBP decreased significantly after the 
glucose drink. Eleven participants (12.8%) had 
PPH. 
Trahair et al. 
[52] 
2016 21 participants with mild to moderate 
PD, 13M:8F, aged 64.2 ± 1.6 years 
Crossover 
study 
75g glucose in 300 mL water SBP and DBP fell following the glucose drink. 
8 participants (38%) had postprandial 
hypotension. 
Trahair et al. 
[144] 
2017 8 healthy older participants, 4M:4F, 
aged 71.0 ± 1.7 years and 8 
participants with PPH 1M:7F, aged 




75g glucose in 300 mL water or water 
alone 
Following the glucose, there were decreases in 
SBP and DBP in both groups, the maximum 
fall in SBP was greater in participants with 
PPH.  
Following the water, there were no changes in 
SBP and DBP in healthy participants, but there 
was a rise in SBP in participants with PPH. 
Trahair et al. 
[367] 
2018 12 obese participants, 10M:2F, aged 
36.6 ± 3.9 years, BMI: 36.1 ± 1.3 
kg/m2) and 23 controls, 16M:7F, aged 





ID infusions of glucose at 1 or 3 
kcal/min, or 0.9% saline, for 60min, 
followed by saline for a further 
60min. 
No changes in SBP in both groups during any 
of the conditions. There was a fall in DBP in 
controls during 1kcal/min and 3 kcal/min 
infusions; and in obese participants during 3 
kcal/min infusion. There was no difference in 
BP responses between the groups. 




Umehara et al. 
[50] 
2014 37 patients with de novo PD (17 with 
PPH, 4M:13F, aged 76.8 ± 6.1 years; 
20 without PPH, 8M:12F, aged 74.4 ± 
7.5 years) and 10 healthy controls, 




75g glucose in 300 mL water Of the 37 patients, 17 (45.9%) had PPH, 15 
(40.5%) had OH and 8 (21.6%) had both PPH 
and OH. 2 controls had PPH. The maximum 
fall in SBP after the glucose drink significantly 
correlated with that on head-up tilt-table 
testing in PD patients.  
Umehara et al. 
[51] 
2016 64 de novo patients with PD, 




75g glucose in 300 mL water 29 patients had PPH. Patients with PPH 
experienced greater reductions in SBP (30 ± 11 
vs 11 ± 15 mmHg) and DBP (14 ± 9 vs 7 ± 5 
mmHg) after glucose drink compared to 
patients without PPH.  
van Orshoven 
et al. [88] 
2008 8 healthy young participants (4M:4F, 
aged 28.8 ± 3.4 years), 8 healthy 
elderly (4M:4F, aged 75.3 ± 1.6 
years). 2 female patients with 





ID infusion of 25% glucose at 3 
mL/min for 60min. Saline was 
infused for 30min before and after ID 
glucose.  
ID glucose decreased SBP, in both the young 
and older people, but the fall in SBP was 
greater in the older group (−6.5 ± 1.6 vs −17.0 
± 4.1 mmHg). 2 PPH patients had a greater fall 
in SBP than the two healthy groups (-21 and -
98 mmHg). 
Vanis et al. [24] 2011 12 healthy older participants, 6M:6F, 




ID infusion of glucose at either 1, 2 or 
3 kcal/min or 0.9% normal saline for 
60min, followed by saline for a 
further 60min. 
There was a fall in SBP and DBP during 2 and 
3 kcal/min glucose infusions, but not during 
saline or 1 kcal/min glucose infusion. There 
was no difference in the maximum falls in SBP 
during 2 kcal/min (15 ± 2mmHg) and 3 
kcal/min (12 ± 2mmHg) loads.   
Vanis et al. 
[104] 
2011 8 healthy older participants, 6M:2F, 




300 mL drink of water, 50g glucose or 
50g d-xylose. 
There was a fall in SBP after glucose drink and 
no change after xylose or water drink. 
Vanis et al. 
[368] 





The four treatments were as follows: 
ID glucose (3 kcal/min) + barostat 
(distension) (GD), ID saline + 
barostat (SD), ID glucose (G), and ID 
saline (S). 
SBP and DBP fell during G, but not during S 
or GD; and increased during SD. The 
maximum changes in SBP during G, GD, S and 
SD were -14 ± 5, -3 ± 4, +11 ± 2, and +15 ± 3 
mmHg respectively. 
Vanis et al. [90] 2012 9 participants, all M, aged 65-75 years Randomised 
crossover 
study 
ID glucose infusion (3 kcal/min) and 
gastric distension at a volume of 1) 0 
mL (V0), 2) 100 mL (V100), 3) 300 
mL (V300), or 4) 500 mL (V500). 
SBP and DBP fell during V0, but did not 




2006 12 elderly participants, 6M:6F, aged 




300 mL drink of either (1) CHO (75g 
glucose and 93g Polyjoule (CHO 
polymer)-653 kcal); (2) 88 % fat 
SBP decreased following the CHO drink and 
the high-fat drink but not water; there was no 
difference in the magnitude of the decrease 




(cream blended with milk-653 kcal) 
or (3) water. 
between the CHO and fat drinks. The onset of 
the SBP fall was slower after the fat drink (26.5 
± 17.1 min vs 13.0 ± 11.7 min).  
Visvanathan et 
al. [133] 
2005 10 healthy older participants, 4M; 6F, 




300 mL of either 50g glucose, 50g 
sucrose, 50g fructose or water + 30 
mL lemon juice 
SBP decreased significantly following glucose 
(-3.96 ± 1.38 mmHg) and sucrose (-3.03 ± 
1.37mmHg) ingestion, increased non-
significantly following fructose ingestion (2.59 
± 1.62 mmHg). The decrease in SBP occurred 
earlier after glucose than sucrose ingestion 
(7.33 ± 2.19 vs 21.0 ± 4.30min). 
Wu et al. [369] 2017 Study A: 16 participants with T2D, 
11M: 5F, 65.5 ± 2.4 years. 
 
Study B: 9 participants with T2D, all 




Study A: vildagliptin (50mg) or 
placebo was given 60min before ID 
glucose infusion at 2 or 4 kcal/min 
(ID2 or ID4).  
Study B: Participants received 
metformin (850mg) or placebo for 7 
days. On the study day, metformin 
(850 mg) or placebo was given 30min 
before ID2. 
Study A: SBP and DBP decreased after 
vildagliptin, but not after placebo, without any 
difference between ID2 and ID4.   
Study B: SBP and DBP decreased on both days 
without any difference between metformin and 
placebo.  
T2D = type 2 diabetes; BP = blood pressure; SBP = systolic blood pressure; DBP = diastolic blood pressure; HR = heart rate; ID = intraduodenal; MAP = mean arterial pressure; 
PD = Parkinson’s disease; MSA = multi-system atrophy; PPH = postprandial hypotension; OH = orthostatic hypotension; CHO = carbohydrate; GLP-1 = glucagon-like peptide-












Table 5.2. Studies relating to the effects of other nutritive sweeteners on blood pressure. 
Study Year Participant characteristics Study Design Sweeteners 
assessed rather 
than glucose 
Test meal Effects on blood pressure 
Brown et al. 
[359] 
2008 15 healthy normal-weight 





Fructose 500 mL of either water, 
60g glucose, or 60g 
fructose. 
Oral fructose, but not glucose, significantly 
increased SBP and DBP. The maximum rise 
in SBP after fructose was 6.2 ± 0.8 mmHg. 
Charriere et 
al. [370] 







500 mL of water 
containing 60g of either 
glucose, fructose or 
galactose. 
The increase in SBP after fructose (7–8 
mmHg) was greater than after glucose (4–5 
mmHg) or galactose (2–3 mmHg). DBP 
increased to a greater extent with fructose 
(~5 mmHg), compared to non-significant 




2005 8 healthy older participants, 5M:3F, 




Sucrose 300 mL drink of 100g 
sucrose and 30 mL lemon 
juice with or without 
100mg acarbose 
There was a fall in SBP and DBP on the 
control day while there was an overall 
increase in SBP on the acarbose day. 
Gentilcore et 
al. [107] 
2011 8 healthy older participants, 4M:4F, 




Sucrose ID infusion of sucrose 
(100g/300 mL) at ∼6 
kcal/min with or without 
acarbose (100mg), over 
60min. 
There were significant falls in SBP 
(maximum fall: 11.2 ± 2.0mmHg) during 
control, but not after acarbose. The fall in 
DBP was greater after control (10.9 ± 
0.9mmHg) than after acarbose (8.1 ± 
1.5mmHg). 
Grasser et al. 
[360] 
2014 12 healthy young adults, 7M:5F, 






500 mL drink of either 
60g sucrose, 60g glucose, 
60g fructose or 30g 
fructose. 
Ingestion of fructose (60 or 30g) elevated 
SBP, DBP and MAP. Ingestion of glucose 
elevated SBP. Ingestion of sucrose showed 
no BP changes. The increases in DBP and 
MAP were significantly higher for fructose 
(60 or 30 g) than for either glucose or 
sucrose. The increase in SBP was 
significantly higher for fructose than for 
sucrose. 
Jansen et al. 
[134] 
1987 10 young normotensive people, 
aged 28 ± 1 years (YN), 10 young 
hypertensive patients, aged 44 ± 2 




Fructose 300 mL drink of either 
75g glucose or 75g 
fructose 
Glucose decreased MAP significantly in the 
EH, EN and YH group. After fructose, BP 
remained unchanged in 4 groups. 




normotensive people aged 75 ± 2 
years (EN), 10 elderly hypertensive 
patients aged 75 ± 1 years (EH) 
Mathias et al. 
[40] 
1989 6 patients with chronic autonomic 
failure (CAF), 4M:2F, aged 42-68 
years; 6 age-matched participants 
without CAF, aged 45-70 years; and 




Xylose An iso-osmotic solution 
of glucose (1g/kg body 
weight) or xylose 
(0.83g/kg body weight) 
in 250 mL water. 
Xylose caused a lower and more transient 
fall in BP than glucose in patients with CAF 
(15 ± 6% vs. 34 ± 7%). After glucose, there 
was a substantial fall in 6 age-matched 




1992 5 people with age-related OH, 
2M:3F, aged 73-88 years, 3 people 
with autonomic failure, 1M:2F, 
aged 72-79 years and 5 controls, 




Xylose 50g glucose or 42g 
xylose in 100 mL water 
There were no significant BP changes in the 
control group. In OH and autonomic failure 
groups, the SBP decreased comparably 
following glucose and xylose, DBP was 




2014 48 participants, 31M; 17F, aged 58 






Test drink of 70g either 
protein (pea protein 
isolate, milk protein 
isolate, egg white protein 
isolate or mixed protein), 
sucrose or maltodextrin. 
DBP and MAP were significantly decreased 
after maltodextrin, but not after protein mix 
or sucrose. SBP was not significantly 
changed after any of the meals. 
 





8 healthy older participants, 6M:2F, 








300 mL drink of water, 
50g glucose or 50g d-
xylose. 
 
There was a fall in SBP after glucose drink 
and no change after xylose or water drink. 
Visvanathan 
et al. [133] 
2005 10 healthy older participants, 






300 mL of either 50g 
glucose, 50g sucrose, 50g 
fructose or water + 30 mL 
lemon juice 
SBP decreased significantly following 
glucose (-3.96 ± 1.38mmHg) and sucrose (-
3.03 ± 1.37 mmHg), but not fructose, 
ingestion (2.59 ± 1.62 mmHg). The decrease 
in SBP occurred earlier after glucose than 
sucrose ingestion (7.33 ± 2.19 vs 21.0 ± 4.30 
min). 
T2D = type 2 diabetes; BP = blood pressure; SBP = systolic blood pressure; DBP = diastolic blood pressure; ID = intraduodenal; MAP = mean arterial pressure; MSA = 
multi-system atrophy; PPH = postprandial hypotension; OH = orthostatic hypotension. 
 
 




Table 5.3. Studies relating to the effects of non-nutritive sweeteners on blood pressure. 





Test meal  Effects on blood pressure 




200 students divided equally into 4 
groups: A (aged 18.82 ± 0.80 
years), B: (aged 18.60 ± 0.57), C 
(aged 18.64 ± 0.59) and D (18.64 ± 
0.59)  
Parallel study  Aspartame, 
Acesulfame-K,  
sucralose 
Group A (control): 10g 
of cellulose. Group B: 
0.36gm (5mg/kg) 
sucralose. Group C: 
10.8g (150mg/kg) 
aspartame. Group D: 
3.24g (45 mg/kg) 
Acesulfame-K. 
There was no difference in BP between 
group A and B. SBP was lower at 60, 90 and 
120min for group C; and at 60 minutes for 
group D compared to control.  




12 healthy participants, 6M: 6F, 




Sucralose ID infusion of either 
glucose (25%, ∼1400 
mOsmol/L), sucralose (4 
mmol/L, ∼300 
mOsmol/L) or saline 
(0.9%, ∼300 mOsmol/L) 
at a rate of 3 mL/min for 
60min followed by ID 
saline for a further 
60min.  
MAP decreased during glucose but not 
during sucralose or saline. By t = 60min, 
MAP was lower after glucose (85.9 ± 2.8 
mmHg) than after sucralose (93.1 ± 2.2 
mmHg) infusions without significant 
difference between sucralose and saline 
infusions. 
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Postprandial hypotension (PPH) is now recognised as a frequent and important clinical 
problem, particularly in the healthy elderly (24 – 38%) [5] and in autonomic dysfunction (e.g. 
diabetes (∼40%) [1, 5] and Parkinson’s disease (PD) (40 – 100%)) [1, 5]. It is frequently 
associated with syncope and falls [1, 4] as well as increased mortality [68]. 
 
The pathophysiology of PPH is multifactorial and incompletely understood. It involves the 
interplay between autonomic and neural mechanisms, including the release of gut hormones, 
which are influenced by meal composition, gastric distension, and small intestinal nutrient 
delivery. After a meal, there is a doubling of superior mesenteric artery (SMA) blood flow [1]. 
In healthy young individuals with intact baroreflex function, the increase in splanchnic blood 
flow is accompanied by concomitant increases in heart rate (HR), peripheral vascular 
resistance, stroke volume and cardiac output [12]. In patients with PPH, these compensatory 
responses are inadequate [1]. We have shown that the postprandial fall in BP is greater when 
gastric emptying is more rapid [7], whereas, gastric distension attenuates the fall in BP in 
healthy young and older, people [141-143]. 
 
All macronutrients reduce BP comparably [9, 83, 128, 130]; we have shown that the 
hypotensive responses to fat and protein are similar, but occur slightly later, than the response 
to glucose [9], probably reflecting the more prolonged time for digestion. The effects of 
carbohydrate on glycaemia/insulinaemia are not apparently related to the hypotensive response 
(e.g. iv glucose has little effect on BP and PPH occurs frequently in type 1 diabetes (T1D) [5]. 
Studies by our group [413, 430] and others [417, 431] have highlighted the importance of sweet 
taste receptors (STRs; T1R2/T1R3) in the proximal intestine in the detection of luminal glucose 
and artificial sweeteners, and release of gut hormones, particularly the ‘incretin hormones’, 




glucose-dependent insulinotropic peptide (GIP) [413] and glucagon-like peptide-1 (GLP-1) 
[413, 415, 417, 432]. Intestinal STRs also specifically regulate levels of the intestinal glucose 
transporter, sodium-glucose cotransporter-1 (SGLT-1). We have shown that xylose, a poorly 
absorbed pentose sugar, empties comparably to glucose, but has no effect on BP in healthy 
older subjects [104], as is the case for fructose [133]. While sugars and artificial sweeteners 
are perceived by lingual taste as equivalent, neither xylose nor fructose is a substrate for SGLT-
1, suggesting a role for SGLT-1 in mediating the hypotensive response to carbohydrate, rather 
than sweet taste per se. Non-caloric artificial sweeteners, including sucralose, are now used 
widely as a substitute for carbohydrate. Surprisingly, there is no information about the effect 
of artificial sweeteners on postprandial BP.  
 
We aimed to evaluate the effects of intraduodenal (ID) administration of the artificial 
sweetener, sucralose, compared to glucose and saline, on BP and SMA blood flow in healthy 
older subjects. 
 
6.2 Materials and methods 
6.2.1 Subjects 
The study included twelve healthy, volunteers (six male, and six female, mean age 73.2 ± 1.1 
years, BMI 26.9 ± 0·9 kg/m2). All subjects were non-smokers, and none had a history of 
gastrointestinal disease or surgery, diabetes, significant respiratory, renal or cardiac disease, 
chronic alcohol abuse, epilepsy, or were taking medication known to influence BP or 
gastrointestinal function. 
 




The study was conducted in accordance with the Declaration of Helsinki, and all procedures 
involving human subjects were approved by the Human Research Ethics Committee of the 
Royal Adelaide Hospital. Written informed consent was obtained from all subjects. 
 
6.2.2 Protocol  
Each subject was studied on 3 occasions, separated by at least 7 days, in a randomised, double-
blind, crossover design. Randomisation was performed using a computer-generated program. 
On each study day, the subject attended the Discipline of Medicine, Royal Adelaide Hospital, 
the University of Adelaide, at ∼ 09.00 h after a fast (14 h for solids; 12 h for liquids) [75]. A 
multi-lumen silicone catheter (∼ 3.4-mm diameter) (Dentsleeve International Ltd, Mui 
Scientific, Mississauga, Canada), which included an infusion channel with a port located ∼12 
cm distal to the pylorus (i.e. in the duodenum) and 2 other channels, 1 positioned in the antrum 
(2.5 cm proximal to the pylorus) and the other in the duodenum (2.5 cm distal to the pylorus), 
was introduced into the stomach via an anesthetised nostril [75]. The latter 2 channels were 
perfused with normal saline (0.9%). The correct positioning of the catheter was maintained by 
continuous measurement of the transmucosal potential difference between the antral (−40 mV) 
and the duodenal (0 mV) channels [228]. For this purpose, an intravenous cannula filled with 
sterile saline was placed subcutaneously in the left forearm and used as a reference electrode 
[228]. The tip of the catheter was allowed to pass into the duodenum by peristalsis, which took 
between t = 30 and 180 min. When the catheter was positioned correctly, the subject was placed 
in the supine position. An intravenous cannula was inserted into an antecubital vein for blood 
sampling and an automated BP cuff placed around the opposite arm. 
 




Following a stabilisation period of at least 15 min, subjects received an ID infusion of glucose 
(25%w/v ~1400mOsmol/L), sucralose (Tate & Lyle, Decatur, IL, USA) (4mmol/L, 
~300mOsmol/L) or saline (0.9%w/v ~300mOsmol/L) at a rate of 3mL/min (i.e. 3 kcal/min for 
the glucose solution) from t = 0 – 60 min. ID infusions were administered via a volumetric 
infusion pump (Gemini PC-1; IMED Corp, San Diego, CA, USA) and both the subject and the 
study investigators were blinded to the study condition. On all study days, saline (0.9%w/v) 
was infused at a rate of 3mL/min between t = 60 and 120 min. All solutions were infused at 
room temperature (∼22oC). At t = 120 min, the catheter was removed, subjects offered a light 
lunch and a final blood sample and BP measurement were taken. Subjects were permitted to 
leave the laboratory once their BP and blood glucose had returned to baseline levels. 
 
6.2.3 Measurements 
6.2.3.1 Blood pressure and heart rate 
Systolic and diastolic BP (SBP and DBP) and HR were measured with an automated 
oscillometric BP monitor (DINAMAP ProCare 100, GE Medical Systems, Milwaukee, WI, 
USA) at t = -9, -6, and -3 min before commencement of the ID infusion and, subsequently, 
every 3 min between t = 0 and 120 min. Baseline BP and HR were calculated as the mean of 
measurements obtained at t = -9, -6, and -3 min before commencement of the ID infusion. The 
mean arterial pressure (MAP) was calculated using the formula MAP = DBP + [(SBP - 
DBP)/3]. 
 
6.2.3.2 Superior mesenteric artery blood flow 
SMA blood flow was measured at t = -2 min, and then every 15 min between t = 0 – 120 min 
using a Logiq e ultrasound system with a 3.5 C broad-spectrum 2.5 – 4 MHz convex linear 




array transducer (GE Healthcare Technologies, Sydney, NSW, Australia). SMA blood flow 
(mL/min) was calculated instantaneously by using the following equation [433]: 
 
                                            Blood flow (mL/min) = π x r  x TAMV x 60  
where r = the radius of the SMA, and TAMV is the time-averaged mean velocity. 
 
6.2.3.3 Blood glucose concentrations 
Venous blood samples (~ 15 mL) were obtained immediately prior to commencement of the 
infusion (t = −2 minutes) and at t = 15, 30, 45, 60, 90 and 120 min. Blood glucose 
concentrations were determined immediately using a portable blood glucose meter (Medisense 
Companion 2 Meter, Medisense Inc., Waltham, MA, USA) [434, 435]. 
 
6.2.4 Statistical analysis 
MAP, HR, SMA blood flow and blood glucose concentrations were analysed and presented as 
absolute values. One-way ANOVA was used to evaluate the effects of time on absolute values 
for MAP, HR, SMA blood flow and blood glucose. The maximum falls in MAP and rise in 
HR, SMA blood flow, blood glucose concentrations were defined as the greatest change from 
baseline in each subject at any given time point for each treatment. Areas under the curve 
(AUCs) were calculated using the trapezoidal rule and analysed by one-way ANOVA to 
evaluate a treatment effect from t = 0 to 60 min and from t = 0 to 120 min for MAP and HR, 
from t = −2 to 60 min and from t = -2 to 120 min for SMA blood flow, and blood glucose. All 
analyses were performed using SPSS version 23 (SPSS, Chicago, IL, USA). Data are presented 
as mean values ± SEM, unless stated otherwise. A P value < 0.05 was considered significant 
in all analyses.  




6.3 Results  
The studies were well tolerated. One subject experienced symptoms referable to 
hypoglycaemia (dizziness, headache, sweating, extreme hunger and thirst; blood glucose 
2.8mmol/L at only 1 time point i.e. t = 120 min). The symptoms resolved promptly following 
ingestion of a glucose drink and all data were included in the analysis. 
 
6.3.1 Blood pressure and heart rate 
There were no differences in baseline (t = 0 min) BP or HR among the 3 days (saline vs. 
sucralose vs. glucose, respectively) (Table 6.1).  
 
6.3.1.1 Mean arterial pressure 
Between t = 0 and 60 min, there was a fall (P = 0.001) in MAP with glucose, but no overall 
change during either sucralose (P = 0.32) or saline (P = 0.59), infusions (Figure 6.1A). There 
was a treatment effect (P = 0.005) for the AUC of the change in MAP, so that MAP was lower 
during glucose (P = 0.035) compared with saline, without any difference between sucralose 
and saline (P = 1.0) or sucralose and glucose (P = 0.071). At the end of the glucose infusion at 
t = 60 min, MAP (85.9 ± 2.8 mmHg) was lower than saline (95.3 ± 2.5 mmHg, P = 0.001) and 
sucralose (93.1 ± 2.2 mmHg, P = 0.01) infusions, while there was no significant difference in 
MAP between sucralose and saline infusions (P = 0.54) (Figure 6.1A). 
 
Between t = 0 and 120 min, there was a treatment effect (P = 0.001) for the AUC of the change 
in MAP, so that MAP was lower on the day with glucose, when compared with both saline and 
sucralose, infusions (P = 0.021 for both), while there was no difference between saline and 
sucralose infusions (P = 1.0) (Figure 6.1A). The maximum fall in MAP from baseline was 




greater (P = 0.019) during glucose (11.6 ± 2.0 mmHg), compared with saline, infusion (5.1 ± 
0.6 mmHg).  
 
At t = 120 min, MAP did not differ from baseline after glucose infusion (93.3 ± 3.9 mmHg, P 
= 0.62), but was greater after sucralose (98.3 ± 2.9 mmHg, P = 0.043) and saline (100 ± 3.0 
mmHg, P < 0.001) infusions.  
 
6.3.1.2 Heart rate 
Between t = 0 and 60 min, there was a rise in HR during the glucose (P < 0.0001), but no 
change during the sucralose (P = 0.12) or saline (P = 0.12), infusions (Figure 6.1B). While 
there was an overall treatment effect (P = 0.034) for the AUC of the change in HR, there were 
no significant differences between the three infusions - i.e., glucose vs. sucralose (P = 0.09), 
glucose vs. saline (P = 0.26) and sucralose vs. saline (P = 1.0).  
 
Between t = 0 and 120 min, there was a treatment effect (P = 0.008) for the AUC of the change 
in HR, so that HR was greater on the day with glucose infusion, when compared with sucralose 
(P = 0.047) infusions, while there was no difference between saline infusion and sucralose (P 
= 1.0) or glucose infusions (P = 0.07) (Figure 6.1B). The maximum rise in HR from baseline 
was greater (P = 0.007) on the study with glucose (15 ± 2 bpm) compared with saline (6.5 ± 
1.2 bpm) infusion. There was no significant difference in the maximum rise in HR between the 
sucralose (8.8 ± 0.98 bpm), saline (P = 0.37) and glucose (P = 0.09) infusion study days.  
 
At t = 120 min, HR was greater than baseline after the three infusions (saline vs. sucralose vs. 
glucose: 63 ± 2 bpm, P = 0.01 vs. 62 ± 2 bpm, P < 0.001 vs. 67 ± 3 bpm, P < 0.01, respectively). 
 




6.3.2 Superior mesenteric artery blood flow 
There was no difference (P = 0.85) in baseline (t = −2 min) SMA blood flow among the 3 days 
(Table 6.1). 
 
Between t = -2 and 60 min, there was a rise in SMA blood flow with the glucose (P < 0.0001), 
but no significant change with the sucralose (P = 0.15) or saline (P = 0.22), infusions (Figure 
6.2).  
 
Between t = -2 and 60 min or t = -2 and 120 min, there was a treatment effect (P < 0.001) for 
the AUC of SMA blood flow, so that SMA blood flow was greater during glucose, compared 
with sucralose and saline (P < 0.001 for both) infusions without any difference between 
sucralose and saline (P = 1.0) (Figure 6.2). The maximum rise in SMA blood flow during 
glucose infusion (514 ± 61 mL/min) was greater than during saline (53 ± 14 mL/min) and 
sucralose (43 ± 14mL/min) infusions (P < 0.001 for both), while there was no difference in the 
maximum rise in SMA blood flow between sucralose and saline infusions (P = 1.0). 
 
At t = 120 min, SMA blood flow did not differ from baseline among the 3 days (saline vs. 
sucralose vs. glucose: 281 ± 12 mL/min, P = 0.28 vs. 300 ± 18 mL/min, P = 0.75 vs. 308 ± 26 
mL/min, P = 0.98, respectively) (Figure 6.2). 
 
6.3.3 Blood glucose  
There was no difference (P = 0.43) in baseline (t = −2 min) blood glucose among the 3 days 
(Table 6.1). 
 




Between t = -2 and 60 min, there was a rise in blood glucose during the glucose (P < 0.0001) 
but no change during the sucralose (P = 0.66) or saline (P = 0.77) infusions (Figure 6.3). 
 
Between t = -2 and 60 min and t = -2 and 120 min, there was a treatment effect (P < 0.001) for 
the AUC of blood glucose, so that blood glucose was higher during glucose, compared with 
sucralose and saline, infusions (P < 0.001 for both) without any difference between sucralose 
and saline infusions (P = 0.26 between t = -2 and 60 min, P = 0.12 between t = -2 and 120 min) 
(Figure 6.3). Peak blood glucose during glucose infusion (11.3 ± 0.43 mmol/L) was also greater 
than saline (5.3 ± 0.09 mmol/L) and sucralose (5.4 ± 0.07 mmol/L) infusions (P < 0.001 for 
both), while there was no significant difference in the peak blood glucose between sucralose 



















Figure 6.1. Mean arterial blood pressure (A), and heart rate (B) in 12 healthy older subjects 
following intraduodenal infusion of glucose, sucralose, and saline. Infusions were given 
between t = 0 - 60 min followed by saline. Data are analysed with one-way ANOVA with 
Bonferroni correction and presented as mean values ± SEM. Mean arterial blood pressure 
treatment effect between t = 0 and 120 min: P < 0.05 for glucose compared with sucralose; P 
< 0.05 for glucose compared with saline; P = 1.0 for sucralose compared with saline. Heart rate 
treatment effect between t = 0 and 120 min: P < 0.05 for glucose compared with sucralose; P 
= 0.07 for glucose compared with saline; P = 1.0 for sucralose compared with saline.  
  





Figure 6.2. Superior mesenteric artery (SMA) blood flow in 12 healthy older subjects 
following intraduodenal infusion of glucose, sucralose, and saline. Infusions were given 
between t = 0 - 60 min followed by saline. Data are analysed with one-way ANOVA with 
Bonferroni correction and presented as mean values ± SEM. Between t = 0 and 120 min: P < 
0.001 for glucose compared with sucralose; P < 0.001 for glucose compared with saline; P = 
1.0 for sucralose compared with saline. 
  





Figure 6.3. Blood glucose concentration in 12 healthy older subjects following intraduodenal 
infusion of glucose, sucralose, and saline. Infusions were given between t = 0 - 60 min followed 
by saline.  Data are analysed with one-way ANOVA with Bonferroni correction and presented 
as mean values ± SEM. Between t = 0 and 120 min: P < 0.001 for glucose compared with 

















Our study confirms that in healthy older subjects, ID infusion of glucose at a rate of 3 kcal/min 
is associated with a substantial fall in BP and rises in both HR and splanchnic blood flow [83]. 
In contrast, ID infusion of sucralose had no effect on BP, HR or splanchnic blood flow. These 
outcomes indicate that sucralose does not affect BP and provide a rationale for the use of 
sucralose, and potentially other artificial sweeteners, in the management of PPH. 
 
In healthy older subjects and patients with type 2 diabetes (T2D), the magnitude of the 
postprandial fall in BP is greater when gastric emptying is relatively more rapid. By contrast, 
gastric distension by ingestion of water [15] or a balloon [10, 89] attenuates the fall in BP in 
response to both oral and ID glucose and consumption of water before a meal has been 
advocated in the management of PPH [11, 140-142]. In this proof of principle study, we 
accordingly infused glucose intraduodenally and at a rate with the normal range for gastric 
emptying (i.e. 3 kcal/min) [220].  
 
A variety of non-caloric artificial sweeteners, including sucralose, are increasingly being used 
in the food industry as an alternative to sugar, particularly directed to obese people and those 
with diabetes, with the aim of reducing energy intake and minimizing the carbohydrate load 
[341]. The dose of sucralose evaluated equates to 4 mmol/L (i.e. 0.067 mmol/L/min), which is 
a substantially greater osmotic load than that usually ingested in the diet. 
 
A simple carbohydrate meal has been reported to have a greater hypotensive effect than an 
isocaloric complex carbohydrate meal in healthy older people, which is likely to reflect 
different rates of absorption in the small intestine [132]. In healthy older subjects, while both 
glucose and sucrose lead to comparable reductions in BP, fructose [133, 134] and xylose [40, 




103] have no effect on BP. These observations suggest that the hypotensive effect of glucose 
is probably not mediated by STRs per se, but rather by another glucose-specific factor [134], 
such as SGLT-1, that has the capacity for substantial modulation of GLP-1 or GIP secretion.  
 
Several studies have confirmed the presence of heterodimeric sweet taste receptors (STRs, 
T1R2+TR3) in intestinal brush and enteroendocrine cells at the human upper gastrointestinal 
tract, which are analogous to lingual sweet taste receptors [430, 436-438]. They are paired with 
the G-protein, α-gustducin, to activate the transient receptor potential cation channel M5 
(TRPM5) [439]. STRs play an important role in perceiving sugars and artificial sweeteners in 
intestinal lumen as well as in stimulating the secretion of gut hormones, especially incretin 
hormones such as GLP-1 and GIP [439-441].  
 
The postprandial increase in splanchnic blood flow is likely to be integral to the fall in BP. 
Octreotide, which is known to suppress the release of gut hormones, attenuates both the 
postprandial increase in SMA blood flow, and the postprandial fall in BP in patients with 
autonomic failure [137]. Our observation that ID sucralose did not affect SMA blood flow, is 
not surprising given the absence of an effect on BP and may be because sucralose has no effect 
on insulin, GLP-1 or GIP release [413, 415]. A comparable mesenteric hyperaemia following 
the glucose drink is observed in both healthy subjects and patients with autonomic failure, but 
only patients with autonomic failure experience falls in BP, suggesting that PPH appears to 
result from inadequate sympathetic compensation [78]. Moreover, glucose consumption results 
in an increase in the sympathetic nervous system activity [442], which aggravates the situation. 
Meredith et al. found that non-caloric sugars did not stimulate sympathetic activity in the rat 
[443], however, there has been no information about the effect of artificial sweeteners 
specifically on human sympathetic nervous system activity.  




Limitations of our study should be acknowledged. It was not feasible to match sucralose and 
glucose solutions for osmolarity, and while we cannot exclude a potential effect, we have 
reported that glucose concentration does not affect the postprandial hypotensive response to ID 
glucose in healthy older subjects [75] and that neither xylose [104] nor fructose [133] had an 
effect on BP. We did not assess whether sucralose could modify the response to carbohydrate, 
such as glucose, however, both an acute [432] and a 12 week-daily sucralose [431] 
consumption had no effect on the glucose absorption. This ‘proof of principle’ study had a 
relatively small sample size and insulin, GLP-1 and GIP were not assessed. Finally, 
observations relating to sucralose should not be extrapolated to other non-caloric sweeteners. 
 
In conclusion, this study has demonstrated that acute ID administration of sucralose does not 
influence postprandial BP, HR and splanchnic blood in healthy human subjects. Accordingly, 
although further work in this area is needed, artificial sweeteners may have therapeutic benefit 
in the dietary management of PPH.




Table 6.1. Baseline characteristics of the healthy older subjects (n = 12)1 
 Saline Sucralose Glucose P-value 
SBP (mmHg) 138 ± 6 140 ± 5 134 ± 5 0.12 
DBP (mmHg) 71 ± 2 71 ± 2 70 ± 2 0.33 
MAP (mmHg) 93.5 ± 2.9 94.5 ± 2.4 91.7 ± 2.6 0.075 
HR (beats/min) 59 ± 2 57 ± 2 58 ± 2 0.44 
SMA blood 
flow (mL/min) 
295 ± 13 304 ± 24 309 ± 22 0.85 
Blood glucose 
(mmol/L) 
5.1 ± 0.1 5.2 ± 0.1 5.2 ± 0.1 0.43 
 
1 All values are absolute values. Differences between study days were tested via one-way 
ANOVA analyses. Values are means ± SEMs. SBP, systolic blood pressure; DBP, diastolic 
blood pressure; MAP, mean arterial pressure; HR, heart rate; SMA, superior mesenteric artery. 
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Postprandial hypotension (PPH), usually defined as a fall in systolic blood pressure (BP) of ≥ 
20 mmHg, within 2 hours of a meal [1, 4], occurs frequently, e.g. in 24–38% of ‘healthy’ older 
adults [68] and 25-40% of patients with type 2 diabetes (T2D) [1, 5], and is associated with 
major adverse sequelae, including syncope and falls [1, 4], as well as increased mortality [68]. 
Current management is suboptimal [5]. 
 
The pathophysiology of PPH is heterogeneous, which may account for the lack of effective 
management. Multiple factors appear to be involved, including autonomic dysfunction, the 
release of gastrointestinal hormones, meal composition, gastric distension, and small intestinal 
nutrient delivery. After a meal, there is substantial splanchnic blood pooling [1], and in healthy 
young individuals, baroreflex mechanisms protect against a post-meal decrease in BP through 
compensatory increases in heart rate (HR), stroke volume and cardiac output [12]. In ‘healthy’ 
older adults and in patients with PPH, these compensatory responses are inadequate to maintain 
BP [1]. We have shown in healthy older adults and people with T2D that the magnitude of the 
postprandial fall in BP is greater when the rate of gastric emptying [7], or direct small intestinal 
nutrient delivery [8, 24], is relatively more rapid. For example, when glucose is infused into 
the duodenum at rates spanning the normal physiological range, a 3 kcal/min load induces a 
much greater decrease in BP and rises in HR and superior mesenteric artery (SMA) blood flow 
than 1kcal/min [8]. Moreover, PPH is associated with more rapid gastric emptying [74]. In 
contrast to the effect of small intestinal nutrient delivery, gastric distension appears to be 
protective in PPH. Drinking water with a meal has been reported to attenuate the postprandial 
fall in BP in healthy older adults [141, 142], as well as in patients with autonomic failure [141-
143], probably primarily by inducing gastric distension. For example, Gentilcore et al. (2008) 
reported that gastric distension with water at a volume as low as 300 mL diminished the fall in 




BP in response to intraduodenal (ID) glucose in the healthy elderly [15]. The pressor response 
to water may also be greater in patients with autonomic failure [142]. 
 
The α-glucosidase inhibitor, acarbose, is used widely in the management of T2D. By delaying 
intestinal disaccharide absorption, it reduces postprandial glycaemia [164]. Acarbose also 
stimulates the release of the incretin hormone, glucagon-like peptide-1 (GLP-1) [168], and 
slows gastric emptying [162], which may contribute to glucose-lowering in T2D. We reported 
previously that acarbose (100mg) attenuated the fall in systolic BP induced by oral sucrose in 
healthy older adults, an effect associated temporally with slowing of gastric emptying and 
stimulation of GLP-1 [18]. However, when administered intraduodenally i.e. bypassing any 
effect of slowing gastric emptying, acarbose also attenuated the fall in BP induced by sucrose 
[107], which may reflect an effect of acarbose to reduce splanchnic blood flow [107]. 
Subsequent studies support the efficacy of acarbose in the management of PPH to attenuate 
[167, 169], but not abolish, the fall in BP, although these have, for the main part, employed 
small cohorts and associated with substantial methodological limitations. Somewhat 
surprisingly, only one study has hitherto evaluated the effect of acarbose (50mg) on the 
splanchnic blood flow response to a meal [165], which appears central to the hypotensive 
response. Furthermore, this study was in a heterogeneous group of individuals with PPH and 
was neither randomised nor blinded in design, compromising meaningful interpretation [165]. 
 
While it is apparent that gastric distension (induced by water drinking) and acarbose 
theoretically have complementary effects to attenuate the postprandial fall in BP, this has 
hitherto not been evaluated, which is surprising given the simplicity and safety of both 
approaches. The aim of this study was to determine the acute effects of water drinking and 
acarbose, alone and combined, on the BP and SMA blood flow responses to oral sucrose. To 




establish ‘proof-of-principle’, we studied a cohort of healthy older adults, rather than patients 
with PPH.  
 
7.2 Materials and methods 
7.2.1 Subjects 
Ten healthy older adults living in the community (2 male, and 8 female, mean age 74.0 ± 1.4 
years, BMI 26.2 ± 1.1 kg/m2) were recruited by advertisements placed around the hospital, in 
newspapers and via social media, and from a database of subjects who had participated in 
research studies and consented to be contacted. All healthy subjects were non-smokers and 
none had a history of gastrointestinal disease or surgery, diabetes, significant respiratory, renal 
or cardiac disease, chronic alcohol abuse, epilepsy, or was taking medication known to 
influence BP or gastrointestinal function. The study was conducted in accordance with the 
Declaration of Helsinki following the provision of written informed consent by each of the 
participants. The study was registered at http://www.ANZCTR.org.au 
(ACTRN12618000152224) and approved by the Human Research Ethics Committee of the 
Royal Adelaide Hospital. The study adheres to CONSORT guidelines. 
 
7.2.2 Protocol  
Each subject was studied on 4 occasions, separated by at least 1 week, in a randomised, 
crossover design. On each study day, the subject attended the University of Adelaide, 
Discipline of Medicine at the Royal Adelaide Hospital at ∼ 09.00 h after an overnight fast (14h 
for solids; 12h for liquids) [75]. Subjects were seated in a chair, an intravenous cannula was 
inserted into an antecubital vein for blood sampling and an automated BP cuff placed around 
the opposite arm. Following a period of ‘rest’ of 15-30 minutes to allow baseline BP to stabilise 




[24], subjects were given, in random order, either the (i) control treatment (C): a test drink 
comprising 100g sucrose dissolved in 300 mL of water (~407 kcal), (ii) distension treatment 
(D): a ‘preload’ of 300 mL water 15 minutes before the ingestion of the test drink, (iii) acarbose 
treatment (A): 100mg acarbose (Glucobay, Bayer Schering Pharma AG, Berlin, Germany) 
dissolved in the test drink or (iv) combined treatment (AD): the water preload was given 15 
minutes before the ingestion of acarbose which was dissolved in the test drink. Both the 
‘preload’ and test drink were consumed within 2 minutes with time zero (t = 0 min) defined as 
the end of test drink ingestion (Figure 7.1). 
 
Measurements of BP, HR and SMA blood flow were performed at regular intervals until t = 
120 min, as the greatest fall in postprandial BP is known to occur within that time [68]. At the 
end of each study day, each subject was provided with lunch and a final BP measurement was 
taken prior to them leaving the laboratory. 
 
7.2.3 Measurements 
7.2.3.1 Blood pressure and heart rate 
Systolic and diastolic BP (SBP and DBP) and HR were measured with an automated 
oscillometric BP monitor (DINAMAP ProCare 100, GE Medical Systems, Milwaukee, WI, 
USA) at 3-min intervals prior to ingesting the test drink, and, subsequently, every 3 min 
between t = 0-120 min [7, 8, 15, 18, 22, 23, 75, 140, 155, 197, 444]. An average of BP and HR 
measurements obtained at t = -24, -21, -18 min prior to the ingestion of the preload (t = -15 
min), or, on the study day without a preload, at t = -9, -6, -3 min prior to ingestion of the test 
drink, were calculated to represent baseline BP and HR. The mean arterial pressure (MAP) was 




calculated using the formula MAP = DBP + [(SBP - DBP)/3]. PPH was defined as a fall in 
systolic BP of at least 20 mmHg that was sustained for 30 min or more [7]. 
 
7.2.3.2 Superior mesenteric artery blood flow 
SMA blood flow (mL/min) was measured prior to the ingestion of the preload (t = -17 min) 
and/or test drink (t = −2 min), and then every 15 min between t = 0-120 min using a Logiq e 
ultrasound system (GE Healthcare Technologies, Sydney, NSW, Australia) incorporating a 
3.5C broad-spectrum 2.5–4 MHz convex linear array transducer [433]. 
 
7.2.3.3 Blood glucose concentrations 
Venous blood samples (~15 mL) were drawn immediately before ingestion of the preload (t = 
-17 min) and /or test drink (t = -2 min) and then at t = 30, 60, 90 and 120 min. Blood glucose 
concentrations were determined during the study using a portable glucometer (Medisense 
Companion 2 Meter, Medisense Inc., Waltham, MA, USA) [434]. 
 
7.2.3.4 Autonomic nerve function 
Autonomic nerve function was assessed on one of the four days using standardised 
cardiovascular reflex tests with an appropriately sized BP cuff in a temperature-controlled, 
quiet, clinical study room (ANX-3.0 autonomic monitoring system (ANSAR Medical 
Technologies, Inc., Philadelphia, PA)) [445-447]. Testing was performed in the fasting state, 
preceded by 10-15 minutes of rest in the recumbent position. Parasympathetic function was 
evaluated by: i) the variation (R-R interval) of the HR during deep breathing whereby 6 
respiratory cycles were performed and E/I ratio calculated from the peak expiratory and peak 
inspiratory heartbeat intervals and ii) the response to standing (30:15 ratio), with the relevant 




ECG parameters captured and analysed electronically [445]. Sympathetic function was 
assessed by the fall in systolic BP in response to standing whereby baseline BP was taken 
following 10-15 minutes in a semi-recumbent position immediately and 3 minutes after 
standing. An abnormal BP response to standing was defined as a decrease in BP of 20/10mmHg 
or more upon standing over resting. Each of the test results was scored according to predefined 
criteria that were adjusted for age where 0 was considered normal, 1 as borderline, and 2 as 
abnormal providing a total maximum score of 6 [447]. A score of at least 3 was considered to 
suggest autonomic dysfunction. 
 
7.2.4 Statistical analysis 
The maximum fall in MAP and rise in HR were defined as the greatest change from baseline 
in each subject at any given time point for each treatment. Areas under the curve (AUCs) were 
calculated using the trapezoidal rule from t = 0-120 min for MAP and HR, and from t = -2-120 
min for SMA blood flow and blood glucose. Repeated measures two-factor ANOVA was used 
to evaluate the effects of acarbose, gastric distension and their interaction for the AUCs for 
MAP, HR, SMA blood flow and blood glucose. All analyses were performed using SPSS 
version 23 (SPSS, Chicago, IL, USA). MAP and HR are presented as change from baseline 
values and SMA blood flow and blood glucose concentrations as absolute values. Data are 
presented as mean values ± SEM, unless stated otherwise. A P value <0.05 was considered 
significant in all analyses. 
 
7.3 Results  
The studies were reasonably well tolerated. Flatulence and/or diarrhoea were reported by 3 of 
the 10 subjects on acarbose days; in each case, the onset of symptoms was about 3-4 hours after 




ingestion. Three subjects fainted during the study (2 subjects on the distension day and 1 on 
the acarbose day between t = 60-75 min), which, in each case, resolved promptly after lying 
supine for 15-30 min. In 1 of the 3 subjects, fainting was concordant with PPH on the distension 
day. No subject had autonomic neuropathy (mean score: 1.4 ± 0.2). In 1 subject, the ultrasound 
images of SMA blood flow were suboptimal on all study days due to the presence of bowel 
gas, precluding their use. In another subject, insertion of the intravenous cannula for blood 
sampling was unsuccessful on all 4 study days due to poor venous access. Accordingly, BP and 
HR data are available in 10, while SMA blood flow and blood glucose data are available in 9, 
subjects. 
 
7.3.1 Blood pressure and heart rate 
There were no differences in baseline BP or HR among the 4 treatments (control vs. distension 
vs. acarbose vs. combined treatment, respectively): SBP (133 ± 3.7 mmHg vs. 128 ± 2.8 mmHg 
vs. 125 ± 3.6 mmHg vs. 129 ± 3.7 mmHg; P = 0.19); DBP (72 ± 2.6 mmHg vs. 73 ± 2.8 mmHg 
vs. 70 ± 1.9 mmHg vs. 73 ± 1.7 mmHg; P = 0.23); MAP (92 ± 2.2 mmHg vs. 91 ± 2.4 mmHg 
vs. 88 ± 2.1 mmHg vs. 92 ± 1.9 mmHg; P = 0.18) and HR (67 ± 2.1 beats/min vs. 68 ± 2.5 
beats/min vs. 66 ± 2.8 beats/min vs. 67 ± 2.6 beats/min; P = 0.76). One subject on the control 
day and another on the distension day had PPH. No subject experienced PPH on either of the 
acarbose study days. 
 
7.3.1.1 Mean arterial pressure 
Between t = 0-120 min, there was a fall in MAP during control and distension treatments (P < 
0.001 for both), but no overall change during either acarbose (P = 0.44), albeit a non-significant 
trend for combined (P = 0.06), treatments. There was a treatment effect for acarbose, so that 
the AUC0-120min for MAP was greater during treatments with acarbose (A: 10,625 ± 237 




mmHg.min and AD: 10,721 ± 232 mmHg.min; P = 0.005) compared to control (C: 10,366 ± 
281 mmHg.min), but not for distension (D: 10,106 ± 252 mmHg.min; P = 0.68). There was 
also no interactive effect between acarbose and distension on the AUC0-120min for MAP (P = 
0.44) (Figure 7.2A). 
 
The maximum fall in MAP from baseline was less during treatments with acarbose (P = 0.006) 
(acarbose: -6.9 ± 1.8 mmHg and combined treatment: -8.2 ± 1.5 mmHg) compared with control 
(-12.2 ± 1.4 mmHg). There was no effect of gastric distension alone (-15.3 ± 1.8 mmHg, P = 
0.21) and no difference between the acarbose treatments with or without gastric distension (P 
= 0.58).  
 
7.3.1.2 Heart rate 
Between t = 0-120 min, there was a rise in HR among 4 treatments (P < 0.005 for all) (Figure 
7.2B). There was a treatment effect for acarbose, so that the AUC0-120min for HR was lower 
during treatments with acarbose (A: 8057 ± 356 bpm.min and AD: 7985 ± 315 bpm.min; P = 
0.04) compared to control (C: 8252 ± 357 bpm.min), but not for distension (D: 8165 ± 312 
bpm.min; P = 0.55). There was also no interaction between acarbose and distension on the 
AUC0-120min for HR (P = 0.92) (Figure 7.2B). 
 
There was no treatment effect for the maximum rise in HR from baseline among the 4 
treatments, so that there was no significant difference in the maximum rise in HR during 
acarbose (10.4 ± 1.4 bpm, P = 0.93), distension (10.5 ± 1.9 bpm, P = 1.0) and combined 
treatments (10.6 ± 2.4 bpm, P = 0.88), compared to control (10.7 ± 2.5 bpm). 
 
 




7.3.2 Superior mesenteric artery blood flow 
There was no difference (P = 0.83) in baseline (t = -2 min) SMA blood flow among the 4 
treatments (control vs. distension vs. acarbose vs. combined treatment: 543 ± 55 mL/min vs. 
583 ± 91 mL/min vs. 538 ± 75 mL/min vs. 579 ± 50 mL/min, respectively) (Figure 7.3). 
 
Between t = -2-120 min, there was a rise in SMA blood flow with the control (P < 0.001) and 
distension (P = 0.02), and a trend for an increase after acarbose alone (P = 0.08) and combined 
(P = 0.07), treatments (Figure 7.3). There was a treatment effect for the AUC0-120min of SMA 
blood flow for acarbose, so that SMA blood flow was less during acarbose treatments, with or 
without distension (A: 86,689 ± 10,725 mL/min.min and AD: 87,720 ± 6750 mL/min.min; P 
= 0.003), compared with control (C: 111,738 ± 12,631 mL/min.min). There was no difference 
between distension (D: 95,846 ± 11,418 mL/min.min) and control (P = 0.41), and no additive 
effect between acarbose and distension in the combined treatment (P = 0.15) (Figure 7.3).  
 
The maximum rise in SMA blood flow during acarbose treatments (acarbose: 963 ± 123 
mL/min and combined treatment: 983 ± 102 mL/min) was less (P = 0.03), compared to control 
(1173 ± 111 mL/min). There was no difference between distension (1073 ± 140 mL/min) (P = 
0.67) and control and no interaction between acarbose and distension (P = 0.42) in the 
maximum rise in SMA blood flow (Figure 7.3). 
 
7.3.3 Blood glucose  
There was no difference (P = 0.56) in baseline (t = -2 min) blood glucose among the 4 
treatments (control vs. distension vs. acarbose vs. combined treatment: 5.6 ± 0.16 mmol/L vs. 
5.6 ± 0.14 mmol/L vs. 5.6 ± 0.10 mmol/L vs. 5.7 ± 0.20 mmol/L, respectively) (Figure 7.4). 





Between t = -2-120 min, there was a rise in blood glucose with all treatments (P < 0.001 for 
all) (Figure 7.4). There was a treatment effect for the AUC0-120min for blood glucose for 
acarbose, so that blood glucose was less during acarbose treatments with and without distension 
(A: 827 ± 28.9 mmol/L.min and AD: 863 ± 30.3mmol/L.min; P = 0.03), compared with control 
(C: 919 ± 41.9 mmol/L.min). There was no difference between distension (D: 948 ± 53.9 
mmol/L.min) and control (P = 0.12), nor any additive effect between acarbose and distension 
when combined (P = 0.92) (Figure 7.4). 
 





Figure 7.1. Schema of the study protocol. 
  





Figure 7.2. Changes in mean arterial pressure (A), and heart rate (B) from baseline in response 
to control (C), distension (D), acarbose (A) and combined (AD) treatments. Data are mean 
values ± SEM (n = 10). The AUC0-120 for MAP was greater (A and AD compared to C; P = 
0.005) with both acarbose treatments with no difference between C and D. The AUC0-120 for 
HR was less (A and AD compared to C; P = 0.04) with both acarbose treatments with no 
difference between C and D.  
  





Figure 7.3. Superior mesenteric artery blood flow in response to control (C), distension (D), 
acarbose (A) and combined (AD) treatments. Data are mean values ± SEM (n = 9). The AUC0-
120 for SMA flow was less (A and AD compared to C; P = 0.003) with both acarbose treatments 
with no difference between C and D.  
  





Figure 7.4. Blood glucose concentrations in response to control (C), distension (D), acarbose 
(A) and combined (AD) treatments. Data are mean values ± SEM (n = 9). The AUC0-120 for 
blood glucose was reduced (A and AD compared to C; P = 0.03) by both acarbose treatments 


















7.4 Discussion   
This study evaluated the acute effects of acarbose and water drinking, alone and combined, on 
the BP and SMA blood flow responses to oral sucrose in healthy older adults. We demonstrated 
that in this group, ingestion of sucrose induced a substantial increase in SMA blood flow and 
fall in BP, as predicted [18, 107]. These changes were essentially abolished by acute 
administration of acarbose in a dose of 100mg; which was well tolerated. In contrast, water 
drinking alone (300 mL, 15 min before the sucrose load) to induce gastric distension had no 
significant effect on either BP or splanchnic blood flow and did not modify the response to 
acarbose. 
 
This is the first study to evaluate the interaction between acarbose and gastric distension on 
‘postprandial’ BP based on their potential for synergetic, or additive, effects. The observed 
responses to acarbose are consistent with previous reports, including our own [18, 107, 165, 
166], and support the concept that acarbose will be useful in the management of PPH. We have 
further demonstrated that acarbose causes a profound attenuation of the rise in SMA blood flow 
induced by oral sucrose [107, 165] which is likely to be central to its anti-hypotensive effect. 
Such an effect was suggested in a previous study that was methodologically flawed [165]. The 
reduction in the splanchnic blood flow response to oral sucrose induced by acarbose is likely 
to reflect mechanisms unrelated to slowing of gastric emptying per se [18], given that the 
increase in SMA blood flow induced by ID administration of sucrose in healthy older adults is 
also markedly attenuated by acarbose [107]. The stimulation of GLP-1 as a result of the 
presence of nutrient in the more distal intestine may be relevant. In particular, we have 
demonstrated in healthy older adults that intravenous GLP-1 reduces the SMA blood flow 
response to ID glucose [106] and that the ‘short-acting’ GLP-1 agonist, lixisenatide, prevents 
the fall in systolic BP and reduces the rise in SMA flow following a 75g oral glucose load in 




healthy older subjects and T2D patients [111]. However, in relation to a role for endogenous 
GLP-1, it would be expected that stimulation of GLP-1 would be associated with a concurrent 
equivalent increase in glucagon-like peptide-2 (GLP-2) [96, 448], which would be expected to 
stimulate SMA blood flow [114]. The reduction in plasma glucose induced by acarbose is 
predictably associated with a reduction in plasma insulin, which has vasodilatory properties 
[4]. 
 
We were surprised that water drinking had no significant effect on either BP or SMA blood 
flow. There are a number of potential explanations. We selected a relatively low volume (300 
mL) drink to optimise tolerability, influenced by the outcome of our previous study 
demonstrating that this intragastric volume of water markedly attenuated the hypotensive 
response to intraduodenal glucose in healthy older adults [15]. With our study design, it would 
be anticipated that the majority of water would have been emptied from the stomach in the 15 
minutes before the ingestion of the sucrose. Furthermore, the effects of gastric distension are 
known to be volume-dependent [90]. Hence, we cannot discount the possibility that a larger 
volume of water, given immediately before the sucrose may have been more effective. 
Moreover, the pressor effect of water drinking may also reflect changes in plasma osmolality 
[141, 142]. While there was a substantial fall in BP in response to sucrose, we studied healthy 
older adults, rather than patients with PPH, and none had evidence of autonomic neuropathy, 
although assessment of autonomic nerve function was indirect. The latter may also be of 
relevance to the negative outcome given that the pressor response to water appears to be 
exaggerated in patients with autonomic impairment [142]. It should also be appreciated that 
the number of subjects we studied was relatively small and there were non-significant trends 
for minor effects of water drinking soon after the sucrose drink. Accordingly, a type 2 error 
cannot be excluded. In addition, GLP-1 was not measured, which may have provided 




mechanistic insights into the role of acarbose in modulating postprandial BP. A strength of our 
study was the inclusion of splanchnic blood flow measurement. 
 
Previous studies have suggested that both acarbose and gastric distension may be potential 
approaches to reduce the postprandial fall in BP and our study aimed to evaluate the interaction 
between these interventions. The outcomes provide additional evidence to support the use of 
acarbose to attenuate the magnitude of the postprandial fall in BP, but not in combination with 
water drinking. The latter concept should, however, not be dismissed pending the outcome of 
further studies with greater subject numbers and particularly in patients with PPH and where 
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The use of a macronutrient preload - a small amount of nutrient given 15-30 min before a main 
meal - to diminish postprandial glycaemic excursions, represents a novel approach to the 
management of type 2 diabetes (T2D) [149, 449-451]. The underlying rationale is that the 
presence of nutrients in the small intestine will stimulate the release of gut hormones, including 
glucagon-like peptide-1 (GLP-1), to augment insulin secretion and slow gastric emptying of 
the subsequent meal [452]. Gastric emptying, which exhibits a substantial inter-, but relatively 
low intra-individual, variation in health [326], is now recognised to be normal, or modestly 
accelerated, in the majority of people with uncomplicated T2D and relatively good glycaemic 
control [304]. In this group, slowing of gastric emptying is associated with a reduction in 
postprandial glucose [304], which is the major determinant of average glycaemic control, as 
assessed by HbA1c [304]. We have recently evaluated a preload containing whey (17g) and 
guar (5g), added to a ‘shake and take’ cup containing 150 mL water in participants with T2D 
[149].  Whey protein (a by-product of the cheese-making process) and guar gum (a viscous 
soluble fibre) have both been associated with slowing of gastric emptying [149, 451]. In these 
studies, the preload was well-tolerated when taken twice a day and substantially reduced the 
glycaemic response to a mashed potato meal, and modestly decreased glycated hemoglobin 
(0.1%) in T2D patients who were already well-controlled (mean HbA1c 6.6 ± 0.1%), without 
inducing weight gain [149].  A subsequent study suggested that these effects were mediated 
predominantly by the whey protein; guar, in a dose of 5g, was less effective for lowering 
postprandial glucose compared with 17g whey [451]. In both studies, the reduction in 
postprandial glucose was associated with a tendency for a reduction in plasma insulin. Gastric 
emptying was assessed using an indirect stable isotope breath test technique in both studies, 
and reported to be slowed by the preload after both acute and 12 weeks’ administration [149, 
451]. However, a fundamental limitation of the breath test is that it cannot discriminate between 




effects on gastric emptying from those on small intestinal glucose absorption, unlike the ‘gold 
standard’ technique of scintigraphy [453]; changes in small intestinal motility/absorption have 
been shown to have a major effect on postprandial glycaemia [454]. Accordingly, the effect of 
this preload on gastric emptying remains uncertain.  
 
Preloads, including the guar/whey combination, also have potential to mitigate postprandial 
hypotension (PPH) – defined as a greater than 20 mmHg fall in systolic blood pressure (BP) 
after a meal, a condition which is associated with falls and syncope [1, 4], as well as increased 
mortality [68]. PPH currently lacks an effective treatment and occurs in up to 40% of patients 
with T2D [1, 5] and ~ 15% of the ‘healthy’ elderly [5, 74]. We have shown that the magnitude 
of the postprandial fall in BP is greater when gastric emptying is relatively more rapid in both 
healthy older subjects [70, 74] and patients with T2D [7], while slowing gastric emptying with 
guar gum attenuates the fall [22, 155]. Moreover, exogenous administration of GLP-1 [106] 
and the ‘short-acting’ GLP-1 receptor agonist, lixisenatide [111], both slow gastric emptying, 
and this is associated with marked attenuation in the magnitude of the fall in BP. Accordingly, 
a guar/whey preload has the potential to represent a simple, safe and inexpensive approach to 
the management of PPH.  
 
The aims of this study were to determine the effects of the guar/whey preload on gastric 
emptying (measured with scintigraphy), intestinal glucose absorption and the glycaemic and 
BP responses to an oral glucose load in healthy older subjects.  
 







Eighteen healthy older subjects (7 male and 11 female, mean age 72.6 ± 1.1 years, BMI 26.3 ± 
0.5 kg/m2) participated in the study. All were non-smokers and none had a history of 
gastrointestinal disease or surgery, diabetes, significant respiratory, renal or cardiac disease, 
chronic alcohol abuse, epilepsy, or was taking medication known to influence BP or 
gastrointestinal function.  
 
The study was registered at http://www.ANZCTR.org.au (ACTRN12619000438156), 
conducted in accordance with the Declaration of Helsinki, and approved by the Human 
Research Ethics Committee of the Royal Adelaide Hospital. Written informed consent was 
obtained from all participants. 
 
8.2.2 Protocol  
Each participant was studied on 2 occasions, separated by at least 7 days, in a randomised, 
crossover design. Randomisation was performed at the beginning of the first visit of each 
participant by an investigator tossing a coin. On each study day, participants attended the 
Clinical Research Facility, Adelaide Health and Medical Sciences building at The University 
of Adelaide at ∼ 09.00 h after an overnight fast (14h for solids; 12h for liquids) [75]. They 
were seated with their back against a gamma camera (Siemens e.cam single-head gamma 
camera, Siemens Medical Solutions USA Inc, Knoxville, TN, USA), an intravenous cannula 
was inserted into an antecubital vein for blood sampling and an automated BP cuff placed 
around the opposite arm. After a ‘rest period’ of 15-30 minutes, to allow baseline BP to stabilise 




[24], each participant was given either (i) a drink containing 50g glucose, 5g 3-O-
methylglucose (3-OMG) and 20 MBq 99mTc-calcium phytate, made up to 300 mL with water 
[52] (the ‘control’ day) or (ii) a ‘preload’ containing 16.4g whey protein and 4.4g guar (90 
kcal) (Vanilla flavour - GlucoControlTM, Faulding; Omni Innovation, Campbellfield, VIC, 
Australia) made up to 150 mL with water 15 minutes before the drink (the ‘preload’ day). The 
preload and drink were both consumed within 2 minutes. Time zero (t = 0 min) was defined as 
the time of drink completion. 
 
Measurements of gastric emptying, plasma glucose, plasma insulin, serum 3-OMG, superior 
mesenteric artery (SMA) blood flow, BP and heart rate (HR) and were obtained until t = 120 




8.2.3.1 Gastric emptying  
Radioisotopic data were acquired in 1-min frames for the first 60 min and at 3-min frames 
thereafter up to 120 min. A region-of-interest was drawn around the total stomach and data 
were corrected for participant movement, radionuclide decay and γ-ray attenuation [7, 109]. 
Gastric emptying curves (expressed as % of the maximum content of the total stomach) were 
derived, and the intragastric content and at t = 0, 15, 30, 45, 60, 90 and 120 min and the 50% 








8.2.3.2 Plasma glucose and insulin 
Venous blood samples (~10 mL) were obtained immediately prior to the ingestion of the 
preload (t = -18 min) and /or drink (t = -3 min) and then at t = 15, 30, 45, 60, 90 and 120 min. 
Samples were collected into ice-chilled EDTA-treated tubes and plasma was separated by 
centrifugation at 1996 ×g for 15 minutes at 4°C within 15 minutes of collection and stored at 
−80°C until assayed [455]. 
 
Plasma glucose was measured using the hexokinase technique (2900D Biochemistry Analyzer, 
YSI Incorporated, Yellow Springs, Ohio, USA) [455]. Plasma insulin was measured by ELISA 
(Diagnostics 10-1113, Mercodia, Uppsala, Sweden). The sensitivity of the assay is 1.0 mU/L 
and intra- and inter-assay coefficients of variation are 2.9% and 6.7%, respectively [455]. 
 
The insulinogenic index (the ratio of change in insulin over change in glucose over the first 
30 min after the glucose drink) was calculated to estimate early-phase insulin secretion [456]. 
 
8.2.3.3 Oral glucose absorption (serum 3-OMG) 
Venous blood samples (~5 mL) were collected into untreated tubes and allowed to clot. Serum 
was separated by centrifugation at 1996 ×g for 15 minutes at 4°C and stored at −80°C until 
assayed [455]. Serum 3-OMG concentrations were measured by liquid chromatography and 
mass spectrometry, with a sensitivity of 0.0103 mmol/L [457]. 
 
8.2.3.4 Superior mesenteric artery blood flow 
Superior mesenteric artery (SMA) blood flow (mL/min) was measured immediately prior to 
the ingestion of the preload (t = -18 min) and/or drink (t = -3 min), and then at t = 15, 30, 45, 




60, 90 and 120 min using a Logiq e ultrasound system with a 3.5C broad-spectrum 2.5–4 MHz 
convex linear array transducer (GE Healthcare Technologies, Sydney, NSW, Australia) [366].  
 
8.2.3.5 Blood pressure and heart rate 
Systolic and diastolic BP (SBP and DBP) and HR were measured with an automated 
oscillometric BP monitor (DINAMAP ProCare 100, GE Medical Systems, Milwaukee, WI, 
USA) at 3-min intervals prior to administration of the drink, and then at 5-min intervals from t 
= 0 - 120 min. Fasting BP and HR were calculated as an average of measurements obtained at 
t = -24, -21, -18 min prior to the ingestion of the preload (t = -17 min), or at t = -9, -6, -3 min 
prior to the ingestion of the drink (t = -2 min) on the study day without a preload. PPH was 
defined as a fall in SBP ≥ 20 mmHg that was sustained for ≥ 30 min [7]. 
 
8.2.3.6 Cardiovascular autonomic nerve dysfunction 
Standardised cardiovascular reflex tests were used to assess autonomic nerve function [445-
447]. Parasympathetic function was evaluated by the variation (R-R interval) of HR during 
deep breathing and the immediate response to standing (“30:15” ratio). Sympathetic function 
was assessed by the decrease in SBP in response to standing. Each result was scored according 
to age-adjusted predefined criteria: 0 = normal, 1 = borderline and 2 = abnormal, for a 
maximum total score of 6. A score ≥ 3 was considered to indicate autonomic dysfunction [447]. 
 
8.2.4 Statistical analysis 
Gastric emptying, plasma glucose and insulin, serum 3-OMG, SMA blood flow, SBP, DBP 
and HR were analysed and presented as absolute values. Two-way repeated-measures analysis 
of variance (ANOVA) with treatment and time as factors, with Bonferroni's correction for post 




hoc comparisons, was used to analyse gastric emptying, plasma glucose, plasma insulin, serum 
3-OMG and SMA blood flow. One-way repeated-measures ANOVA was used to evaluate the 
effect of time on SBP, DBP and HR. The maximum falls in SBP and DBP and increases in HR, 
plasma glucose and insulin, serum 3-OMG and SMA blood flow were defined as the greatest 
change from t = -3 min in each subject at any given time point on each study day. Areas under 
the curves (AUCs) for SBP, DBP, HR, and serum 3-OMG were calculated. Incremental areas 
under the curves (iAUCs) were calculated for plasma glucose and insulin. AUCs for SBP, DBP 
and HR, the insulinogenic index and maximum increases/falls in the two study days were 
compared using Student's paired t-test. Pearson's correlations were used to evaluate 
relationships between plasma glucose, plasma insulin and serum 3-OMG between the two 
study days. All analyses were performed using SPSS version 24 (SPSS, Chicago, IL, USA); a 
P-value < 0.05 was considered significant. Data are shown as mean values ± SEM. 
 
8.3 Results 
The studies were generally well tolerated. No participant had autonomic nerve dysfunction. In 
one participant, extensive small intestinal overlap precluded acceptable gastric emptying 
analysis and the scintigraphic data were not included. In another subject, 3-OMG was 
inadvertently not included in the drink on one of the two days. Accordingly, paired BP, HR, 
SMA blood flow, plasma glucose and insulin data were available in 18 subjects, while gastric 
emptying and serum 3-OMG data were available in 17 subjects. 
 
8.3.1 Gastric emptying  
Gastric emptying of the glucose drink approximated an overall linear pattern (time effect: P < 
0.001, Figure 8.1). There was no difference in gastric retention evaluated by ANOVA 




(treatment effect: P = 0.96, treatment × time interaction: P = 0.24, Figure 8.1), nor T50 (preload: 
76.5 ± 4.3 vs control: 76.5 ± 4.8 min, P = 0.99). At t = 120min, gastric emptying was incomplete 
in all subjects on both days. 
 
8.3.2 Plasma glucose and insulin 
There were no differences in baseline (fasting) plasma glucose or insulin between the two days 
(Table 8.1). After ingestion of the preload, there was no change in plasma glucose between t = 
-18 min and t = -3 min (5.2 ± 0.1 vs 5.0 ± 0.2 mmol/L, P = 0.26), while plasma insulin increased 
(5.3 ± 0.8 vs 7.0 ± 1.1 mU/L, P = 0.02).  
 
There was a rise in plasma glucose on both days following the glucose drink (time effect: P < 
0.001, Figure 8.2A). Plasma glucose concentrations were lower after the preload compared to 
control (treatment effect: P = 0.02), with significant differences at t = 30, 45 and 60 min (P < 
0.05 for each, Figure 8.2A). The maximum rise in plasma glucose after the glucose drink was 
also less after the preload (preload: 3.7 ± 0.4 vs control: 4.3 ± 0.3 mmol/L, P = 0.007). 
 
There was a rise in plasma insulin on both days following the glucose drink (time effect: P < 
0.001, Figure 8.2B). Plasma insulin concentrations were greater after the preload (treatment x 
time interaction: P = 0.03) at t = 15 and 30 min (P < 0.001 for each, Figure 8.2B). There was 
no difference in the maximum rise in plasma insulin after the glucose drink between the two 
days (preload: 63.1 ± 8.5 vs control: 62.8 ± 11.8 mU/L, P = 0.97). 
 
The insulinogenic index at 30 min was higher after the preload, compared with control 
(preload: 18.1 ± 2.4 vs control: 10.9 ± 1.5, P = 0.002). 
 




8.3.3 Glucose absorption  
There was an increase in serum 3-OMG on both the preload and control study days following 
the glucose drink (time effect: P < 0.001, Figure 8.2C). Serum 3-OMG concentrations were 
lower after the preload (treatment effect: P = 0.003 and treatment x time interaction: P = 0.002) 
with significant differences at t = 45, 60, 90 and 120 min (P < 0.05 for each, Figure 8.2C). The 
peak serum 3-OMG concentrations were also less after the preload (preload: 0.84 ± 0.04 vs 
control: 0.92 ± 0.03 mmol/L, P = 0.01). 
 
8.3.4 Superior mesenteric artery blood flow  
There was no difference in baseline (fasting) SMA blood flow between the two study days 
(Table 8.1). Following the preload, there was no change in SMA blood flow between t = -17 
min to t = -2 min (329 ± 24.8 vs 371 ± 27.5 mL/min, P = 0.10).  
 
There was an increase in SMA blood flow on both days following the glucose test drink (time 
effect: P < 0.001 for all, Figure 8.3). This rise was attenuated after the preload (treatment effect: 
P < 0.001 and treatment x time interaction: P = 0.003) with significant differences at t = 15, 60, 
90 min (P < 0.05 for each, Figure 8.3). The maximum increase in SMA flow was also less 
following the preload (preload: 365.5 ± 29.4 vs control: 488.2 ± 42.5 mL/min, P = 0.002).  
 
8.3.5 Blood pressure and heart rate 
There were no differences in baseline (fasting) SBP, DBP and HR between the two days (Table 
8.1). Following ingestion of the preload, there was a trend for an increase in SBP (120.0 ± 3.2 
vs 124.3 ± 3.9 mmHg, P = 0.06), with no change in DBP (67.3 ± 1.9 vs 69.2± 2.1 mmHg, P = 
0.22) or HR (63.1 ± 2.3 vs 63.1 ± 2.4 bpm, P = 0.17) from t = -18 min to t = -3 min. No 




participant had PPH, i.e. a sustained fall in SBP of more than 20mmHg for 30 min, compared 
to their fasting measurement on either day. 
 
8.3.5.1 Systolic blood pressure   
There was a modest fall in SBP on both days (P = 0.001 for both; Figure 8.4A), without any 
difference in the AUC0-120min for SBP (P = 0.98), or the maximum fall in SBP (preload: -13.2 
± 2.5 vs control: -12.4 ± 1.7 mmHg; P = 0.77) between the two days.  
 
8.3.5.2 Diastolic blood pressure   
There was a modest fall in DBP on both days (P < 0.01 for both; Figure 8.4B), without any 
difference in the AUC0-120min for DBP (P = 0.55) or the maximum fall in DBP (preload: -11.4 
± 1.4 vs control: -11.1 ± 1.1 mmHg; P = 0.82) between the two days. 
 
8.3.5.3 Heart rate  
There was a modest increase in HR on both the preload (P = 0.001) and control (P = 0.009) 
days (Figure 8.4C). The AUC0-120min for HR was greater (P = 0.007) on the preload day. The 
maximum rise in HR after the glucose drink also tended to be greater after the preload (preload: 
11.3 ± 2.0 vs control: 7.9 ± 1.0 bpm, P = 0.08). 
 
8.3.6 Relationships between plasma glucose and insulin or serum 3-OMG between the two 
study days 
Between t = 0 - 120 min, there was a correlation between the difference in iAUCs for plasma 
glucose and the difference in AUCs for serum 3-OMG between the preload and control days 




(R = 0.71, P = 0.002, Figure 8.5). However, there was no correlation between the difference in 
iAUCs for plasma glucose and the difference in iAUCs for plasma insulin between the preload 
and control days (R = 0.31, P = 0.21). 






Figure 8.1. Gastric retention following ingestion of 50 g glucose in 300 mL water on the 
control and preload days. Results of repeated measures ANOVA are reported as P values for 
differences by treatment (treatment), differences over time (time) and differences due to the 
interaction of treatment and time (treatment*time). Data are mean ± SEM (n = 17). 
  





Figure 8.2. Plasma glucose (A), plasma insulin (B) and serum 3-OMG (C) on the control and 
preload days. Results of ANOVA are reported as P values for differences by treatment 
(treatment), differences over time (time) and differences due to the interaction of treatment and 
time (treatment*time). Post hoc comparisons, adjusted by Bonferroni's correction, were 
performed, if ANOVA values (treatment*time) were significant. + P < 0.05 and ++ P < 0.01. 
Data are mean values ± SEM (n = 18 for plasma glucose and insulin and n = 17 for 3-OMG). 
 





Figure 8.3. Superior mesenteric artery blood flow on the control and preload days. Results of 
ANOVA are reported as P values for differences by treatment (treatment), differences over 
time (time) and differences due to the interaction of treatment and time (treatment*time). Post 
hoc comparisons, adjusted by Bonferroni's correction, were performed, if ANOVA values 
(treatment*time) were significant. + P < 0.05, ++ P < 0.01, +++ P < 0.001. Data are mean 
values ± SEM (n = 18). 
  





Figure 8.4. Systolic (A) and diastolic BP (B) and heart rate (C) on the control and preload 
days. Data are mean values ± SEM (n = 18).  
 





Figure 8.5. Relationship between the difference in iAUCs for plasma glucose between the 
preload and control days with the difference in AUCs for serum 3-OMG between the preload 












8.4 Discussion  
Our study has demonstrated that a guar/whey preload diminishes the glycaemic response to a 
glucose drink in healthy older subjects, as previously demonstrated in participants with T2D 
[149, 449]. However, this effect was not associated with slowing of gastric emptying. There 
was a substantial delay in small intestinal glucose absorption, and stimulation, rather than a 
reduction, in insulin secretion. Moreover, changes in glycaemia and glucose absorption were 
related. The preload had no effect on the reduction in BP following the glucose load, but the 
latter was modest, and no subject had PPH. In contrast, the rise in SMA blood flow was 
attenuated by the preload.  
 
The pivotal importance of upper gastrointestinal function to postprandial glycaemia in health 
and diabetes is now widely appreciated [458, 459]. The focus has hitherto been on gastric 
emptying, which is frequently disordered in diabetes [71], albeit usually normal, or modestly 
accelerated, in uncomplicated T2D patients [304]. Postprandial glycaemic excursions are a 
major determinant of glycated haemoglobin, particularly when the latter is ≤ 8.0% [149], and 
can be diminished by slowing gastric emptying, which has stimulated the development of 
dietary and pharmacological strategies to target this mechanism. Examples of the latter are the 
amylin agonist, pramlintide [312] and ‘short-acting’ GLP-1  receptor agonists [460]. Our 
previous studies suggested that a guar/whey ‘preload’ reduced postprandial glycaemia in T2D 
predominantly by slowing gastric emptying [149, 451]. However, the latter was assessed using 
a stable isotope breath test technique, which cannot discriminate effects on gastric emptying 
from those on small intestinal carbohydrate absorption. In the current study, the preload 
reduced glycaemia substantially, particularly given that healthy subjects were studied, rather 
than those with T2D, but had no effect on gastric emptying; indeed, the gastric emptying curves 
were essentially superimposed.  





It should be appreciated that the preload (90 kcal) was taken 15 min before the drink and, 
because gastric emptying is usually in the range of 1-4 kcal/min [220, 221], would not be 
expected to have emptied completely from the stomach at the time of ingestion of the drink. 
Furthermore, at 120 min, the drink has not emptied from the stomach completely. Accordingly, 
we cannot exclude the possibility that, because of its higher intragastric caloric content, after 
the preload, while the rate of gastric emptying of the drink was unaffected between 0-120min, 
the drink may have taken longer to empty completely. A reduction in small intestinal glucose 
absorption is shown unequivocally by the observed marked reduction in the rate of 3-OMG 
absorption in the absence of any difference in gastric emptying and is, accordingly, likely to 
contribute to glucose-lowering. This concept is also supported by the observed relationship 
between the changes in plasma glucose and 3-OMG. In contrast to previous studies [149, 461], 
the preload was associated with an increase in plasma insulin, which is likely to reflect 
stimulation of insulin secretion by amino acids in the whey protein [451, 452]. Slowing of 
gastric emptying has the capacity to override insulinotropic responses, as shown by the 
reduction in postprandial insulin induced by exogenous administration of GLP-1 [285, 462].  
 
Our study also evaluated the potential for the guar/whey preload in the management of PPH. 
Both oral (9g) [155] and intraduodenal (4g) [23] administration of guar diminish the 
hypotensive response to carbohydrates. There was, however, only a modest fall in BP in 
response to oral glucose, presumably because participants were all healthy, and no effect of the 
preload on BP. In contrast, the preload attenuated the rise in SMA blood flow substantially, 
presumably secondary to the reduction in glucose absorption. The small rise in HR after the 
preload might be attributable to the sympathetic effect of insulin [463, 464]. Altogether, further 
studies in patients with PPH are indicated before the approach is dismissed.  





In interpreting our observations, specific limitations should be appreciated: the study was not 
placebo-controlled, the size of the cohort was relatively small, healthy older subjects rather 
than T2D were studied, and responses to oral glucose, rather than a meal, were evaluated. 
Moreover, we did not measure GLP-1 or glucose dependent insulinotropic polypeptide (GIP) 
levels.  
 
In conclusion, the reduction in the glycaemic response to oral glucose by a guar/whey preload 
in healthy older subjects reflects a slowing of small intestinal glucose absorption and 
stimulation of insulin secretion, rather than a delay in gastric emptying.  
  




Table 8.1. Baseline (fasting) measurements in the subjects (n = 18)1 
 Control (t = -3) Preload (t = -
18) 
P value 
SBP (mmHg) 122.1 ± 3.2 120.0 ± 3.1 0.10 
DBP (mmHg) 68.2 ± 1.9 67.3 ± 1.9 0.38 
HR (beats/min) 62.1 ± 1.7 63.9 ± 2.3 0.09 
Plasma glucose (mmol/L) 5.2 ± 0.1 5.2 ± 0.1 0.68 
Plasma insulin (mU/L) 5.2 ± 0.9 5.3 ± 0.8 0.68 
SMA blood flow (mL/min) 344 ± 23.6 329 ± 24.8 0.34 
 
1 All values are absolute values. Differences between study days were tested via paired t-tests. 
Values are means ± SEMs. SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, 
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9.1 Introduction  
The incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic 
polypeptide (GIP), released from the small intestine in response to nutrient exposure (GLP-1 
from ‘L’ cells located predominantly in the distal small intestine and GIP from ‘K’ cells located 
more proximally) are important regulators of postprandial glycaemia through glucose-
dependent insulinotropic effects [297]. They account for the so-called ‘incretin effect’ - the 
markedly increased insulin response when glucose is delivered enterally when compared with 
an isoglycaemic intravenous infusion [279, 465]. There is a substantial inter-individual 
variation in GLP-1 and GIP responses to nutrients [466], which is probably not systematically 
affected by the presence of type 2 diabetes (T2D) [466]. GLP-1 impacts on glucose homeostasis 
through a number of actions, in addition to stimulation of insulin secretion, including 
suppression of glucagon, slowing of gastric emptying and enhanced satiety to reduce food 
intake [119, 467]. In contrast, GIP, which may stimulate glucagon, particularly in response to 
hypoglycaemia [468], has little, or no, effect on gastric emptying or appetite [282, 468], but 
may affect fat metabolism [119, 469]. In T2D the incretin effect is diminished, at least in part, 
as a result of a marked attenuation of the insulinotropic effect of GIP [289]. This observation 
has stimulated the development of GLP-1-based therapy – ie. GLP-1 receptor agonists and 
dipeptidyl peptidase 4 (DPP-4) inhibitors – for the management of T2D [311, 470]. 
 
It is now appreciated that the rate of gastric emptying, which varies substantially between 
individuals (usually in the range of 1-4 kcal/min), is a major determinant of the glycaemic 
response to carbohydrate-containing meals in healthy subjects [251, 298, 299, 301, 471] as well 
as individuals with T2D [7, 472]. Gastric emptying may also impact on postprandial GLP-1 
and GIP secretion [326]. We have demonstrated that the rate of intraduodenal (ID) glucose 
delivery has differential effects on GLP-1 and GIP in health [305, 306, 308] and type 2 diabetes 
  Chapter 9 
206 
 
[308, 455]. Specifically, a rate of > 2kcal/min is required to stimulate GLP-1, whereas the 
stimulation of GIP is approximately linear in the rage of 1-4 kcal/min [305, 306, 326]. Using 
the specific GLP-1 antagonist, exendin 9-39, we have also shown that endogenous GLP-1 
slows gastric emptying [473]. 
 
While gastric emptying is known to slow modestly with healthy ageing [70, 249], it is not 
known whether baseline and/or nutrient-stimulated GLP-1 or GIP levels are subject to intra-
individual variation or whether they are affected by ageing. Specifically, previous studies have 
all been cross-sectional in design, with the inherent limitations in this approach. We have now 
re-evaluated a cohort of healthy older subjects after an interval of ~ 5.9 years to evaluate 
changes in fasting and glucose-stimulated plasma GLP-1 and GIP concentrations, and their 
relationships with gastric emptying.  
 
9.2 Materials and methods 
9.2.1 Subjects  
87 healthy older individuals who took part in a study, performed between July 2010 and July 
2012, evaluating the effect of gastric emptying on the glycaemic and incretin hormone 
responses to a 75g oral glucose load [299] were invited by mail to participate in the present 
follow-up study. Of the original cohort, none had died, 41 agreed to participate, 11 had medical 
conditions that precluded their involvement, 13 refused to participate, 21 did not respond to the 
letter and, in 1 case, the invitation letter was returned and the individual considered to be lost 
to follow-up. Demographic information and medical history were updated. Individuals were 
excluded if they had a history of gastrointestinal disease or surgery, significant respiratory or 
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cardiac disease, alcohol intake > 20g/day or were taking medication known to affect gastric 
emptying.  
 
The protocol was approved by the Human Research Ethics Committee of the Royal Adelaide 
Hospital, and each subject provided written informed consent. All experiments were carried 
out in accordance with the Declaration of Helsinki. 
 
9.2.2 Protocol 
The protocol was identical to that used in the initial study [299]. Individuals attended the Royal 
Adelaide Hospital, at ∼08.30 h after an overnight fast (14 h for solids; 12 h for liquids) [75]. 
They were seated in an arm-chair, and a cannula was inserted into an antecubital vein for blood 
sampling. After a ‘rest period’ of 15-30 min, each participant consumed a drink containing 75g 
glucose and 150mg 13C-acetate (Cambridge Isotope Laboratories, Tewksbury, MA, USA), 
made up to 300mL with water, within 2 minutes. Time zero (t = 0) was defined as the time of 
completion of the drink. 
 
Venous blood samples (~ 15 mL) were obtained immediately prior to the commencement of 
the drink (t = −3 minutes) and at t = 30, 60, 90 and 120 min. The intravenous cannula was then 
removed and the subject offered a light lunch before leaving the laboratory. 
 
9.2.3 Measurements 
9.2.3.1 Blood glucose concentrations  
Fasting and two-hour blood glucose concentrations were determined using a portable 
glucometer (Medisense Companion 2 Meter, Medisense Inc., Waltham, MA, USA) [434, 435]. 
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Subjects with fasting blood glucose ≥7.0 mmol/L and/or 2h blood glucose ≥11.1 mmol/L were 
classified, according to WHO criteria, as having diabetes [474].  
 
9.2.3.2 Plasma GLP-1 and GIP 
Total GLP-1 was measured by radioimmunoassay (GLPIT-36HK, Millipore, Billerica, MA, 
USA). The minimum detectable limit was 3 pmol/L, intra- and inter-assay CVs were 8.0% and 
10.0% respectively [306]. Plasma GIP was measured by radioimmunoassay. The minimum 
detectable limit was 2 pmol/L, interassay CV was 9.4% and intra-assay CV was 4.4% [475]. 
The assays used for the initial and follow-up measurements were identical, although they were 
not performed at the same time. 
 
9.2.3.3 Gastric emptying  
Exhaled breath samples were collected before ingestion of the drink (t = -3 min), every 5 
minutes for the first hour (commencing at t = 5 min) and then every 15 minutes for the second 
hour, for assessment of gastric emptying. The 13CO2 concentration in the breath samples was 
measured by an isotope ratio mass spectrometer (ABCA 20/20; Europa Scientific, Crewe, UK), 
and the gastric 50% emptying time (T50) was calculated, using the formula described by Ghoos 
et al. [264]. 
 
9.2.4 Statistical analysis 
Plasma GLP-1 and GIP were analysed and presented as absolute values and changes from 
baseline. One-way repeated-measures ANOVA was used to evaluate the effects of time (t = 0-
120 mins) on the change from baseline values for plasma GLP-1 and GIP, at each visit. 
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The peak and time to peak for GLP-1 and GIP were calculated, as well as areas under the curve 
(AUCs) from 0 – 120 min, the latter using the trapezoidal rule. Differences between the initial 
study and follow-up were assessed using Student's paired t-tests.  
 
The changes in AUCs for plasma GLP-1 (Δ.GLP-1.AUC), plasma GIP (Δ.GIP.AUC) and 
gastric emptying (ΔGE) between the initial and follow-up studies were calculated. Linear 
regression analysis was performed to evaluate correlations for GLP-1 and GIP concentrations 
between the two study days. Multiple linear regression was performed to gain insights into the 
potential effects of ΔGE, GLP-1 and GIP responses at the initial study, and BMI at the initial 
study on the changes in GLP-1 or GIP.  All analyses were performed using SPSS version 24 
(SPSS, Chicago, IL, USA). A P value < 0.05 was considered significant in all analyses. Data 
are presented as mean values ± SEM, unless stated otherwise 
 
9.3 Results  
Of the 41 older individuals (20 female and 21 male) who agreed to return, the mean age at the 
initial study was 71.2 ± 3.8 (SD) years and body mass index [BMI] 25.8 ± 2.7 (SD) kg/m2. At 
‘follow-up’ (mean interval of 5.9 ± 0.1 years), age was 77.1 ± 3.8 (SD) years and body mass 
index [BMI] 26.5 ± 3.1 (SD) kg/m2 (P = 0.3). There were no demographic differences at 
baseline between those who participated in the study and those who did not. The studies were 
generally well tolerated and there were no adverse events. Five subjects were shown to have 
diabetes and were excluded from analyses. In another 6 subjects, a nonlinear regression model 
could not be fitted to the measured 13CO2 concentrations at the initial and/or the follow-up 
study. Paired plasma GLP-1 and GIP data were available in 36 subjects, while gastric emptying 
data were available in 30 subjects. 
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9.3.1 Plasma GLP-1 
There was a reduction in fasting plasma GLP-1 (21.0 ± 1.0 vs 15.3 ± 0.7 pmol/L, P < 0.001) at 
follow-up compared to the initial study. Between t = 0 and 120 min, there was a rise (P < 0.001 
for both) in plasma GLP-1 on both study days. The AUC for plasma GLP-1 (P = 0.001) (Figure 
9.1A) and the maximum rise in plasma GLP-1 (41.3 ± 2.6 vs 35.4 ± 2.2 pmol/L, P = 0.03) were 
less, and the time to peak was longer (33.4 ± 2.0 vs 47.5 ± 3.6 min, P = 0.001), at follow-up. 
Changes in GLP-1 were not influenced by gender (data not shown). 
 
9.3.2 Plasma GIP 
There was a reduction in fasting plasma GIP (19.8 ± 1.2 vs 17.1 ± 0.9 pmol/L, P = 0.03) at 
follow-up compared to the initial study. Between t = 0 and 120 min, there was a rise (P < 0.001 
for both) in plasma GIP on both study days. There was no difference (P = 0.26) in the AUC for 
plasma GIP between the initial and follow-up studies (Figure 9.1B), or in the maximum rise in 
plasma GIP (56.1 ± 2.8 vs 54.2 ± 2.4 pmol/L, P = 0.43). However, the time to peak was shorter 
(98.3 ± 3.7 vs 76.7 ± 5.9 min, P = 0.001) at follow-up. Changes in GIP were not influenced by 
gender (data not shown). 
 
9.3.3 Gastric emptying 
Gastric emptying (T50) was slower at follow-up than at the initial study (136.5 ± 4.9 vs 164.7 
± 10.6 min, P = 0.008).  
 
9.3.4 Relationships for GLP-1, GIP and gastric emptying between the two study days 
Fasting GLP-1 concentrations at the initial and follow-up studies were not related (R = 0.23, P 
= 0.18; n = 36). In contrast, there was a correlation between but fasting GIP concentrations 
  Chapter 9 
211 
 
between the initial and follow-up days (R = 0.72, P < 0.001; n = 36). There were significant 
relationships between AUC0-120min for plasma GLP-1 (R = 0.50, P = 0.002; n = 36) (Figure 
9.2A), plasma GIP (R = 0.60, P < 0.001; n = 36) (Figure 9.2B) and gastric emptying (R = 0.38, 
P = 0.04; n = 30) at the initial and follow-up studies. 
 
9.3.5 Predictors of changes in glucose-stimulated plasma GLP-1 and GIP  
Multiple linear regression analysis was performed to investigate potential predictors of the 
Δ.GLP-1.AUC in the subjects with complete data (n = 30). Variables in the model included the 
ΔGE between the two study days, GLP-1.AUC at the initial study and BMI at the initial study. 
GLP-1.AUC at the initial study (β = -0.47 ± 0.17 (SE), P = 0 .01), but not ΔGE (β = 1.5 ± 3.4 
(SE), P = 0.96) or BMI at the initial study (β = 35.5 ± 62.0 (SE), P = 0.57), was a significant 
predictor. The overall model fit was r2 = 0.26, P = 0.046.  
 
Similarly, multiple linear regression analysis was also performed to investigate potential 
predictors of the Δ.GIP-1.AUC in the subjects with complete data (n = 30). Variables in the 
model included the ΔGE between the two study days, GIP.AUC at the initial study and BMI at 
the initial study. GIP.AUC at the initial study (β = -0.48 ± 1.4 (SE), P = 0.002), but not ΔGE 
(β = 0.38 ± 4.7 (SE), P = 0.94) or BMI at the initial study (β = 37.8 ± 93.2 (SE), P = 0.69), was 
a significant predictor. The overall model fit was r2 = 0.33, P = 0.02. 




Figure 9.1. Plasma (A) GLP-1 and (B) GIP concentrations before and after 75g glucose at the 
initial and follow-up studies in healthy older subjects (n = 36). Data are mean values ± SEM. 
  




Figure 9.2. Relationship between AUC0-120min for plasma (A) GLP-1 and (B) GIP at the initial 
study and follow-up (n = 36). 




9.4 Discussion  
To our knowledge, this study represents the first longitudinal evaluation of fasting and oral 
glucose-stimulated incretin hormone responses in healthy older people. Previous studies have 
all been cross-sectional. Novel observations are that fasting GIP and GLP-1, and glucose-
stimulated GLP-1 decreased significantly over a mean period of ~5.9 years and there was a 
reasonable correlation between GLP-1 and GIP responses at baseline and at follow-up. Neither 
the slight slowing of gastric emptying nor BMI at the initial study predicted the changes in 
GLP-1 or GIP.  
 
Existing information relating to the effects of ageing on incretin hormones in healthy people 
and patients with T2D is inconsistent. Some cross-sectional studies have reported that fasting 
and/or ‘postprandial’ plasma GIP [476-478] and GLP-1 [256, 478, 479] concentrations do not 
differ between healthy young and older subjects. However, in other studies, postprandial GIP 
[480, 481] and GLP-1 [478, 480, 482] were reported to be slightly greater in healthy older 
subjects. In T2D, postprandial GIP has been reported to be greater [476, 483] or comparable 
[477], while GLP-1 has been reported to be less in older subjects with T2D [477]. The 
fundamental limitation of these cross-sectional studies is the inability to account for intra-
individual changes over time. 
 
Our study indicates that ageing is associated with modest reductions in fasting GLP-1 and GIP, 
and oral glucose-stimulated GLP-1, but not GIP. The pathophysiology underlying the changes 
in fasting and postprandial incretin hormones is uncertain. Our focus was the incretin secretory 
responses and we, accordingly, measured plasma concentrations of total, rather than intact, 
GLP-1 and GIP which include both intact hormones and inactive metabolites [465]. 
 




The relevance of the observed changes is also uncertain. However, Færch et al. have suggested 
that a reduction in the GLP-1 response to oral glucose could predispose to the development of 
T2D [484]. This is supported by recent longitudinal observations in 121 subjects (non-diabetic 
lean and obese adult men and women) in the Hoorn Meal Study in which a reduced GLP-1 
response in an oral glucose tolerance test was associated with a greater increase in fasting 
glucose 7 years later [485], although an oral glucose tolerance test was not performed at follow-
up, and gastric emptying was not studied. Nevertheless, our data add to the concern that a 
reduction in fasting and glucose-stimulated GLP-1 may predispose to impairment in glucose 
tolerance and T2D.  
 
We observed strong correlations in fasting GIP, and glucose-stimulated GLP-1 and GIP 
concentrations, between the initial and follow-up studies. The absence of a relationship with 
fasting GLP-1 may well reflect a type 2 error. Accordingly, despite the substantial 
interindividual variation in fasting and postprandial GLP-1 and GIP, within the same 
individual, there is a reproducible pattern. The determinants of this phenomenon remain to be 
characterised. – The observed slowing of gastric emptying, which may be a determinant of, as 
well as determined by, plasma GLP-1 concentrations, did not appear to be relevant. 
 
Limitations of our study should be appreciated. The size of the cohort was relatively small and 
just under 50% of those studied originally participated in the follow-up study with the inherent 
potential for selection bias. In addition, the 5 subjects with T2D were excluded. Gastric 
emptying data of another 6 subjects were removed from the analyses due to technical issues, 
which may have reduced the predictive power of our multiple linear regression models. 
Furthermore, gastric emptying was assessed by the indirect breath test technique. This method 
has been shown to correlate closely with scintigraphy, the ‘gold standard’ technique [337, 338], 




although the measurements should be regarded as notional, rather than precise [7]. We used 
the same assays, under the same conditions, to measure GLP-1 and GIP at the initial study and 
follow-up, but it should be appreciated that inevitably the batch numbers differed given the 
timing of assays.  
 
In conclusion, our study demonstrates that in healthy older people fasting GLP-1 and GIP, and 
glucose-stimulated GLP-1 decrease over a period of ~5.9 years, and that longitudinal intra-
individual fasting GIP and glucose-stimulated GLP-1 and GIP concentrations correlate.  The 
reduction in incretin hormone responses with ageing may potentially predispose to the 














Chapter 10  
The relationship between plasma glucose-
dependent insulinotropic peptide and glucagon-
like peptide-1 levels in people with normal and 
impaired glucose tolerance  
  Chapter 10 
218 
 
Statement of Authorship 
Title of paper The relationship between plasma glucose-dependent 
insulinotropic peptide and glucagon-like peptide-1 levels in 
people with normal and impaired glucose tolerance.  
Publication Status Accepted for publication 
Publication Details Marathe CS, Pham HT, Marathe JA, Trahair LG, Huynh L, 
Wu T, Phillips LK, Rayner CK, Nauck MA, Horowitz M, 
Jones KL. Relationships between GIP and GLP-1 secretion 
in response to an oral glucose load in participants with 
normal and impaired glucose tolerance. Acta Diabetologica. 
 
Principle Author 
Name of Principal 
Author (Candidate) 
Hung T Pham  
Contribution to the 
Paper 
Conducted research, analysed and interpreted data and 
reviewed paper. 
Overall percentage  45% 
Certification  This paper reports on original research I conducted during 
the period of my Higher Degree by Research candidature and 
is not subject to any obligations or contractual agreements 
with a third party that would constrain its inclusion in this 
thesis. I am the joint primary author (equal contribution by 
CSM and HTP) of this paper. 




Signature  Date Aug 2019 
 
Co-Author Contributions 
By signing the Statement of Authorship, each author certifies that: 
i.  the candidate’s stated contribution to the publication is accurate (as detailed above);  
ii.  permission is granted for the candidate in include the publication in the thesis; and  
iii.  the sum of all co-author contributions is equal to 100% less the candidate’s stated 
contribution.   
 
Name of Co-Author Chinmay S Marathe 
Contribution to the 
Paper 
Conducted research, analysed and interpreted data, 
reviewed paper and approved the final version of paper. 
Signature  Date Aug 2019 
 
Name of Co-Author Jessica A Marathe 
Contribution to the 
Paper 
Analysed and interpreted data and reviewed paper. 
Signature  
 
Date Aug 2019 
 
Name of Co-Author Laurence G Trahair 
Contribution to the 
Paper 
Conducted research and reviewed paper. 




Signature  Date Aug 2019 
 
Name of Co-Author Lian Huynh 
Contribution to the 
Paper 
Analysed data and reviewed paper. 
Signature  
 
Date Aug 2019 
 
Name of Co-Author Tongzhi Wu 
Contribution to the 
Paper 
Interpreted data and reviewed paper. 
Signature  Date Aug 2019 
 
Name of Co-Author Liza K Phillips 
Contribution to the 
Paper 
Interpreted data and reviewed paper. 
Signature  
 
Date Aug 2019 
 
Name of Co-Author Christopher K Rayner 




Contribution to the 
Paper 
Interpreted data and reviewed paper. 
Signature  
 
Date Aug 2019 
 
 
Name of Co-Author Michael A Nauck 
Contribution to the 
Paper 
Conceived and designed research and reviewed paper. 
Signature  Date Aug 2019 
 
Name of Co-Author Michael Horowitz 
Contribution to the 
Paper 
Conceived and designed research, interpreted data and 
reviewed paper.  
Signature  Date Aug 2019 
 
Name of Co-Author Karen L Jones 
Contribution to the 
Paper 
Conceived and designed research, interpreted data and 
reviewed paper. 
Signature  Date Aug 2019 




Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), are 
released from the small intestine in response to macronutrient exposure (carbohydrate, lipid or 
protein). GIP is released from enteroendocrine ‘K’ cells, located predominantly in the proximal 
small intestine, and GLP-1 from ‘L’ cells, located predominantly in the distal small intestine 
and colon [486]. It has been suggested that GIP and GLP-1 account, in approximately equal 
proportions, for the ‘incretin effect’ (the amplified insulin secretory response to oral compared 
with intravenous glucose) in health, although the outcome of a recent study is indicative of a 
dominant contribution of GIP [487]. The incretin effect is a major determinant of the 
postprandial insulin secretory response in health, although its magnitude is reduced in type 2 
diabetes (T2D), at least in part because the insulinotropic effect of GIP is markedly diminished 
[290]. GLP-1, unlike GIP, largely retains its insulinotropic (and glucagonostatic) properties in 
T2D, which has stimulated the development, and current widespread use, of GLP-1 based 
therapy (GLP-1 receptor agonists and DPP-4 inhibitors) for T2D. It is uncertain whether GLP-
1 and GIP secretion are related. A study by Nauck et al in first-degree relatives of people with 
T2D and healthy controls reported a strong correlation between plasma GIP and GLP-1 levels 
following a 75g oral glucose tolerance test [465, 488], but the number of subjects (n = 15 
relatives, n = 10 controls) was small. In general, macronutrients will be exposed earlier to ‘K’ 
than ‘L’ cells, but, unlike rodents, it is not clear if GIP influences GLP-1 secretion [465]. The 
current study was conducted to evaluate whether there is a relationship between plasma GIP 
and GLP-1 levels in a larger cohort of individuals with normal (NGT), or impaired (IGT), 
glucose tolerance. 
 




10.2 Materials and Methods 
10.2.1 Participants 
100 healthy Caucasian volunteers were recruited through local advertisement. Participants with 
a history of gastrointestinal disease, other significant medical illness, or taking medication 
known to affect gastrointestinal motility, were excluded. The Royal Adelaide Hospital Human 
Research Ethics Committee approved the study protocol, which conformed to the principles of 




Each subject fasted overnight (14 hours for solids and 12 hours for liquids) and attended the 
Department of Nuclear Medicine, PET and Bone Densitometry (Royal Adelaide Hospital) at 
0800h when they drank 350 mL water containing 75g glucose within 2 minutes. Time zero (t 
= 0) was considered as the end of consumption of the drink.  
 
10.2.3 Measurements of blood glucose, serum insulin, GIP and GLP-1   
Venous blood was obtained at t = -2, 30, 60, 120, 180 and 240 min. Plasma was separated by 
centrifugation and stored at −70°C for subsequent assays. Blood glucose concentrations were 
determined using a glucometer (Medisense Precision QID; Abbott Laboratories, Bedford, MA, 
USA). Each subject was classified, according to WHO criteria, as having NGT (fasting blood 
glucose < 6.1 mmol/L, and 2 h < 7.8 mmol/L), IGT (2 h blood glucose < 11.1 mmol/L, but > 
7.8 mmol/L), or diabetes (fasting blood glucose ≥7.0 mmol/L and/or 2 h blood glucose ≥11.1 
mmol/L) [474]. Serum insulin concentrations were determined by ELISA (10-1113 Mercodia, 
Uppsala, Sweden), with assay sensitivity of 1.0 mU/L and coefficient of variation 2.5% within 




assays and 7.4% between assays [299]. Total GLP-1 was measured by radioimmunoassay 
(GLPIT- 36HK, Millipore, Billerica, MA, USA). The minimum detectable limit was 3 pmol/L, 
intra and interassay CVs were 7.7% and 9.4%, respectively [299]. Plasma total GIP was 
measured by radioimmunoassay. The minimum detectable limit was 2 pmol/L, interassay CV 
was 8.7%, and intraassay CV was 5.0% [299].  
 
10.2.4 Statistical analysis 
Blood glucose, serum insulin, plasma GIP and GLP-1 were analysed and presented as changes 
from baseline (t = -2 min). One-way repeated-measures ANOVA was used to evaluate the 
effect of time on blood glucose, insulin, GIP and GLP-1. Incremental areas under the curve 
(iAUC0-240min) for blood glucose, insulin, GIP and GLP-1 were determined for the NGT and 
IGT groups and compared using Student's paired t-test. Pearson’s correlation was used to assess 
linear relationships between variables. Data are shown as mean values ± SEM. Statistical 
significance was set at P  < 0.05. 
 
10.3 Results  
All subjects tolerated the study well and there were no adverse events. Nine participants were 
found to have diabetes and were excluded from the analysis. Of the remaining 91 healthy 
Caucasian volunteers (46 male and 45 female participants, mean age 68 ± 0.8 years, mean BMI 
26 ± 0.3 kg/m2), 50 had NGT and 41 had IGT.  The overall glycaemic response, as assessed by 
iAUC0-240 min for glucose was greater in IGT (310  22 for NGT vs. 630  29 for IGT, P < 
0.0001, Figure 10.1A). 
 




There were substantial rises in serum insulin, plasma GIP and GLP-1 following the glucose 
load (P < 0.01 for all).  The overall insulinaemic response as assessed by iAUC0-240 min for 
insulin was comparable in the two groups (NGT: 8127  917 vs. IGT: 8637  863 mU/L.min, 
P = NS, Figure 10.1B). There was also no difference in the overall GIP response, as assessed 
by iAUC0-240 min for GIP (NGT: 6027 ± 346 vs. IGT: 5172 ± 371 pmol/L.min; P = NS, Figure 
10.1C). In both cohorts, plasma GIP levels were low at baseline, rising promptly following 
consumption of glucose drink with peak levels at ~t = 30 min, maintained until ~t = 120 min 
and followed by decline to near baseline level at t = 240 min (Figure 10.1D). The GLP-1 
response as assessed by iAUC0-240 min for GLP-1 was higher in NGT, but this difference was 
not significant (NGT: 1550 ± 260 vs. IGT: 1187 ± 176 pmol/L.min, P = NS) (Fig 1C).  In both 
cohorts, plasma GLP-1 levels were low at baseline, and rose promptly following consumption 
of glucose drink with peak levels at ~t = 30 min, followed by a sharp decline to the baseline 
level at t = 120 min, which was maintained until t = 240 min.  There was no relationship 
between baseline GIP and GLP-1 in the combined group (R = 0.14, P = NS), NGT (R = 0.13, 
P = NS) or IGT (R = 0.16, P = NS).  There was a significant relationship between the iAUC0-
240 min for GIP and GLP-1 in the combined group (R = 0.23, P = 0.015), and in the IGT group 
(R = 0.34, P = 0.01), but not in the NGT group (R = 0.15, P = NS) (Figure 10.2). 





Figure 10.1. Blood glucose (A), serum insulin (B), plasma GLP-1 (C), and plasma GIP (D) 
levels immediately before and following a 75g oral glucose load in individuals with NGT (n = 
50) and those with IGT (n = 41). Data are mean ± SEM. 
 






Figure 10.2.  Relationship between the incremental areas under the curve (iAUC) from 0-240 
min for plasma GIP and GLP-1 in a cohort of people with NGT (n = 50) and IGT (n = 41) 
following a 75g glucose drink.  





















Whole group (r=0.23, P=0.015)
      = NGT (r=0.15, P=NS)     
      = IGT (r=0.34, P=0.01)





We have evaluated, in subjects with (i) NGT or (ii) IGT, whether there is a relationship between 
the GIP and GLP-1 responses to a 75g oral glucose tolerance test (OGTT). Our observations 
indicate that there is a relationship which is significant, but only weakly positive. The lack of 
statistical significance in the NGT group alone may well be a type II error.  The factors 
potentially affecting GLP-1 and GIP secretion following macronutrient ingestion include the 
type of macronutrient stimulus (e.g. carbohydrate and lipid appear to be more potent stimuli of 
GLP-1 secretion than protein), caloric content, the rate of delivery of nutrients from the 
stomach to the small intestine (i.e. gastric emptying), integrity (or the lack of) upper 
gastrointestinal anatomy (for example, GLP-1 secretion is markedly enhanced post-Roux-en-
Y gastric bypass surgery) and the gastrointestinal autonomic system [465]. An association 
between GIP and GLP-1 levels (and presumably secretion) might reflect (i) a common stimulus 
or (ii) the influence of one on the other. While GIP and GLP-1 are known to be released from 
distinct intestinal cells, some entero-endocrine cells may co-secrete GIP and GLP-1 [489]. GIP 
and GLP-1 share some key commonalities  (the same macronutrient stimuli induce the 
secretion of GIP and GLP-1 and the same ubiquitous enzyme, dipeptidyl peptidase-4 (DPP-4), 
is responsible for the degradation of both [474]. Intuitively, as K cells are located more 
proximally, GIP may influence GLP-1 secretion, which is the case in some animal species 
[490]. However, intravenous infusion of supra-physiological doses of exogenous GIP, does not 
stimulate GLP-1 secretion in humans [288]).  
 
Our analysis is indicative of only a modest correlation between the secretory responses of the 
two hormones, which was weaker than that observed by Nauck et al. [488] in a small cohort of 
first-degree relatives of people with T2D and healthy controls. We did not relate the incretin 
response to the rate of gastric emptying, which may be a significant determinant [308]. Gastric 




emptying exhibits a wide inter-individual variation (between 1-4 kcal/min in health) and our 
previous studies employing a naso-duodenal catheter to infuse glucose directly into the 
proximal duodenum have shown that the rate of intraduodenal (ID) delivery of glucose has a 
major, but differential, impact on both GIP and GLP-1 secretion [308]. When the rate was 
increased from 1 to 4 kcal/min (i.e. within two extremes of the physiological range of gastric 
emptying), GIP secretion increased proportionately. In contrast, there was minimal, if any 
elevation in GLP-1 at rates of 1 to 2 kcal/min, but a sustained and exaggerated response when 
the rate was increased to 3 kcal/min and beyond, indicative of a ‘threshold’ rate of delivery (or 
gastric emptying rate) between 2 and 3 kcal/min [306]. It is, accordingly, possible that a 
stronger correlation between GIP and GLP-1 might be observed in those individuals who have 
an intrinsically higher rate of gastric emptying (i.e. >2 kcal/min).   
 
In interpreting our observations, some limitations should be appreciated: (1) a correlation 
between GIP and GLP-1 secretion does not establish causality; (2) our cohort was comprised 
predominantly of older men, and it is not known if age affects the relationship; (3) we did not 
account for variations in gastric emptying or small intestinal absorption; (4) we only 
characterised the response to glucose and not protein or fat; (5) for convenience, we used a 
glucometer to determine glucose concentrations, which were taken from venous rather than 
capillary or arterial samples. 
 
In conclusion, our study indicates that while there is no relationship between fasting GIP and 
GLP-1, there is a weak, but statistically significant relationship between GIP and GLP-1 
responses to oral glucose in individuals without diabetes. 
 





Chapter 11  
CONCLUSIONS  
  




This thesis presented a series of studies that provide novel and important insights into the 
underlying pathophysiology, natural history, and approaches to management, of postprandial 
hypotension (PPH), as well as longitudinal changes in the pre- and post-prandial release of the 
incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose dependent insulinotropic 
polypeptide (GIP) as well as the relationship between them. 
 
In Chapter 4, longitudinal changes in the blood pressure (BP) response to, and gastric 
emptying of, oral glucose in healthy older people were evaluated. After a period of ~5.8 years, 
the prevalence of PPH doubled from 9.1% to 18.2%. More importantly, gastric emptying was 
slower and the hypotensive response to glucose, greater, at follow-up. Consistent with previous 
studies, the fall in systolic BP (SBP) was related directly to the rate of gastric emptying at both 
the initial study and at follow-up. The change in the maximum fall in SBP was related to the 
increase in baseline SBP. These observations demonstrated that in healthy older people over a 
period of ~5.8yr, there was an increased prevalence of PPH and a modest slowing of gastric 
emptying. The latter was related directly to a greater hypotensive response. 
 
In Chapter 5, the acute effects of nutritive and non-nutritive sweeteners on postprandial BP 
were reported in a systematic review of 62 relevant papers. Current data indicate that the BP 
response to ingestion of sweeteners is generally unaffected in healthy young subjects, however, 
in elderly individuals, glucose induces the greatest decrease in postprandial BP, while the 
response to sucrose is less pronounced. The limited studies investigating other nutritive and 
non-nutritive sweeteners have demonstrated minimal or no effect on postprandial BP. Dietary 
modification by replacing high nutritive sweeteners (glucose, fructose, and sucrose) with low 
nutritive (D-xylose, xylitol, erythritol, maltose, maltodextrin, and tagatose) and non-nutritive 
sweeteners may be a simple and effective approach in the management of PPH. 




Chapter 6 presented the effects of intraduodenal (ID) administration of a widely used artificial 
sweetener, sucralose, in comparison to saline and glucose, on BP and superior mesenteric artery 
(SMA) blood flow in healthy older subjects. As expected, blood glucose concentrations 
increased in response to glucose, but not saline or sucralose. There was a fall in mean arterial 
BP during ID glucose, but not during ID saline or ID sucralose. Heart rate (HR) and SMA 
blood flow also increased during ID glucose, but not during ID saline or ID sucralose. 
Accordingly, ID administration of the artificial sweetener, sucralose, is not associated with 
changes in BP or SMA blood flow in healthy older subjects. Artificial sweeteners may have 
therapeutic benefit in the non-pharmacological management of PPH. Further studies are now 
warranted in these patients. 
 
In Chapter 7, the hypothesis that gastric distension (using a water preload administered 15min 
prior to a test drink) and the α-glucosidase inhibitor, acarbose, may attenuate the postprandial 
fall in BP by complementary mechanisms was evaluated. The AUC0-120min for mean arterial 
pressure (MAP) was greater, and the maximum fall in MAP less, during treatments with 
acarbose. However, gastric distension did not affect the MAP response to acarbose, and there 
was no effect of gastric distension alone. Both acarbose treatments attenuated the rise in SMA 
blood flow, whereas gastric distension had no effect. The study demonstrated that acarbose 
(100mg), but not gastric distension, attenuates the fall in BP and rise in SMA blood flow after 
oral sucrose in healthy older adults. These observations support the use of acarbose, but not 
combined with gastric distension, to attenuate a postprandial fall in BP. However, the effect of 
a larger volume of water given immediately prior to food ingestion should be investigated 
further. 
 




Chapter 8 presented the results of a study evaluating the effects of a guar/whey preload given 
15 min before a test drink containing 50g glucose in healthy older subjects. Gastric emptying 
(measured with scintigraphy), intestinal glucose absorption and the glycaemic and BP 
responses to the glucose drink with or without the guar/whey preload was assessed. The 
guar/whey protein preload reduced plasma glucose, serum 3-O-methylglucose (3-OMG) and 
increased plasma insulin. Furthermore, SMA blood flow was reduced and HR increased by the 
preload. However, there was no difference in gastric emptying or BP between the two days. 
The reduction in plasma glucose on the preload day compared to control was related to the 
reduction in glucose absorption. These observations indicate that in healthy older people, the 
glucose-lowering effect of a whey protein/guar preload may relate to delayed small intestinal 
glucose absorption and insulin stimulation, rather than slowing of gastric emptying and that the 
preload has no potential benefit in the management of PPH.  
 
In Chapter 9, the first longitudinal assessment of fasting and oral glucose-stimulated incretin 
hormone responses in a cohort of 41 healthy older people was conducted. Participants had 
measurements of plasma GLP-1 and GIP while fasting and after a 75g oral glucose load on two 
occasions separated by 5.9 ± 0.1 years. Breath samples were also collected to calculate the 
gastric 50% emptying time (T50). For GLP-1, both fasting concentrations and AUC0-120min 
were decreased at follow-up. Fasting GIP was also lower at follow-up, but there was no change 
in the AUC0-120min. The gastric emptying T50 was slower at follow-up. Neither the change in 
T50 nor the BMI at the initial study was a determinant of the change in incretin responses. 
Between the two study days, fasting GIP correlated well, but not fasting GLP-1. However, both 
glucose-stimulated GLP-1 and GIP showed correlations between the initial and follow-up 
studies. In summary, fasting GIP, and glucose-stimulated GLP-1 and GIP concentrations 
correlate within individuals over a follow-up period of ~ 5.9 years. Ageing is associated with 




reductions in fasting GLP-1 and GIP, and glucose-stimulated GLP-1, which may predispose to 
the development of glucose intolerance and type 2 diabetes (T2D). 
 
In Chapter 10, the relationship between plasma GIP and GLP-1 responses to 75g oral glucose 
in individuals with normal (NGT), or impaired (IGT), glucose tolerance was reported. In both 
groups, there were increases in plasma GIP and GLP-1 following the glucose drink, with no 
difference in the magnitude of the responses between t = 0-240 min. There was a weak 
relationship between the iAUC0-240 min for GIP and GLP-1 in the combined and in the IGT, but 
not in the NGT group. Our conclusion is that there is a weak relationship between oral glucose-
induced GIP and GLP-1 secretion in a cohort of non-diabetic individuals. Further studies are 
required in T2D. 
 
In summary, while the studies presented in this thesis have provided fundamental insights 
relating to postprandial BP regulation in healthy older people, future studies are now warranted 
in patients with symptomatic PPH. The studies relating to GIP and GLP-1 secretion indicate 
changes with ageing and a correlation between, GLP-1 and GIP. Future studies with larger 
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